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Carbapenemases are enzymes able to hydrolyze the last resort b-lactam antibiotics 
(carbapenems), which are used for the treatment of infections caused by resistant bacteria. 
Carbapenemases are structurally and mechanistically classified into serine-b-lactamases 
(SBLs) and metallo-b-lactamases (MBLs). In order to combat the hydrolytic activity of these 
enzymes, combination therapy of b-lactam with b-lactamase inhibitor have been clinically 
successful. Nevertheless, clinically approved inhibitors for a number of important 
carbapenemases are still missing and resistance against some of the clinically successful 
combinations have been already reported.1 Therefore, there is an urgent need to find new 
effective inhibitors that could potentially reach clinical use. The approach targeted in this thesis 
is to design new inhibitors against carbapenemases that could be used in the combination 
therapy with a carbapenem antibiotic to restore its effect. 
 The goal of my work was to develop synthetic methods for the synthesis of inhibitors 
targeting two clinically relevant carbapenemases - the serine-b-lactamase oxacillinase 48 
(OXA-48) and the metallo-b-lactamase Verona integron-encoded metallo-b-lactamase (VIM-
2). For the design and development of inhibitors, a fragment-based approach based on 
previously discovered inhibitory fragments and structural data of the fragments in complex with 
the target enzymes was choosen.  
 In this thesis I discuss the developed synthetic strategy towards unsymmetrical 3,5-
disubstituted benzoic acids using selective Suzuki-Miyaura cross-coupling. Applying the 
developed method, I synthesized a small extended fragment library of both symmetrical and 
unsymmetrical 3,5-disubstituted benzoic acids targeting OXA-48. The aim of synthesizing 
these extended fragments was to target two directions in the binding pocket as suggested by 
overlaying structural data of smaller fragments in complex with OXA-48.  
 I also developed a synthetic strategy towards 2-aroylbenzoic acid analogues via 
carbonylative Suzuki coupling using CO in a safe fashion. 2-Aroylbenzoic acids were known 
to inhibit the carbapenemase VIM-2. Through my investigations about a general synthetic 
strategy towards 2-aroylbenzoic acid, I found some limitations about substrates with ionizable 





better reaction conditions for carbonylative coupling reactions. I also introduced sustainability 
to the project by using renewable solvents aiming for better reactivity in palladium-catalyzed 
C-C, C-O, C-N bond forming carbonylative couplings.  
 In summary, through the presented work a range of carbapenemase (OXA-48 and VIM-
2) inhibitors have been synthesized. Additionally, the developed synthetic strategies are 
considered to be a starting point to build a general approach to synthesize a wide range of potent 








Ampc Class C b-lactamase 
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1. Introduction  
 
Antibiotic resistance is among the most challenging threats to the global health in the 21st 
century and soon will be one of the top public health challenges unless urgent actions are taken. 
Infections such as pneumonia, tuberculosis, gonorrhea and salmonellosis are becoming more 
challenging to treat as the bacteria are becoming more resistant to the current antibiotics.2 
Antibiotic resistance is mainly caused by their misuse in humans, animals and accelerating 
agricultural processes. The world needs urgent actions to find solutions for the spread of 
resistant bacteria not only by developing new medicines but also by changing the public 
behavior towards antibiotic consumption.2 
β-Lactam antibiotics are one of the most widely used antibiotics and they include 
penicillins, cephalosporins, monobactams and carbapenems. All members of β-lactam 
antibiotics share the β-lactam ring as the common feature in their chemical structure.3,4 The 
continuous evolution of bacteria containing β-lactam antibiotic-hydrolyzing enzymes is one of 
the main reasons behind the rise of antibiotic resistance. The enzymes hydrolyzing β-lactam 
antibiotics are called β-lactamases and they are divided into two main groups based on their 
hydrolyzing mechanism: serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs). The 
β-lactamases (BLs) with activity towards carbapenems are called carbapenemases and they are 
of high importance as they are threatening the most important groups of β-lactams, 
carbapenems, used for the treatment of serious bacterial infections. Carbapenemases can be 
serine-β-lactamases (SBLs) or metallo-β-lactamases (MBLs) that are active against the last 
resort antibiotics- carbapenems. In addition, carbapenemases not only can hydrolyze 
carbapenems but also nearly all groups of β-lactams.5–9 
There are several approaches to combat the threat of the antibiotic resistance such as the 
continuous development of new antibiotic lines against the resistant bacteria or the development 
of inhibitors that could suppress or disturb the resistance mechanism of the bacteria. A very 
successful approach to overcome bacterial resistance caused by β-lactamases is the combination 
therapy using an antibiotic and a β-lactamase inhibitor. The role of the β-lactamase inhibitor is 
to block the hydrolyzing enzyme from reaching the antibiotic and thus preserving the 







The combination therapy approach has proven to be a successful strategy regarding β-
lactamases. Combination therapy using β-lactamase inhibitors such as tazobactam, clavulanic 
acid, sulbactam, etc. targeting SBLs that are not active against carbapenems have been available 
for clinical use.1 There are several inhibitors against serine-β-lactamases, which are active 
against carbapenems that have recently been approved for clinical use or are in a late stage of 
the drug development process.1 However, there are no MBL inhibitors that have reached 
clinical use so far. In addition, MBL carrying bacteria are spread globally. Therefore, the lack 
of MBL inhibitors can eventually lead to the world standing helpless against common bacterial 
infections that are caused by bacteria carrying MBLs. Thus, the global need for carbapenemase 
inhibitors restoring the potency of the last-line antibiotics is outstanding.4,10,11 
1.1 Aim of the study 
The long-term goal of our work is to develop carbapenemase inhibitors that could potentially 
block the resistance enzymes and restore the activity of the carbapenem. Our research group is 
especially interested in carbapenemases (e.g., VIM-2, NDM-1, GIM-1, TMB-1, KPC and 
OXA-48).12–15 Over time, the group has obtained structural data from crystal structures of these 
enzymes in complex with a range of inhibitory fragments (small-sized compounds MW < 300) 
and inhibitors. The structural data gives us insight into the binding site and assists us with 
generating ideas for further development of active inhibitors by structure-based drug design 
(SBDD).  
The overarching aim of my PhD work was to develop active inhibitors of two 
carbapenemases to restore the carbapenem antibiotic activity. I have mainly focused on two 
carbapenemases- the verona integron-encoded metallo-β-lactamase (VIM-2) and the serine-β-
lactamase oxacillinase-48 (OXA-48).  
In order to achieve the overall aim, the work in the thesis had several subgoals: 
• Use the structural data from two carbapenemases (VIM-2 & OXA-48) in complex with 
inhibitory fragment complexes to develop fragment libraries (Figure 1). The crystal 
structures gave us insight into the binding site and helped identify possible interactions 








Figure 1. (left) Fragment 1 targeting VIM-2, (right) Fragment PI-2 targeting OXA-48. 
• Develop efficient synthetic methods for the synthesis of fragment libraries. 
• Synthesize analogues of the initial fragment and evaluate their inhibitory activity. 
1.2 Outline   
The thesis consists of 9 chapters. The first three chapters introduce the research question, the 
background and the existing knowledge. Chapter 4, 5 and 6 present the three papers resulting 
from the research described in the thesis. Chapter 7 presents the concluding remarks, while 
chapter 8 highlights open research question for future studies. A more detailed presentation of 
the content of the chapters follows:  
Chapter 1 Introduces the aim of the study and places the study in a wider context. 
Chapter 2 Discusses β-lactamase antibiotics including carbapenems and the antibiotic 
resistance assembled in carbapenemases. It also addresses the different 
carbapenemase enzymes and their mode of action. Furthermore, it discusses the 
combination therapy approach and the evolution of inhibitors used against 
carbapenemases. The chapter also includes a short introduction to fragment-
based drug design. 
Chapter3 Provides the chemical background for the reactions applied in this thesis. For 
each reaction an overview of the reaction mechanism is provided. In addition, 
some examples from literature are discussed to provide some knowledge about 
the reaction applications. Green solvents. 
Chapter 4 Introduces the background for the research described in paper I. In addition, it 
illustrates the fragment design and important features that should be included in 
the structure to target both binding sites R1 & R2. The chapter also discusses a 
developed general synthetic strategy to synthesize a number of extended 
fragments against OXA-48 via the selective Suzuki-Miyaura coupling. Finally, 












Chapter 5 Introduces the background for the research described in paper II. The chapter 
illustrates the different possible synthetic routes to synthesize active fragments 
containing the 2-aroylbenzoic acid moiety against VIM-2. I highlight the best 
synthetic route in my hands towards the targeted VIM-2 fragments. The chapter 
also discusses reaction optimization for carbonylative Suzuki-Miyaura coupling 
and our efforts to suppress the competing normal Suzuki-Miyaura coupling 
required to synthesize a number of developed fragments against VIM-2. Finally, 
it addresses results presented in the paper together with some findings about the 
reaction limitations. 
Chapter 6 Is a continuation of the work conducted in paper II. It discusses the extended 
optimization of carbonylative Suzuki-Miyaura coupling to find a better system 
and cover the reaction limitation addressed in paper II. In this chapter I 
introduce sustainability character to my research by using new renewable 
solvents and test them for better reactivity within Pd-catalyzed carbonylation 
reactions such as carbonylative Suzuki-Miyaura coupling (C-C), 
alkoxycarbonylation (C-O), aminocarbonylation (C-N). The chapter highlights 
that changing the common organic solvents to greener alternatives is a positive 
step towards sustainability without losing activity in the chemical reactions. A 
number of applications is mentioned to address the importance of the studied 
solvents in both academia and industry. Finally, it addresses some results 
presented in the paper. 
Chapter 7 Conclusion. 
Chapter 8 Future direction 
Chapter 9 Appendix: this chapter includes experimental details and spectral data of 












2. Relevant background for the thesis 
2.1 Antibiotics & antibiotic resistance  
An antibiotic is a substance that can kill or cause inhibition of the microbial growth. The name 
“antibiotic” was first introduced by Selman Waksman in 1942. Since their discovery, antibiotics 
have saved many lives and improved life quality.16,17 
There are several classes of antibiotics such as β-lactams, macrolides, sulfonamides, 
aminoglycosides, quinolones etc. Each class of antibiotics affect the bacteria in different ways. 
For instance, β-lactams interfere with the cell-wall synthesis of the bacteria, thus killing it. 
While quinolones inhibit topoisomerases preventing the DNA replication and cause death of 
the bacteria.18 
Due to the overuse of antibiotics and the resulting evolutionary pressure, bacteria have 
learnt to resist antibiotics. Bacteria identify antibiotics, and thus adapt and build immunity 
against them. Furthermore, the rapid generation time of bacteria makes it even quicker for the 
bacteria to evolve and build resistance against antibiotics in a short time.19 The uncontrolled 
growth of bacterial resistance leads to the suppression of the antibiotics effect. Bacterial 
infection and associated diseases that could be treated by antibiotics earlier are becoming harder 
to treat.2 This is a growing concern threatening the health and welfare of the population 
worldwide and thus needs an urgent resolution. 
2.2 β-lactam antibiotics  
β-Lactams are considered to be among the most used antibiotics, more than 65% of the 
antibacterial prescriptions include β-lactam antibiotics.20 There are several β-lactam antibiotics 
on the market. The class of β-lactam antibiotics shares a common core structure, which is a four 
membered ring known as the β-lactam ring. The importance of this class of antibiotics lies in 
their broad-spectrum antibacterial activity as they are active against both gram-negative and 
gram-positive bacteria.3 β-lactams are structurally classified into penicillins, cephalosporins, 







Figure 2. Chemical structure of β-lactam antibiotics with a common β-lactam ring. The R groups differs in various 
antibiotics. The X in the monobactam chemical structure represents α-methyl. 
Penicillins: were the first developed β-lactam antibiotics and were used to treat a wide range 
of infections caused by bacteria such as streptococcus, staphylococcus. Penicillins have a five 
membered ring fused to the β-lactam ring and an amide moiety attached to the β-lactam ring. 
There are several penicillins available on market, all of which are β-lactam antibiotics and only 
differ in the side chain of the penicillin. Ampicillins, oxacillin and amoxicillin are examples of 
penicillins.21,22 
Cephalosporins: have a six membered ring fused to the β-lactam ring and an amide moiety 
attached to the β-lactam ring as in penicillins. Cephalosporins cover a broader spectrum of both 
gram-negative and gram-positive bacteria than penicillins.23–25 Cephalosporins are grouped into 
different generations based on the modified structure and the activity spectrum. For instance, 
the first generation was similar to the cephalosporine C, which was introduced in 1940s. 
Structural modification of the cephalosporine C by adding a methoxy group on the β-lactam 
ring resulted in the second generation of cephalosporines e.g. cefoxitin. The methoxy group 
added some steric hindrance to the β-lactam ring, which made it harder to hydrolyze by the 
BLs. Ceftazidime is an example of the third generation cephalosporines, they are characterized 
by the aminothiazole ring added to the side chain of the cephalosporine structure.22,24 The new 






gram-negative bacteria and increased the potency against penicillin-binding proteins (PBPs). 
Cefepime belongs to the fourth generation, while ceftobiprole26 and ceftaroline27 belong to the 
fifth generation.22 Cefiderocol is a recently US FDA-approved cephalosporin, which is used for 
the treatment of urinary tract infections. Moreover, cefiderocol is currently being tested in phase 
III against nosocomial pneumonia and infections resulted from carbapenem-resistant gram-
negative bacteria.28 
Monobactams: are the only β-lactam antibiotics that have no ring fused to the β-lactam ring. 
Monobactams are only active against gram-negative bacteria such as Neisseria and 
pseudomonas.29 Tigemonam, nocradicin30, taboxin and aztreonam are examples of 
monobactams.22 
Carbapenems: have an unsaturated five membered ring fused to the β-lactam ring, they also 
have a chiral center with a hydroxyethyl side chain on the β-lactam ring. An example of a 
carbapenem is thienamycin, which has potency against both gram-positive and gram-negative 
bacteria but it is unstable for clinical applications.31 Imipenem is also a carbapenem but it is 
hydrolyzed by dehydropeptidase (human enzyme). However, a dehydropeptidase inhibitor 
(cilastatin) could be used to prevent the human enzyme from hydrolyzing the imipenem and 
thus could be used as an antibiotic.22 Meropenem, doripenem and ertapenem are more stable 
carbapenems than thienamycin and imipenem due to the bulkier substituents on the five 
membered ring. Carbapenems are known for their broad-spectrum activity against gram-
negative bacteria, gram-positive bacteria and anaerobes.31 Carbapenems are also used recently 
as last resort antibiotics against antibiotic-resistant bacteria. Tebipenem is one of the latest 
















Table 1. Examples of available β-lactam antibiotics. 












2.3 Antibiotic resistance: bacterial resistance modes against β-
lactam antibiotics 
Bacteria adapt to the known antibiotics by developing several mechanisms to gain resistance 
against antibiotics (Figure 3).32 Bacteria can as well combine the different mechanisms and 
become multidrug resistant, which increases the severity of the problem.17,33 Bacteria can obtain 
resistance to the antibiotic by reducing the permeability of the drug into its cell wall. Bacteria 
with no cell walls e.g. mycoplasma-genus are not affected by antibiotics targeting the cell wall 
and tend to express their resistance in another way. For instance, some other bacteria contain 
efflux pumps that transfer the antibiotics out of the cell directly after their entry before they 
reach the target.34 Another resistance mechanism is based on structurally mutating the targeted 
enzyme so that the antibiotic is not be able to bind to its target.35 An example of the mutating 



































































































































23S rRNA ribosomal subunit of gram-positive bacteria) via selection of mutated copies of the 
gene encoding the targeted subunit.18 Bacteria can use other enzymes to modify the binding site 
itself and thus prevent the drug from recognizing it so that the drug would not bind to the active 
site and lose its activity. Macrolide erythromycin functions by binding to the bacterial ribosome. 
In this case, the bacteria produce an enzyme called erythromycin ribosome methylase, the 
enzyme methylates the binding site and prevents the antibiotic from binding. In addition, some 
gram-positive and gram-negative bacteria tend to produce specific enzymes to modify or 
inactivate the antibiotic itself and make it lose its activity. For instance, BLs enzymatically 
hydrolyze β-lactam antibiotics leaving them inactive.36,37,18,32 
 
Figure 3. General presentation of the main bacterial resistance mechanism. Red represents the antibiotic, yellow 
represents the different bacterial resistance actions. The picture acquired from Gonzalez-Bello.32 
2.4 β-Lactamases, carbapenemases and their classification 
The biological effect of β-lactams depends on their availability to their target and the ability to 
inhibit these targets. As mentioned before, bacteria have several resistance mechanisms. The 
most common mechanism of resistance towards β-lactam antibiotics in gram-negative bacteria 
is to produce specific hydrolytic enzymes that inactivate β-lactam antibiotics by hydrolyzing 
the drug core of the β-lactam ring, these hydrolyzing enzymes are known as β-lactamases.38,39 
They were first reported even before the clinical release of penicillin in Escherichia coli (E. 
coli) in 1940. So far 4944 β-lactamases have been reported in gram-positive, gram-negative 
bacteria and mycobacteria.8,40-42 β-lactamases are of great diversity, they are classified based 
on their amino acid sequence and biochemical properties into four classes A, B, C, D; known 
as the Ambler classes.5,43,44 Nevertheless, the 4 Ambler classes (Figure 4) can be structurally 






having a serine residue in their active site in a sequence of Ser-X-X-Lys motif, and MBLs, 
which consist of class B, they contain Zn atom(s) in the active site, which is very important for 
the catalytic activity of MBLs.45 Both groups are β-lactam hydrolytic enzymes that use different 
hydrolysis mechanisms to inactivate the antibiotic. Among the most important BLs are those 
who are active against the last resort antibiotics - carbapenems (e.g. meropenem). These BLs 
are called carbapenemases and they belong to both class A and D SBLs (e.g. KPC, OXA-48, 
AmpC) and MBLs (e.g. VIM, NDM, GIM) as shown in Figure 4.  
 
Figure 4. Ambler classification of lactamases and examples of BLs. Both metallo and serine carbapenemases are 
shown in green. 
2.4.1 Serine β-lactamases 
Generally, most β-lactamases are serine-β-lactamases; they constitute Ambler classes A, C, D, 
which share common active site features including the serine residue (Ser70). Only KPC-2 and 
SME-1 of class A and OXA-23 and OXA-48 of class D are described as carbapenemases with 
catalytic efficiencies for carbapenem hydrolysis. Among the most common serine 
carbapenemases are OXA-48 and KPC-2.46 OXA-48 is the most efficient SBL in class D as it 
rapidly transfers high-level antibiotic-resistance genes to human pathogens such as E. coli and 
Acinetobacter baumannii (A. baumannii).47 OXA-48 has a broad activity spectrum not only 
against carbapenems but also against penicillins and some cephalosporins (e.g. cefepime, 
ceftazidime or cefotaxime). OXA-48 was first reported in Klebsiella pneumoniae isolate in 
2008, but it has been recently identified in range of Enterobacteriacea.46-49 Serine 






on the active serine residue (Ser 70 according to DBL numbering). The carboxylated Lys73 
residue is believed to activate the catalytic Ser70 residue.49 
The Ser 70 residue acts as a nucleophile and attacks the carbonyl group in the β-lactam 
ring forming a covalent acyl-enzyme intermediate (Figure 5, Inter I), which then forms an acyl-
enzyme complex by breaking the C-N bond. Lys208 stabilizes the hydroxyl group that attacks 
the carbonyl group of the acyl-enzyme complex to form the second tetrahedral intermediate 
(Figure 5, Inter II) leaving the antibiotic inactive.50  
 
Figure 5. Mechanism of action of SBLs against an example of cephalosporin antibiotics. The picture modified 
from Brem et al.50 
2.4.2 Metallo β-lactamases 
MBLs belong to the metallo-hydrolase superfamily.51 All MBLs are described as 
carbapenemases (metallo carbapenemases) as they exhibit enzyme activities against 
carbapenems. Metallo carbapenemases constitute Ambler class B, which shares common active 
site features including either one Zn2+ ion or two Zn2+ ions coordinated by different ligands and 
a hydroxyl ion, all of which are essential for the hydrolysis of the β-lactam ring.52,44 MBLs are 
divided into three subclasses (B1, B2, B3) based on the structure and if they contain one or two 
zinc ions. All three classes contain a common four-layer “αβ/βα” motif, with the active site 
centered in the groove. The active site is in between the “ββ”- sandwich with Zn2+ ion(s), and 
two α-helices on either side.53,54,171 
The mechanism of meropenem hydrolysis by NDM-1 was previously described and 
supported by X-ray structure in a published study on NDM-1.55,56 The hydrolysis mechanism 
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includes the activation of the hydroxyl groups of the hydroxyl group bridging the Zn2+ ions to 
attack the carbonyl group of the β-lactam ring cleaving the C-N bond.57,58After ring cleavage, 
the second Zn2+ ion coordinates to the negative charge on the nitrogen atom and stabilizes it. A 
proton transfer from the bridging hydroxyl group to Asp120, followed by insertion of a water 
molecule into the active site forms complex 2´. Water molecules serve as a proton source 
throughout the catalytic cycle. The nitrogen will then abstract a proton from the water molecule 
in the binding site (Figure 6, complex 3 and 4´), which would eventually lead to the detachment 
of the inactive meropenem and restoration of the active site 1 (Figure 6).56 
 
Figure 6. NDM-1 hydrolysis mechanism of meropenem. 1 and 2 grey spheres represent Zn+ ions. Figure acquired 
with permission from Triphati et al.56 
2.5 Carbapenemase inhibitors 
One of the most successful therapy approaches against BLs is combination therapy. The 
inhibitors combined with the β-lactam antibiotic inactivate the β-lactamase, thus preventing the 
hydrolysis of the antibiotic, making it possible for the antibiotic to reach its target. This method 
of using β-lactam/ β-lactamase inhibitors has proven to be an effective approach to restore the 
efficacy of the β-lactam antibiotic against pathogens producing BLs (e.g. 
ceftolozan/tazobactam, ceftazidime/avibactam, relebactam/imipenem, 
nacubactam/meropenem, vaborbactam/meropenem, ETX2514/sulbactam, VNRX-






vaborbactam and tazobactam have reached clinical use but they are only active against SBLs 
and inactive against MBLs. Despite the efforts of finding new synthetic or natural compounds 
that show in vitro inhibition against MBLs, none of them have reached clinical use.59,1 
The focus of this work was to develop inhibitors targeting various BL inhibitors including MBL 
and SBL inhibitors that especially show activity against carbapenemases VIM-2 (paper II, III), 
OXA-48(paper I). 
2.5.1 Metallo-β-lactamase inhibitors 
There are several compounds that have showed potency against MBLs (Figure 7).160,61,1 
However, there is still no MBL inhibitor that has reached clinical use until now.  
However, recently, a boronic acid-based inhibitor called taniborbactam (Figure 7) has been 
reported as a “pan-spectrum β-lactamase inhibitor”62 against gram-negative bacteria.63,64 It 
showed a wider scope of activity than the clinically approved vaborbactam (Figure 8). 
Taniborbactam is considered a highly potent inhibitor of all four Ambler classes of β-lactamase 
enzymes. It exhibits inhibition activity against both MBLs (e.g. VIM-2) and SBLs (e.g. OXA-
48, KPC-2) in a wide range of gram-negative bacteria. Structurally, taniborbactam is closely 
related to vaporbactam as they both possess a cyclic boronate, while taniborbactam is a bicyclic 
boronate with N-(2-aminoethyl) cyclohexylamine as the side chain (Figure 8). In vitro, 
cefepime/taniborbactam and meropenem/taniborbactam combinations are active against all six 
of the NDM-1-producing clinical isolates from E. coli and K. pneumoniae. 
Cefepime/taniborbactam also passed phase I of the clinical trials.63  
ANT431 is in preclinical trials as MBL inhibitor in combination with meropenem.1 As 
mentioned before, MBLs express resistance by a different hydrolysis mechanism than SBLs. 
MBLs rely on the Zn2+ in their active site to activate the hydroxyl group to initiate the hydrolysis 
mechanism. Therefore, enzyme activity is affected by the availability of the Zn2+ ions to 
deactivate the antibiotic. As a result, blocking the Zn2+ ions by using metal chelators would 
disturb the hydrolysis mechanism and prevent the antibiotic degradation. EDTA is an example 
of a metal chelator inhibitor (Figure 7) that inactivates the active site of MBLs by coordinating 
to the Zn2+ ions and hinders its hydrolysis ability of the β-lactam.65 EDTA has not reached 
clinical use due to its toxicity. Recently, Samuelsen et al. reported a metal chelator ZN148 that 






restore the effect of meropenem against NDM-1.66 Metal chelator inhibitors show activity 
against MBLs including VIM-1, VIM-2, NDM-1 IMP-1,IMP-8, IMP-7, NDM-4.10,67,66  
Thiol-based mercaptocarboxylates (Figure 7) exhibit high potency and broad-spectrum 
inhibitory activity against MBLs (e.g. IMP-1, VIM-4, VIM-2, NDM-1, CphA, etc). For 
instance, 3-(3-mercaptopropionyl-sulfanyl)-propionic acid derivatives were reported as 
covalent and irreversible inhibitors of IMP-1 that restore the activity of mereopenem.68 
Captopril is a thiol derivative that has been studied as broad-spectrum inhibitor against MBLs, 
it has shown better potency against NDM-1, VIM-2 and IMP-1 rather than other MBL 
inhibitors.69 It is also used as a standard to compare the inhibition potency of new inhibitors.70,71 
In addition, bisthiazolidine possessing inhibitors especially those containing a free thiol, a 
carboxylate group or a tetrahedral nitrogen were found to be effective against most MBLs. 
ME1071 is a maleic acid derivative; it showed in vitro activity against carbapenemases with 
less toxicity to animals compared to other MBL inhibitors. ME1071 potentiates carbapenems 
e.g. biapenem against NDM-1, VIM-2 and IMP-1.72 Natural products and fungus extracts have 
also shown activity against MBLs. Aspergillomarasmine A is a fungal natural product that 
shows inhibition potency against VIM-2 and NDM-1.73,74 Biphenyl tetrazoles were described 
as potent inhibitors of CcrA and IMP-1. Triazoles such as triazoleylthioacetamide and 
arylsulfonyl-NH-1,2,3-triazole were described to have inhibition potentiality against VIM-2. 
There are several other inhibitors (e.g. thioesters, trifluoromethyl alcohols and ketones, pyridine 
carboxylates, benzohydroxamic acid etc.) that showed inhibition activity against MBLs. 
Phthalic acid/derivatives have shown to express inhibition activity against the MBL IMP-1.75 
The group of Prof. Leiros reported phthalic acid derivatives to have potential inhibition activity 








Figure 7. Examples of inhibitors against MBLs. 
2.5.2 Inhibitors of serine-β-lactamases with carbapenemase activity 
SBLs rely on the active serine residue (Ser70) to initiate the hydrolysis mechanism of the β-
lactams. In principle, blocking the active serine residue would inactivate the enzyme and 
prevent it from hydrolyzing the drug. Inhibitors accompanied with the β-lactam antibiotic such 
as clavulanic acid and derivatives, tazobactam, sulbactam, avibactam, vaborbactam, 
relebactam, are shown to be efficient in suppressing the resistance mechanism in many 
examples for some SBLs. However, of the aforementioned inhibitors only avibactam, 
vaborbactam, relebactam have inhibition activity against carbapenemases.1,77-78 
The combination between ceftazidime/avibactam was approved by the Food and Drug 
Administration (FDA) in February 2015 for the combination therapy.77 Ceftazidime/avibactam 
combination is active against serine carbapenemases OXA-48 and KPC. However, resistance 
towards ceftazidime/avibactam has already been identified in clinical multi-resistant OXA-
48.79 
Avibactam is a reversible β-lactamase inhibitor that binds covalently to the active serine 













































































to tazobactam, sulbactam, and clavulanic acid. Avibactam exhibits activity against most BLs 
of class A and C such as TEM-1, KPC-2 and extended spectrum β-lactamases (ESBLs) such 
as CTX-M-15.32,80 In addition, avibactam inhibits some of class D enzymes such as OXA-48.80 
Moreover, combinations of avibactam with aztreonam (monobactam) or ceftaroline 
(cephalosporine) were found to show inhibition activity against OXA-48 and OXA-24.27 The 
avibactam/aztreonam combination has reached phase III of the clinical trials, while 
avibactam/ceftaroline has reached phase II of clinical trials.78  
Relebactam (MK-7655) is structurally similar to avibactam (Figure 8), it also shares the 
same spectrum of activity as in the case of avibactam. Imipenem/cilastatin+ relebactam 
combination shows great activity against KPC-2 and restores the efficiency of imipenem. 
Moreover, the combination was approved in July 2019 by the FDA and it is used for the 
treatment of complicated urinary tract infections and intra-abdominal infections.31,67,79,81 
Vaborbactam (RPX7009) is a novel boronic acid-based inhibitor that shows activity 
against SBLs.82 The meropenem/vaborbactam combination was approved by the FDA in 
August 2017 for the inhibition of pathogens producing serine carbapenemases KPC-2, KPC-3, 
KPC-4.83 
Taniborbactam (see also chapter 2.5.1) is a promissing inhibitor of all four Ambler 
classes of β-lactamase enzyme including the carbapenemases OXA-48 and KPC-2 in a wide 
range of gram-negative bacteria. 
Recently, Taylor et al. described the high potentiality of CDD-97 and its derivatives 







Figure 8. Examples of SBL inhibitors. 
2.5.3 Summary of MBL and SBL inhibitors in different development 
stages 
As mentioned before using combinations of β-lactam/ β-lactamase inhibitors has proven to be 
an effective approach to restore the efficacy of the β-lactam antibiotic against pathogens 
producing BLs.1 Inhibitors such as clavulanic acid, sulbactam, avibactam, vaborbactam and 
tazobactam have reached clinical use but they are only active against SBLs and inactive against 
MBLs. However, the avibactam/aztreonam combination has reached phase III of clinical trials 
against MBLs.59,1 Combinations such as VNRX-5133/Cefepime (phase I) and 













































































Table 2. Summary of BL inhibitors.1 





Amoxicillin approved yes - - - - 
Ticarcillin approved yes - - - - 







yes - - - - 
Enmetazobactam Cefipeme Phase II yes - - - - 
Avibactam Ceftazidime approved yes yes yes yes  
Aztreonam Phase III yes yes yes yes yes 
Relebactam Imipenem Phase III yes yes yes   
Nacubactam Meropenem Phase I yes yes yes   
Zidebactam Cefepime Phase I yes yes yes   
ETX2514 Sulbactam Phase II yes yes yes yes  
Vaborbactam Meropenem approved yes yes yes yes  
VNRX-5133 Cefepime Phase I yes yes yes yes yes 
ANT431 Meropenem preclinical - - - - yes 
– no useful inhibitory activity shown; DBO, diazabicyclooctanone analogue; ESBL, extended-spectrum 
β-lactamase; MBL, metallo-β-lactamase, carbapenemases (green). 
2.6 Fragment based drug discovery (FBDD) 
In drug discovery campaigns, the identification of lead compounds can be achieved through 
one of the two major approaches: high-throughput screening (HTS) or fragment-based drug 
discovery (FBDD).85  
HTS is based on screening a large collection of drug-like compounds that follow the 
Lipinski’s rule of five,86,87 (i.e. the compounds should have ≤ 5 hydrogen bond donors (N-H 
and O-H bonds), ≤ 10 hydrogen bond acceptors (N, O atoms), molecular weight of ≤ 500 Da 
and an octanol-water partition coefficient (log P) ≤ 5) against a predefined drug target with the 
goal to find potent hits with activity in the low millimolar to nanomolar range. HTS has been 
successfully used in identifying novel inhibitors against MBLs.88–90 One disadvantage of the 
HTS approach is that it can result in misleading information concerning inhibition and binding. 
In the case of large-sized compounds as the space in the binding site is restricted, they are 
prevented from binding efficiently to several different residues. In this way the inhibition might 






In contrast, FBDD91 is based on the screening of a library of smaller compounds -
fragments- that follow the rule of three (i.e. they have molecular weight < 300 Da, ≤ 3 hydrogen 
bond donors/acceptors, and CLogP below 3) in order to find efficient binders with a high 
possible binding efficiency.92 Using smaller compounds increases the chance to detect binding 
possibilities as the smaller size makes the compound more flexible to the binding pocket when 
compared to larger compounds (Figure 9). A well-established value to evaluate the binding 
efficiency of fragments is their ligand efficiency (LE), which is a measure of the binding energy 
per heavy atom in the fragment. The higher the LE-values the better as it is recommended that 
good hits should have LE in the range of 0.3-0.4 kcal/(mol atom).93 The LE can be obtained 
from half maximal inhibitory concentrations (IC50) (or the dissociation constant (Kd)) according 
to the following formula(s): 
∆G = -RT ln(Kd) 
LE = ∆G /N, where N= # of non-hydrogen atoms 93 
LE = 1.4 (-log (IC50))/N 94 
 
 
Figure 9. HTS hit (A) versus FBDD hit (B). Adapted from frontiers in chemistry, in silico strategies to support 
fragment to Lead optimization in Drug Discovery, Neto et al. Copyright (2020), open access.95 
A challenge in FBDD is that the fragments bind only weakly to the enzymes (IC50 in the micro- 
or millimolar range), thus each atom of the fragment has to contribute to the overall binding of 
the fragment to be detected. Another challenge with fragments is the unspecific binding of 
fragments and pan assay interreference compounds (PAINS), which can be solved by using 
orthogonal assays, such as the combination of surface plasmon resonance (SPR) and a 
biochemical assays to identify false positive results.76,96 
Fragments most likely do not have the required potency to be considered as a lead 






information of the fragment in complex with the targeted enzyme are needed to give insight 
into possible interactions in the binding site. This process is called structure-based drug design 
(SBDD) and it relies on the available information about the 3D structure of the drug 
target.85,92,97 The 3D structure of the drug target can be mainly obtained through experimental 
approaches such as X-ray crystallography or nuclear magnetic resonance spectroscopy 
(NMR).98,99 With the structural information in hand, it would be possible to predict the 
necessary characteristics for binding and use this information to evolve the fragments to drug 
candidates of high potentiality to bind to the drug target with higher affinity.85 Fragments 
evolution can be achieved by several approaches:97  
Fragment-growing: It employs modification of the fragments by adding more groups 
in order to increase the size of the fragments without losing binding efficiency (Figure 10. A). 
This approach was the aim of papers II and III. 
Fragment-linking: With the help of the structural information of the inhibitor/enzyme 
complex, if several fragments that bind in adjacent binding sites can be identified, those 
fragments can be chemically connected to form a new optimized ligand with better binding and 
higher potency (Figure 10. B).  
Fragment-merging: This approach is very useful if there are two identified binding site 
and their ligands are competing for the chemical space or if there are two different fragments 
that partially occupy the same site. In either of the cases, overlaying structures of the two 
fragments helps bring the dissimilar parts together and design a new potent fragment towards 
drug like compounds (Figure 10. C). We applied this approach in paper I to optimize fragments 







Figure 10. Different approaches towards fragment optimization. Adapted from frontiers in chemistry, in silico 
strategies to support fragment to Lead optimization in Drug Discovery, Neto et al. Copyright (2020), open 
access.95   
The advantage of the FBDD approach is that it allows for lead optimization to detect the 
chemical space with compounds of high development potentiality within the rule of 5, required 
for identifying lead compounds. Moreover, it allows for more hydrophilic hits that can enhance 
the affinity via the accessible hydrogen bonding. The fragments identified by FBDD can be 
optimized further to acquire drug-like properties such as solubility properties, high potency, LE 
and the size of the compound.100  
FBDD was first employed successfully against kinase targets.101,102 However, it is now 
being applied against a diversity of targets. Zelboraf (a drug for the treatment of late-stage 
melanoma) was the first FDA approved drug developed by FBDD.103,104 In addition, FBDD is 
proven to be a successful approach to develop drugs against both SBLs and MBLs. Chen et al. 
identified micromolar-range noncovalent inhibitors including thiol derivatives and 
dicarboxylates against class A β-lactamases using FBDD approach.105 Moreover, Nicholas et 
al. have modified polycarboxylic acids-based fragments that are considered to be a starting 
point to target SBLs (class A and D) using FBDD (Table 3. entry 1).106  
The group of Prof. Leiros has utilized surface plasmon resonance to identify potent 
inhibitory fragments against both serine- and metallo-carbapenemases (chapter 4.1 and 5.1). 
Christopeit et al. reported inhibitory fragments targeting the MBLs NDM-1 and VIM-2,14,107,76 






(chapter 5).13 Lund et al reported 3,5-disubstituted benzoic acid/ derivatives scaffolds against 
SBLs (OXA-48) using FBDD.15  
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3. Relevant reactions 
 
During the course of our research project on the synthesis of fragment libraries towards a new 
line of carbapenemase inhibitors (OXA-48 and VIM-2), reliable synthetic methods for 
preparing the designed fragment libraries were required.   
 Reactions relevant to the work presented in this thesis are: 
• Suzuki-Miyaura coupling (SMC): used for the preparation of 3,5-disubstituted benzoic 
acids and acid derivatives as inhibitor scaffolds against the SBL OXA-48 (chapter 4). 
• Carbonylative Suzuki-Miyaura coupling: used for the preparation of 2-aroylbenzoic acids 
and acid derivatives as inhibitor scaffolds against the MBL VIM-2 (chapter 5 & 6). 
• Reaction for the preparation of 2-aroylbenzoic acids derivative (chapter 5 & 6). 
• Aminocarbonylation & Alkoxycarbonylation: used for the preparation of primary and 
secondary amides and carboxylic esters as inhibitor scaffolds against MBL VIM-2 (chapter 
5 & 6). 
• The aforementioned reactions have been used as reaction models to test a new series of 
sustainable solvents aiming to find optimized conditions for the preparation of inhibitor 
scaffolds against MBL VIM-2 (chapter 6). 
3.1 Palladium catalyzed C-C couplings - Suzuki-Miyaura 
reaction (SMC) 
Palladium catalyzed couplings are a powerful tool for advanced chemical synthesis of C-C 
bonds for both academic and industrial applications. Negishi, Heck and Suzuki-Miyaura 
couplings are examples of the most commonly used palladium catalyzed reactions.108 However, 
Suzuki-Miyaura coupling is extensively studied. The used boronic acids are generally nontoxic 
and thermally and moisture stable, which is an advantage over other cross-coupling reactions 
that include toxic additives and metals. Negishi couplings require the use of air and moisture 
sensitive organozinc compounds as the nucleophile, which makes the reaction relatively 
intolerant to functional groups in comparison to the Suzuki-Miyaura coupling.108,109 The main 








Scheme 1. Common palladium catalyzed cross-coupling reactions. 
General mechanism of palladium catalyzed C-C cross-couplings 
Palladium activation of Ar-X is commonly used for selective and specific formation of new C-
C bonds in Suzuki-Miyaura coupling by coupling with the corresponding nucleophile. The 
reaction mechanism is similar to most of the cross-coupling reactions. The main difference is 
the choice of the transition metal. Considering the Suzuki-Miyaura coupling as an example of 
general palladium cross-coupling, the reaction mechanism proceeds via a three steps catalytic 
cycle (Scheme 2). The first step is oxidative addition of the organohalide to the active Pd0 
species forms complex A (X-LnPdII-Ar). Electron-rich ligands are favored, as it gives an 
electron-rich metal center that facilitates the oxidative addition. The reactivity of organohalides/ 
pseudo-halides in C-C couplings varies with respect to the bond dissociation energy of the R-
X (I > OTf > Br >Cl > OTs > OAc). The second step in the catalytic cycle is transmetalation 
with the nucleophile in presence of a base to from complex B. Different nucleophiles can be 
introduced in this step based on the type of couplings e.g; boronic acids and derivatives, 
organozinc or -tin reagents, etc. After the two organic groups are coordinated to the PdII 








































reductive elimination. This could be assisted by bulky ligands to furnish the coupled product C 
and to restore again the active Pd0. 
 
Scheme 2. General reaction mechanism for the Suzuki cross-coupling reaction. 
The impact of the reaction components on the reaction rate 
The nature of the coupling partners has a significant influence on the reactivity. It is known that 
palladium cross-coupling reactions can be selective in favor of less sterically hindered and 
electronically more deficient position of the electrophile (Ar-X).111–113 Aryl iodides are more 
active in oxidative addition to Pd0 center than their corresponding bromides and chlorides. 
Oxidative addition of iodobenzene with Pd(PPh3)4 could occur at room temperature while  
heating is required for bromobenzene to undergo oxidative addition. This is the reason for using 
additives such as NaI in reactions including aryl bromides to facilitate oxidative addition step 
by forming in situ aryl iodides. Electron-rich and bulky ligands such as P(t-Bu)3, Buchwald 
phosphine-based ligands, carbene ligands are used for couplings of less reactive aryl bromides 
and chlorides.120,121,116 For instance, coupling of 2,6-di-substituted aryl halides and aryl boronic 
acid was obtained in 91% yield using Pd2(dba)3 and a Buchwald ligand X-Phos122 (Scheme 3). 
 













































The difference in reactivity for example in di-haloaryls can be advantageous as it can lead to 
chemo- or regioselectivity in cross-coupling reactions. There is also reactivity difference 
between transmetalating agents. For example, electron deficient boronic acids or protected 
boronic acids are less reactive than electron rich unprotected boronic acids.  
Chemo- and regio-selectivity in Suzuki-Miyaura coupling 
Over the last decades many catalysts and ligands have been designed and tested in several 
palladium catalyzed cross-couplings. The achievements in this area are related to the design 
and development of ligands that not only promote the catalytic transformation but also provide 
both regio-, chemo- and enantioselective control over the reaction.114  
Regioselectivity of substrates where two of the same halo group are present for coupling 
can be achieved by catalyst control.117,118 Houpis and coworkers reported the regioselective 
coupling reaction of 2,4-dibromobenzoic acid with 4-tolylboronic acid, where the reaction gave 
excellent regioselective coupling at the ortho position in 80% yield when using Pd2(dba)3. On 
the other hand, using the bulky bidentate DPEPhos as a ligand together with Pd(OAc)2 reversed 
the selectivity and the 4-tolyl-2-bromobenzoic acid was formed in 68% yield (Scheme 4).119 
 
Scheme 4. Regioselective Suzuki-Miyaura coupling reaction of 2,4-dibromobenzoic acid with 4-toly-boronic acid. 
An example showing the chemoselectivity is the reaction of 4-chlorophenyl triflate with 2-
methylphenyl boronic acid using two different Pd catalysts, while using the same ligand. 
Pd(OAc)2 and PCy3 gave selective coupling at the triflate position and the product was obtained 
in 87% yield, while using Pd2(dba)3 and PCy3 gave the selective coupling on the chloride 
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Scheme 5. Chemoselective cross-coupling of 4-chlorophenyl triflate with 2-methylphenyl boronic acid. 
Selective Suzuki-Miyaura coupling on di-haloaryls are also considered challenging due to the 
high chances of obtaining mixtures of different coupling products in symmetrical or 
unsymmetrical fashion that might be hard to separate. The key in this process is tuning the 
reaction condition to allow the coupling of only one of the two halogens and result in 
monosubstituted product without affecting the other possible coupling position. For instance, 
using less equivalency of the boronic acid, low temperature, less catalyst loading or by changing 
the nature of the solvent. 
Langer et al. reported chemo and site selective Suzuki-Miyaura coupling on 4-bromo-
2,3,5-trichloro-6-iodopyridine.112 Selective coupling on the active C-I on the 6-position 
occurred using only 1.5 equivalents of the boronic acid, K3PO4 (1.5 equiv.) and Pd(PPh3)4 in a 
solvent mixture of toluene, ethanol and water (6:1:1) (Scheme 6). Although a slight drop in 
yield in case of electron-poor arylborinc acid, the reaction still showed high degree of 
chemoselectivity at position 6. It was also shown that switching the catalyst system to a more 
reactive catalyst Pd(OAc)2 and PCy3 gave 4,6-biarylated compounds as the main product where 
the chemoselectivity on iodide was lost and the reaction occurred on both C-I and C-Br. 
Furthermore, increasing the amount of the base and boronic acid in addition to using more 
active catalyst (Pd/PCy3) allows the chemoselective diarylation of pyridine on both C-I and C-
Br. Although the less active C-Cl stayed unreacted under these conditions, traces of triarylated 
pyridine was observed. This indicated that increasing the amount of the boronic acid and the 
base could lead to highly arylated pyridine. Tuning the reaction conditions could allow for high 
degree of selectivity, which makes it a very useful tool for the synthesis of unsymmetrically 
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Scheme 6. Chemoselective SMC on 4-Bromo-2,3,5-trichloro-6-iodopyridine. 
In some cases, the choice of the solvent can strongly influence the chemoselectivity of the 
reaction. This is illustrated by the selectivity of Suzuki-Miyaura coupling on chloroaryl triflate 
with o-tolylboronic acid (Scheme 7). The reaction using Pd2(dba)3 and P(tert-Bu)3, as catalytic 
system showed reactivity towards the chloride (95%) when using non-polar solvents such as 
toluene. In case of polar solvents such as MeCN and DMF the reactivity was opposite and the 
coupling occurred on the triflate (C-OTf) instead (74%).123,116 This observation is explained by 
the hypothesis that polar solvents stabilizes the charged palladium species. A follow up study 
by Sharon et al. demonstrated that the SMC selectivity on the triflates using Pd/P(t-Bu)3 does 
not generally follow the claimed trend using polar solvents.124 Selectivity on C-OTf is only 
limited to few coordinating solvents such as NMP, DMF, MeCN, DMSO. On the other hand, 
reactivity on the C-Cl was observed with other polar solvents (H2O, MeOH, iPrOH, etc.) as 
with non-polar (toluene, dioxane, etc.) solvents. This observation is related to solvent role 
where it does not only dissolve the reaction component into a homogenous mixture but also 
influences the reaction kinetics by stabilizing charged intermediates in the catalytic cycle.  
 
Scheme 7. Solvent effect on the chemoselectivity of arylchloride triflate. 
3.2 Palladium catalyzed carbonylative transformation of aryl 
halides 
Palladium carbonylative couplings covers many closely related reactions that incorporate CO 
into a substrate by adding it into an aryl-, benzyl- or vinylpalladium complex in the presence of 
various nucleophiles.125 It is a very important tool for a wide range of synthetic transformations 
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and acid derivatives, amides, etc (Scheme 8).126 Based on the type of the nucleophile, the 
transition metal catalyzed carbonylation can be carbonylative Suzuki-Miyaura cross-coupling, 
aminocarbonylation and alkoxycarbonylation (Scheme 8. A, B, C respectively). The reaction 
can occur intermolecularly and/or intramolecularly, which allows a wide application of the 
reaction. Intramolecular carbonylation enables the synthesis of heterocyles for instance, alkoxy- 
or aminocarbonylation of hydroxy or amino-substituted aryl/vinyl halides enables the synthesis 
of lactones, lactams, oxazoles, thiazoles, imidazoles, and other heterocycles.127,128,125 
 
Scheme 8. Examples of palladium catalyzed carbonylation reactions.126 
Palladium catalyzed carbonylation reaction (Scheme 9. cycle B) is mechanistically similar to 
the non-carbonylative one (Scheme 9. cycle A) as it consists of the same basic steps; oxidative 
addition, transmetalation, and reductive amination. It consists of an extra step, which is the 
coordination and the insertion of the CO after the oxidative addition forming the acylpalladium 
intermediate (Scheme 9, complex 2). In general, the aromatic halides (ArX) react with an 
appropriate nucleophile in the presence of catalytic amounts of a palladium complex in carbon 
monoxide atmosphere, where the leaving group X (e.g. I, Br, Cl, OTf, etc.) is replaced by the 
nucleophile with incorporation of the CO molecule(s) (Scheme 9, cycle B).129 The reaction 
often take place at 60–140 °C under 5–60 bar of CO, and may also require a stoichiometric 
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Several factors make it challenging to find suitable catalytic systems and reaction conditions 
for carbonylative couplings. For instance, in carbonylative Suzuki-Miyaura coupling, it is very 
challenging to find a catalytic system and reaction condition to favor the carbonylative reaction 
over the competing non carbonylative reaction. The oxidative addition can favor electron-rich 
metal center in carbonylative coupling reactions.130,126 However, the CO insertion favors an 
electron-deficient metal center.126 On the other hand, reductive elimination can be assisted with 
bulky ligands, while CO insertion requires less bulky ligands. In addition, elevated 
temperatures could be advantageous in favor of oxidative addition, while it could lead to 
decarbonylation of the acylpalladium after CO insertion.128,130-132 Therefore, the success of the 
optimal catalyst/ligands depends most likely on the individual substrates, CO pressure and 
reaction conditions.  
 
Scheme 9. General mechanism of non-carbonylative cross-coupling (A) versus carbonylative cross-coupling (B). 
The product of the carbonylation reaction is dependent on the rate of the CO insertion, which 
should be faster than other processes like transmetalation in order to obtain the carbonylated 
product (Ar-CO-Nu) rather than the non-carbonylated by product (Ar-Nu).133 This could be 
achieved by altering the other reagents by carefully choosing their functionalities or 
concentration by slow addition.133 On the other hand, using CO in high pressure might increase 
the CO insertion rate and thus favor the carbonylative product rather than other by-products 
















































overcome these problems the result might be opposite to the intended one as the palladium 
atoms could cluster and agglomerate forming the nonactive palladium black.134 The Pd0 
reactivity towards oxidative addition could be negatively influenced by the strong binding 
ability of the CO. This is because CO is a good p-acceptor and would receive electrons from 
the metal center to form a p-back bond.130 
All these factors could interrupt the catalytic transformation in one way or another. However, 
a possibility to overcome this problem is to use electron-rich ligands. Generally, ligands with 
strong s donor ability might prevent the direct coordination between Pd0 and the CO.130 Wide 
range of powerful ligands have been developed to accelerate many of the carbonylative 
reactions.135,136,137 The achievement in this area did not only include the most studied phosphine 
ligands (monodentate and bidentate) but also included NHC and other nitrogen and thiourea 
ligands (Figure 11).130,136,138 
 

























































Use of CO gas and potential CO sources 
The installation of the carbonyl group can be achieved by using CO gas. Despite the hazard 
related to the handling of the toxic, corrosive, and high flammable CO gas, it is widely used as 
an available and important C1 building block.129 Synthetic transformations using gaseous 
reagents as CO are commonly performed in autoclaves under high pressure or under 
atmospheric pressure using a balloon. Safety equipment is necessary to reduce safety concerns 
when handling CO. However, it is commonly used in research and industrial process due to its 
availability and low cost.  
Alternatively, safer sources of CO including transition metal carbonyl complexes (e.g. Cr(CO)6, 
W(CO)6, Co2(CO)8, Mo(CO)6)139, carbamoylsilane140, oxalyl chloride141, formats142, aldehydes 
in addition to in situ decarbonylation protocols have been developed.143,144 The use of these 
carbonyl complexes introduces potential byproducts from the CO surrogate, which interrupt or 
get mixed with the desired product and complicate workup and isolation.145 Moreover, they 
could potentially inhibit the possibility of developing novel carbonylative transformations. 
Skrydstrup and coworkers have developed a two-chamber system setup for in situ generation 
of CO from stable solid CO precursors, 9- methylfluorene-9-carbonyl chloride (COgen), which 
releases CO once activated by Pd catalyst or methyldiphenylsilacarboxylic acid (SilaCOgen), 
which is activated by adding fluoride (Figure 12).146 The carbonylation reaction takes place in 
one chamber, while the other chamber is used for the CO release. CO releases upon treating the 
stable acid chloride (COgen) with tri-tert-butylphosphine ligated Pd catalyst and amine base in 
an aprotic solvent. The CO gas release is proven to be almost quantitative as illustrated 
throughout the wide synthetic applications using COgen as the carbonylating agent.146  
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Despite COgen being an expensive source of CO and requiring the use of two chamber systems, 
it gives access to stoichiometric amounts of CO for many low pressure carbonylation reactions 
in a safer fashion than other CO sources. In addition, being a stable solid makes it convenient 
to handle in the lab. Releasing the CO in another chamber than the carbonylation reaction 
chamber prevents problems such as formation of undesired by-product, separation problems 
etc. Moreover, this method allows introducing isotopically labelled CO by using labelled 
COgen.146–148  
3.2.1 Carbonylative Suzuki-Miyaura coupling  
The carbonylative version of the SMC reaction has been investigated using different Pd-based 
complexes/catalysts and reaction conditions. However, most of the literature on this particular 
cross-coupling requires high CO pressure protocols except few reports applying carbonylation 
at atmospheric pressure.129,149,132 
 
Scheme 10. General presentation of Suzuki-Miyaura coupling. 
The common problem with this reaction lies in the formation of biaryl products, which results 
from the competing direct SMC coupling without carbon monoxide insertion. Nevertheless, the 
reaction conditions including nature of the palladium catalyst precursor, ligand, base, additive 
as well as the nature of the substrates (aryl halide and boronic acid), influence the ratio of ketone 
to direct coupling product.  
Suzuki and coworkers described the palladium carbonylative SMC where they synthesized a 
variety of diaryl ketones from aryl iodides and boronic acids in high yields using PdCl2(PPh3)2 
and K2CO3 as a base in anisole (Scheme 11).129 The choice of both base and solvent played an 
important role to obtain the desired ketone with minimum formation of biaryls as by-product. 
A range of bases; K2CO3, Cs2CO3, Tl2CO3, K3PO4 were tested in anisole to test reaction 
selectivity towards carbonylative coupling reaction versus non carbonylative one. Tl2CO3 gave 











BYn = B(OH)2, B(OH)3Na, DABO boronate,…








24% biaryl by-product. On the other hand, K2CO3 in anisole was very efficient to yield the 
desired biaryl ketone in 84% yield, while it gave only 11% of the biaryl by-product. 
 
Scheme 11. Carbonylative Suzuki-Miyaura coupling of aryl iodides and boronic acids. 
Skrydstrup coworkers tested several carbonylative Suzuki-Miyaura coupling of 1-(4-
iodophenyl)ethan-1-on with phenylboronic acid using low CO pressure and a range of Pd 
sources resulted in different ratios between biaryl ketone and biaryl (Table 4, 23, 24, 
respectively).149 The phosphine based Pd(dba)2 and PdCl2 were shown to be favoring the 
carbonylative coupling over the direct coupling (Table 4, entry 2, 4 respectively). It is 
noteworthy that increasing the catalyst loading to more than 1% increased the chance of 
obtaining the undesired biaryl product. The best selectivity towards the desired biaryl ketone 
was obtained using ligand free system based on PdCl2 and K2CO3 in anisole under CO (1 atm). 
A range of substituted biaryl ketones was obtained in moderate to high yield (50-93%). 
Table 4. Selected examples of different palladium sources used in carbonylative SMC. 
 
Entry Pd cat (mol %) Ratio 
23:24 
1 Pd(OAc)2 1 mol% 69:31  
2 Pd(dba)2 1 mol% 71:29 
3 Pd(TFA)2 1mol% 58:42 
4 PdCl2 1mol% 95:5 
 
Bhanage and coworkers reported Pd(tmhd)2 as a catalyst for carbonylative Suzuki-Miyaura 
coupling of aryl iodides with arylboronic acids in anisole under 8 bars of CO. Although the 
reaction gave access to a range of biaryl and heteroaryl ketones in moderate to high yields it 
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still lacks wider scope with respect to ortho substituted aryls and electron-withdrawing groups 
in addition to the required high pressure.150 
The use of carbene ligands and thiourea based ligands has drawn a keen interest in 
carbonylative Suzuki-Miyaura coupling especially with sterically hindered substrates.151 Keffe 
et al. reported the use of NHC palladium complex PEPPSI-iPr in the synthesis of sterically 
hindered biaryl ketones in moderate to high yields (Scheme 12).132 
 
Scheme 12. Suzuki-Miyaura coupling of ortho-disubstituted aryl iodide with NHC catalyst. 
Despite the achievements in this area, coupling of aryl bromides are still challenging especially 
in case of ortho substituted aryl bromides, which is noticeable in many of the published reports. 
Only few methods were successful for carbonylative coupling of aryl bromides and 
chlorides.152,153 The carbonylative Suzuki-Miyaura coupling of aryl bromides and chlorides 
typically requires harsh conditions such as high temperature, high CO pressure and longer 
reaction time in comparison to their corresponding aryl iodides. Additives such as NaI, KI 
would enhance the reaction rate as it might involve in situ generation of aryl iodides and thus 
faster oxidative addition.129 
Coupling of aryl bromides with aryl trihydroxyborates or DABO boronate using 
Pd(acac)2 and the phosphine ligand catacxium A.HI as a ligand in toluene under CO (1 atm) 
gave access to a range of substituted biaryl ketones in moderate to high yields (Scheme 13).153 
Unfortunately, these conditions also showed several limiting factors, as they gave poor yields 
with electron-withdrawing groups and they did not support ortho substituted aryls as they have 
low conversion. In addition, an additional step is required for the preparation of the boronic 
acid derivatives.153 
 


















Pd(acac)2  (5 mol%)















Another catalytic system was reported by Beller and coworkers using CataCXium A as a ligand 
together with Pd(II)acetate to access a wide range of biaryl and heteroaryl ketones. Although 
the reaction showed good tolerance of both electron-rich and electron-deficient aryl halides and 
boronic acids, it required high CO pressure in case of aryl bromides with electron-withdrawing 
groups (2.5-5 bar).152 
3.2.2 Aminocarbonylation  
Amides are considered to be one of the most important functional groups in chemistry, they are 
essential in many biological process and chemicals required for sustaining life. Amides are 
normally found in many natural products, linking amino acids in proteins such as enzymes, they 
are also found in many medicinal and pharmaceutical products. Different synthetic approaches 
towards amides require stoichiometric amounts of amide-coupling reagents, which make it an 
expensive and wasteful procedures. On the other hand, palladium-catalyzed 
aminocarbonylation of aryl or heteroaryl halides give a direct access to the corresponding 
carboxamides.137,139,157–159 
 
Scheme 14. General aminocarbonylation reaction. 
The use of primary or secondary amines as the nucleophile under catalytic conditions will 
provide the desired amide following a similar catalytic cycle as the carbonylative cross-
couplings with differences in the last steps. One possibility for the amine (nucleophile) to 
approach the catalytic cycle is that it could coordinate to the palladium followed be reductive 
elimination to obtain the amide. Another possibility, which is believed to be the dominant route, 
is nucleophilic attack on the acylpalladium carbonyl.160 
Since common catalytic systems for aminocarbonylation showed good tolerance to a 
wide range of functional groups, it is considered to be a versatile method in organic synthesis 
to access amides with a variety of N-substituents. It has been applied for the synthesis of 
molecules of medicinal interest such as lotrafiban, itopride, bromopride and butoxycaine.161–164 
For example, the key step in the synthesis of lotrafiban is the aminocarbonylation step of the 
X
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aryl iodide and the amine using PdCl2(PPh3)2 in anisole for 2.5 h under 1 atm of CO pressure 
to furnish the desired amide (Scheme 15).161 
 
Scheme 15. Aminocarbonyation towards synthesis of lotrafiban. 
Moreover, aminocarbonylation can be used for the synthesis of ferrocene based chiral ligands 
that are used in asymmetric catalysis.165 For instance, the synthesis of asymmetrically 
disubstituted ferrocenbiscarboxamide (Scheme 16) was obtained via aminocarbonylation 
between symmetrical ferrocenyl di-iodide with morpholine and diethylamine under high CO 
pressure (40 atm) yielding the desired asymmetric ligand in 85%.166 
 
Scheme 16. Aminocarbonylation for the synthesis of asymmetrically disubstituted ferrocenebiscarboxamide. 
Weinreb amides are also accessible via aminocarbonylation under mild conditions. Buchwald 
and coworkers reported the synthesis of Weinreb amides from a wide range of electron-rich 
and electron-deficient aryl and alkenyl halides using Pd(OAc) and Xantphos under 1 atm CO 
pressure to furnish the desired amide in moderate to excellent yields (Scheme 17).167 
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3.2.3 Alkoxycarbonylation  
Alkoxycarbonylation is an important method for the synthesis of esters. Different alkyl and aryl 
halides were converted into their corresponding carboxylic esters in presence of transition metal 
complexes and the corresponding alcohol under CO pressure (Scheme 18). Installing the 
carboxylic acid/ester into aryl/alkyl halides is a very attractive tool for late stage 
functionalization and C-C bond formation.  
 
Scheme 18. General transformation of aryl or vinyl halide into their corresponding esters via alkoxycarbonylation. 
Alkoxycarbonyltion follows a similar mechanism as aminocarbonylation where the nucleophile 
is the alcohol or metal alkoxides instead of the amine to form esters. Alkoxycarbonylation e.g. 
methoxycarbonylation are widely described including both inter- and intramolecular 
reactions.168,169,134,170 Intramolecular alkoxycarbonylation of pendant alcohol leads to the 
formation of five, six, and seven membered ring lactones.175 
Buchwald and coworkers reported methoxycarbonylation of a range of aryl bromides 
under low CO pressure (1 atm) using 2 mol% Pd(OAc)2, 4 mol% Xantphos and 10 equiv MeOH 
at 70 °C for 24 h. The reaction gave access to a range of methyl esters with various function 
groups such as aryl nitriles, fluorides, ethyl ether, tert-butyl carbamate, in high yields (80-91%). 
However, scope limitations were described due to low reaction temperature.176 
A variety of methods for the transition metal catalyzed alkoxycarbonyltion of aryl 
halides, tosylates and triflates has been described.177,172 Lou et al. reported the synthesis of N-
hydroxysuccinimido esters from aryl iodide or triflates using Pd(OAc)2 and Xantphos in DMSO 
under 1 atm CO (Scheme 19).177 In addition, Angelina et al. reported also the synthesis of N-
hydroxysuccinimido esters together with active esters from pentafluorophenol, 
hexafluoroisopropyl alcohol, p-nitrophenol and N-hydroxyphthalimide from aryl bromide in 
excellent yields (59-99%) using 3 mol% (Pd(cinnamyl)Cl)2 , HBF4P(tert-Bu)3 (6 mol%) and 















Scheme 19. Synthesis of N-hydroxysuccinimido esters via alkoxycarbonylation. 
Palladium catalyzed alkoxycarbonylation has been performed with the inactivate alkyl halides 
such as inactivated secondary alkyl bromides and alkyl chlorides, which are challenging 
substrates that require harsh conditions, high CO pressure in comparison to more active alkyl 
iodide. Alexanian and coworkers, reported esterification of less active alkyl bromides to the 
corresponding tert-butyl ester version using Pd(PPh3)Cl2 and IMes as a ligand under CO 
pressure of only 2 atm at 50 oC in DMSO, which are milder conditions for this type of reactions 
(Scheme 20). The reaction was tolerant to a variety of function groups such as silyl protecting 
group, esters, five and six membered carbocycles and heterocycles and gave good results with 
alkyl possessing both electron-deficient and electron-withdrawing group with yield range of 
50-87 %. Using carbene ligand (IMes) in this case shown to facilitate the reaction in 
combination with Pd(PPh3)Cl2. Being able to perform this reaction on the stable alkyl bromide 
makes it useful as late stage C-C bond formation.170 
 
Scheme 20. tert-Butyl ester from deactivated alkylbromides. 
Alkoxycarbonylation can be also done using metal alkoxide (e.g. EtONa, tert-BuONa, etc) 
instead of the direct use of the corresponding alcohol. This approach ensures presence of the 
nucleophile in the reaction medium and prevent volatile alcohols (e.g. MeOH, EtOH, etc) from 
escaping the reaction mixture.171,178 Skrydstrup and coworkers reported alkoxycarbonylation of 
aryl bromides into their tert-butyl ester using Pd(dba)2 and DiPrPF under 1 atm of CO pressure 
in THF (Scheme 21). The reaction showed great results with more bulky tertiary alcohols such 
as the sodium adamantoloxide and sodium 9-methyl-9-fluorenoxide, which indicates bulky 
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less bulky alcohols such as sodium methoxide were not successfully used as nucleophiles in 
this reaction.171 
 
Scheme 21. Alkoxycarbonylation of aryl bromide using bulky sodium alkoxides. 
3.3 Reactions for the preparation of 2-aroylbenzoic acid 
derivatives 
2-Aroylbenzoic acids and derivatives have gained noticeable interest as synthetic intermediates 
for accessing bioactive compounds. and they were the aim of the work presented in paper II. 
Only few reported methods towards formation of 2-aroylbenzoic acids are found in literature, 
comprising Friedel-Craft acylation,154 Pd-catalyzed ortho-C–H activation of aryl amides 
followed by coupling with aryl aldehydes,155 Pd-catalyzed ortho-C–H activation of benzoic 
acids followed by decarboxylative coupling with α-oxocarboxylic acids.156 The available 
methods generally show limitation regarding regiocontrol and/or substrate scope especially 
with regard to electron-deficient aryl groups.  
Ge and coworkers reported the synthesis of a range of substituted 2-aroylbenzoic acids 
in moderate yields through chemoselective decarboxylative cross-coupling of benzoic acids via 
C-H bond functionalization with α-oxocarboxylic acid as the coupling partner. The reaction 
required the use of harsh conditions including use of an excess of the oxidant (Ag2CO3), high 
catalyst loading (10 mol%), the elevated temperatures (120-150 oC) and extended reaction time 
up to 48h (Scheme 22). Moreover, the substrate scope suffered from some limitations especially 
with electron withdrawing groups that were not well tolerated under these conditions.156 
 
Scheme 22. Chemoselective decarboxylation cross-coupling of benzoic acids via C-H bond functionalization. 
Another method to access 2-aroylbenzoic acids via C-H activation directed by aryl amides that 
would undergo ortho acylation followed by ring closing to form amide containing four-member 
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then would be submitted to reflux in concentrated aqueous HCl in order to obtain the 2-
aroylbenzoic acids. The reaction had a limited substrate scope, where functional groups like 
esters, nitriles, imines, etc. were not tolerant, due to the harsh acidic conditions required to 
eventually obtain the ketone form of the imino-aryl.155 
 
Scheme 23. C-H activation of aryl amides to form 2-aroylbenzoic acids. 
3.4 Solvent effect and sustainability 
The growing awareness of the impact of chemical process, e.g. solvent use on the environment 
and their contribution to the climate change, has resulted in an increasing interest in both 
research and industry in finding sustainable alternatives.181 Sustainable alternatives are needed 
for media to perform reactions as well as for work-up and purification, catalysts and energy 
sources. Sustainability has been previously described as “resources including energy should be 
used at a rate at which they can be replaced naturally and the generation of waste cannot be 
faster than the rate of their remediation.” 181 This description coincides with the definition by 
the world commission on environment and development stating that sustainability is 
“development that meets the needs of the present without compromising the ability of future 
generations to meet their own needs”.181 A noticeable success has been achieved in the synthesis 
of new products since 1990s when the twelve principles of “green chemistry” were 
formulated.182,183 These principles are considered to be the guidelines that chemists in both 
academia and industry try to follow while carrying out chemical reaction in a sustainable 
fashion. Despite the difficulties following all the twelve principle for preparative purposes, 
chemists and industries have already made noticeable moves towards sustainability by 
considering the key principle of green chemistry.  
The solvent may perform a mechanical role in the mechanism, but sometimes it plays 
also an essential role of bringing the immiscible reactants together rapidly so that the reaction 
could occur. In addition to dissolving reactants, the solvent can participate in several ways to 
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and produce different products.179-184 It might interact with the reactants individually or get 
involved in the transition state.180,181   
Many of the organic solvents that are commonly used in organic synthesis and post 
reaction processes are with poisonous and carcinogenic nature such as halogenated 
hydrocarbons (DCM, CHCl3, CCl4, etc.). This type of solvents has created serious harm to the 
environment and human health in general. However, two of the twelve principles of green 
chemistry are based on usage of safer solvent and reaction conditions and to prevent waste. One 
principle is “Safer Solvents and Auxiliaries” where the use of auxiliary substances such as 
solvent and separation agents are not favorable and should be decreased. The other principle is 
“use of renewable feedstock” where raw materials or feedstock are attractive renewable 
alternatives and should be used whenever possible.182 As a consequence, the direction of using 
less amount of solvents and finding renewable and less toxic solvent alternatives has recently 
gained a lot of attention in the area of green chemistry.183  
One approach is to run reaction in neat conditions without the use of solvent. 
Unfortunately, solvent free reactions are not necessarily solvent free as claimed. Even if the 
reaction itself took place in a solvent free medium, it would still need an appreciable amount of 
solvents for reaction adsorption, elution of products and pre or post handlings of the reaction 
mixture. In addition, many extractions, purifications, and cleaning processes also depend on 
solvents, with large excesses necessary to achieve sufficient product purity.181 A brief survey 
of academic researchers were conducted in 2010 by Jessop, where a question brought up 
“…what class of solvent will be responsible for the greatest reduction in environmental 
damage?”.184 The answers to the raised question were in favor of CO2 derived solvents, water 
and careful selection of organic solvents. This turn our focus now towards CO2 and biomass 
derived solvents.  
3.4.1 Biomass and CO2 derived solvents and their application in Pd 
catalyzed C-C couplings 
Plant biomass (crops) such as corn, sugar cane, citrus, grasses and agricultural residues are all 
considered to be the main feedstock for generating renewable fuels and solvents. Recently, 
biomass derived solvents as well as chemicals derived from the reduction of CO2 have been 
increasingly tested as green medium replacing the common nonrenewable solvents utilized in 






ethanol, glycerol and its derivatives, choline chloride based deep eutectic solvents, as polar 
aprotic solvents; 2-methyltetrahydrofuran (2-MeTHF), cyrene (Cyr) and γ-valerolactone 
(GVL), as well as non-polar aprotic solvent; limonene (Lim) and p-cymene (Cym). In case of 
CO2-derived chemicals, particular attention has been paid to the use of carbonates and ethers 
like methylal (Figure 13). These solvents are shown to be suitable renewable solvent 
alternatives for different chemical transformations in classical condensation reactions and 
transition-metal catalyzed cross-couplings.181,183,185,186 
 
Figure 13. A number of sustainable solvents derived from plant biomass, sugars and oils. lignocellulosic biomass. 
Adapted with permission from Clarke et al (2018).181 
2-MeTHF and GVL are both commercially available solvent obtained from furfural or levulinic 
acid, which are produced from lignocellulosic biomass.181,135 Great attention has been paid to 
the use of these solvents as an alternative bio-based medium for several reactions including 
cross-couplings. Solvents, such as THF, toluene and highly regulated chlorinated solvents 
including dichloromethane and 1,2-dichloroethane can all theoretically be replaced by 2-
MeTHF, due to its stability to acid and base in addition to its low miscibility with H2O. It can 
also be used as a replacement of DCM in biphasic reactions and in work up process. 2-MeTHF 
was used as a sustainable media for a variety of organometallic reactions such as Grignard 






reactions.181,187,188 Few examples of SMC coupling in 2-MeTHF have been reported. Nickel-
catalyzed SMC coupling between arylboronic acids and aryl halides or phenol derivatives in 2-
MeTHF was successfully reported by Garg and coworkers.189 The reaction shown applicability 
with a notable substrate scope of 30 coupled products in 33-100% yield using 1-10 mol% of 
bis(tricyclohexylphosphine) Nickel(II)dichloride NiCl2(PCy3)2. The reaction is also 
reproducible on 5-gram scale, coupling of 5-bromopyrimidine with 3-furanylboronic acid using 
just 0.5 mol% of the nickel catalyst yielded the product in 97% yield (Scheme 24). Nickel 
catalyzed amination of aromatic chlorides and O-sulfamates in 2-MeTHF was also reported by 
the same group using NiCl2(DME)2 as a pre-catalyst, the reaction showed general applicability 
in terms of substrate scope as well.189 
 
 
Scheme 24. Nickel catalyzed amination o f5-bromopyrimidine and 3-furanylboronic acid. 
Recently, our group reported the activity of MeTHF and GVL among other solvents on Cu-
catalyzed carboxylation and decarboxylation reactions. Although 2-MeTHF was not universal 
for all the tested carboxylation reactions, but it was the best alternative in most cases. Cu-
catalyzed carboxylation of organoboronates with both electron-rich and electron-poor 
arylboronic acid pinacol esters showed best results over 16 examples where the yield was 68-
98%. In addition, 2-MeTHF has shown to be a good reaction medium for Cu-catalyzed and Cu-
free hydrocarboxylation of olefins (Scheme 25).190  
	
Scheme 25. Cu-Catalyzed and Cu-free hydrocarboxylation of olefins. 
Similarly, GVL has lately drawn great attention to it as a green solvent. It has been frequently 
used as a food additive and a flavoring agent. It has similar polarity as dipolar aprotic solvents 
such as DMF and NMP. Therefore, it has been intensively studied on cross-coupling reactions 
since they often rely on the use of dipolar aprotic media.188 A couple of examples illustrated 
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arylation and Hiayama couplings.187 Mizoroki-Heck reaction between iodoarenes and styrenes 
or acrylates using 0.1 mol% Pd/C in GVL gave the coupled product after 2.5h (Scheme 26). 
The reaction showed general applicability through a substrate scope, over 20 examples in 80-
90% yields.191 
 
Scheme 26. Mizoroki-Heck reaction catalysed by Pd/C in GVL. 
Glycerol is one of the common green solvents that has shown great applicability in many types 
of reactions such as; catalytic hydrogenation of various unsaturated organic compounds and 
cross-coupling reactions. In addition, condensation reactions are also compatible in glycerol 
due to its hydrogen bonding ability, which might stabilize transition states and intermediates. 
For example, catalyst free (e.g. Lewis acid) condensation of phenylenediamine and 
acetophenone was performed in glycerol with high yield (Scheme 27. condition A).192 
Condensation of phenylenediamine with benzaldehyde under solvent free conditions or reflux 
in ethanol was not successful. However, replacing the solvent with glycerol yielded 91% of the 
benzodiazepine, which support the advantage of using glycerol (Scheme 27. condition B).192 
Scheme 27. Condensation of o-diaminobenzene in glycerol. 
Organic carbonates are considered to be a promising renewable dipolar reaction media, due to 
their biodegradability and low toxicity.193–196 Cyclic carbonates such as propylene carbonate 
(PC), ethylene carbonate (EC) are derived from CO2 and bioethene, which make them of a high 
potential as bio-based solvents.197 A previous study showed the successful application of PC 
and EC as the reaction solvent in the Mizoroki-Heck reaction between aryl iodides/bromides 
and acrylate (Scheme 28). The results in terms of conversion were comparable or even better 
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mentioning that bromobenzene showed no reactivity in NMP, while it gave up to 40% 
conversion in case of EC of the desired product.140  
 
Scheme 28. Mizoroki-Heck cross-coupling reaction in ethylene carbonate or propylene carbonate. 
Palladium catalyzed direct arylation of (hetero) aromatic derivatives has been carried out 
successfully in dialkyl carbonate such as dimethoxycarbonate (DMC), diethoxycarbonate 
(DEC). Direct arylation of benzoxazole with 4-bromoacetophenone using only 1 mol% of 
PdCl(C3H5)(dppb) as the catalyst was reported to provide the coupling product in 85% isolated 
yield (Scheme 29). The reaction performed in diethyl carbonate gave the best alternative 
compared to common organic solvents such as DMF, DMAc, NMP or dioxane as it gave only 
traces of unidentified side-products.197 
 





















R= H, 4-Cl, 3-NO2, 4-COCH3, 2-NO2, 4-CN












solvent        yield (%)
 DEC              85%
 PC                78%
 DMF*            78%
 DMAc            31%
 NMP              51%










General discussion of results from the thesis 
 
The numbering system applied in the discussion part is designed to be as follows: 
Numbering of compounds introduced in papers is with the name Px-y, where x is the number 
of the paper (I, II, III) and y is the compound number used in the paper. Other compounds that 
are not included in the papers are numbered chronologically. 
4. Design, synthesis and evaluation of meta-substituted 
benzoic acid derivatives as OXA-48 inhibitors (Paper 
I) 
4.1 Background for the work in paper I 
 
The work presented in paper I is a continuation of previous research conducted by the group of 
Prof. Leiros in collaboration with our group with focus on screening and development of 
fragments of the carbapenemase OXA-48.15 Previously, a library of 490 fragments was 
screened to identify fragments that showed direct binding to the OXA-48 enzyme using SPR 
as the primary assay. The identified fragments from the SPR were examined further in a 
secondary biochemical screen via enzymatic assays in order to measure the binding efficiency 
of the fragments. Enzyme : inhibitor crystal structures were obtained for 3 fragments.15 
The fragments shared the same core structure of a monosubstituted benzoic acid, and 
thus, shared some similar interactions such as hydrophobic interactions with Ser70, Ser118, 
Gly210, Tyr211. The carboxylate group showed an ionic interaction with Arg250 residue in the 
binding site. The negatively charged carboxylate had a charge induced hydrogen bond with the 
side-chain oxygen of Thr209. In addition, the p-system of the benzoic acid might allow for p-
p stacking depending on the fragment conformation. 
The crystal structure identified two different binding conformations of fragment PI-1. 
The first conformation (Figure 14, 1A) shows the fragment facing out of the active site and has 
hydrophobic interactions with Trp105, Thr209, Gly210, Tyr211, and Leu247 – the fragment is 
occupying the out-pocket (called R2 side in Paper I). In the other conformation (Figure 14, 1B) 






Leu158, and Tyr211 – the fragment is occupying the inn-pocket (called R1 side in Paper I). The 




Figure 14. Crystal structures of OXA-48 (green) in complex with fragments (magenta). Two conformations are 
shown for compound 1 in A−C. Adapted with permission from Lund et al. (2016).15  
As fragment PI-1 tends to bind in two different conformations, it was suggested that structurally 
merging both conformations would lead to a better fragment with higher binding affinity 
occupying both the inn- and out-pocket. The merging resulted in a more potent inhibitor-
fragment PI-2 - with better Kd of 50 µM and lower IC50 of 18 µM (Figure 15). 
 
	
Figure 15. (A and B) Different conformations of fragment PI-1 (light grey) in complex with OXA-48 (dark grey 
surface), (C) the merged compound PI-2 (pink) in complex with OXA-48 (dark grey surface) and (D) a schematic 
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4.2 Research hypothesis of paper II 
Based on the findings described in the previous section, the fragment hit PI-1 was envisioned 
as the starting point for a library of mono-substituted analogues of fragment PI-1 (Figure 16). 
The goal was to find good fragments with affinity for either the inn- or the out-pocket (R1 or 
R2 side) or both. The small size of the fragments makes them more flexible and efficient in 
exploring the binding site, which would allow us to identify better fragments for each pocket 
with a promising overlap. The best fragments that bind to each pocket would then be optimized 
further using a merging approach, which would lead to the synthesis of di-substituted fragments 
based on the suggestions from the overlay structures of the best identified fragments (Figure 
16, PI-2). 
 
Figure 16. Fragment development approach. 
4.3 Evaluation of 3-substituted benzoic acid derivatives  
In paper I, co-authors were able to synthesize a fragment library of 49 candidates of 3-aryl 
benzoic acids and derivatives. The fragments were synthesized via SMC starting from 3-
carboxyphenylboronic acid pinacol ester or 3-bromobenzoic acid, resulting in a wide range of 
3-substitutedaryl benzoic acids. The coupling partners included heterocycles and substituted 
aryls with polar groups such as amides, phenols, sulphonic acid derivatives, esters and 
tetrazoles. The benzoic acid moiety was left unaltered due to the main interaction of the 
carboxylate group with the Arg250. Evaluation using a biochemical assay indicates that most 
of the tested fragments show a similar inhibition level with IC50 values ranging from 200 to 
1000 µM and LE values ranging from 0.2 to 0.42 (-log10IC50/heavy atom). All fragments share 
common interactions such as the ionic bond between the carboxylate group and the Arg250. 
Five fragments (Table 5, PI-4a, PI-21a, PI-26a, PI-26b, PI-35) show stronger inhibition with 












Table 5. Selected best 6 fragments from the 49-fragment library. 
 
Entry ID (Paper I) Ar IC50 (µM) KD (µM) LE Pocket 
1 PI-4a 
 
50 175 0.38 R2 
3 PI-21a 
 
35 100 0.33 R1 
4 PI-26a 
 
60 70 0.3 R2 
5 PI-26b 
 
36 70 0.3 R1 
6 PI-35 
 
35 159 0.42 both 
 
Out of the 49 synthesized fragments, 33 fragments were co-crystallized with the enzyme OXA-
48 and analyzed by X-ray crystallography in order to evaluate the binding poses of the 
fragments. All fragments formed an ionic bond between the carboxylate group and the Arg250.  
Most of the fragments were found to occupy the out-pocket (R2) where they engaged in edge-
to-face p-p stacking with Tyr211. Fragment PI-4a was shown to be the strongest among the R2 
binders with IC50 of 50 µM and LE of 0.38 (Table 5, entry 1). Only fragments PI-21a and PI-
26b were found to bind in the inn-pocket (R1 side) with IC50 of 35 and 36 µM, respectively, 
and LE of 0.33 and 0.30, respectively. Both fragments could form a hydrogen bond with the 
guanidine group of Arg214, which made them loose the p-p stacking with Tyr211 and direct 
them to be oriented towards R1 binding site instead of the common R2. Fragment PI-35 
occupied both binding sites so it was not classified as R1 or R2 binder. However, fragment PI-
35 was the best fragment among the tested fragments as it showed the best ligand efficiency 











K3PO4  (3 equiv)
ArBr (1.5 equiv)
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In order to optimize the fragments into more potent fragments, a merging approach was 
initiated by overlaying two crystal structures of the most promising mono-substituted benzoic 
acids (Table 5). A structural overlay of fragments PI-21a and PI-26b, which were the only R1 
binders with different R2 binders (PI-1, PI-28, PI-35) suggests some promising combination 
(Figure 17) leading to structures PI-39, PI-40 and PI-41. Therefore, we initiated the synthesis 
of a small library including symmetrical and unsymmetrical 3,5-disubstituted benzoic acids 
including the suggested combination from the merging approach using SMC.  
 
                        PI-40                 PI-39                  PI-41 
Figure 17. Overlay structure of the binding poses observed for PI-21a/28 (A), PI-21a/1 (B) and PI-26b/35 (C) 
leading to 3,5-disubstituted benzoic acids PI-40, PI-39 and PI-41. 
4.4 Synthesis and evaluation of symmetrically and 
unsymmetrically 3,5-disubstituted benzoic acid derivatives 
 
I was responsible for developing a method for the synthesis of unsymmetrically 3,5-
disubstituted benzoic acid derivatives. I also contributed to the synthesis of the symmetrically 
3,5-disubstituted benzoic acid derivatives. 
Choosing 3,5-dibromobenzoic acid as a starting point allowed us to access symmetric 3,5-
disubstituted benzoic acid. As 3,5-dibromobenzoic acid 75 contains two coupling positions (m-
BrAr) of the same activity, so the reaction was not regioselective. Using an excess of the boronic 
acid and the base would allow the symmetrical substitution. The synthesis of three fragments 
(Scheme 30, Fragments PI-36, PI-38, PI-37) was achieved under the same reaction conditions 
as for mono-substituted fragments using Pd2(dba)3 (5mol%)/XPhos(5 mol%) or XPhos-Pd G2 







Scheme 30. Synthesis of symmetric 3,5-disubstituted benzoic acid derivatives. 
For the synthesis of unsymmetrical 3,5-disubstituted benzoic acids, chemoselectivity was 
required in order to introduce different boronic acids to the 3- and the 5- position of the 
dihalobenzoic acid. The first approach was based on using 3,5-dibromobenzoic acid and 
sequentially adding the two different boronic acids and/or reducing the amount of the boronic 
acid under the previously established conditions (Scheme 31. A). This approach was not 
successful as it only yielded 15% of the desired product. For example, fragment PI-39 was 
obtained from the 3,5-dibromobenzoic acid in a very low yield (11%). In addition, a mixture of 
mono-substituted 5-bromobenzoic acid, symmetrical and unsymmetrical 3,5-disubstituted 
benzoic acids was always obtained. Moreover, purification of the reaction mixture was found 
to be difficult and required several HPLC purifications.  
 
 Scheme 31. Initial attempts of the preparation of unsymmetrical 3,5-disubstituted benzoic acids.  
To introduce a higher degree of selectivity, we changed the starting material to 3-bromo-5-
iodobenzoic acid (Scheme 31. B). As mentioned before (Chapter 3.1), Ar-I is more active than 
Ar-Br in SMC reactions, which could allow a faster reaction on C-I than C-Br and limit the 
formation of symmetrical compounds. We initiated a chemoselective reaction of 3-iodo-5-
bromobenzoic acid with 6-quinolineboronic acid pinacol ester to form a mono-substituted 
product using Pd2(dba)3. CHCl3 (5 mol%) and SPhos (5 mol%) in dioxane/water (1:1) at 60 oC. 
























X1= X2=  Br
ArB(OR)2 (1.5 equiv)
PdCl2(PPh3)2 (10 mol%)






K3PO4  (3 equiv)
dioxane: water (1:1)
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We then started reaction optimization to find conditions that would suppress the second 
coupling in favor of obtaining only the mono-substituted product after the first coupling. The 
model reaction was carried out between 3-bromo-5-iodobenzoic acid with 6-quinolineboronic 
acid pinacol ester. The reaction optimization included different catalysts (e.g. RuPhos-Pd G3, 
Sphos/Pd2(dba)3, Xphos/Pd2(dba)3, SPhos-Pd G3, XPhos-Pd G2, Pd2(dppf)Cl2), solvents 
(toluene/water, anhydrous THF, dioxane/water, tert-butanol), reaction temperature (40–80 °C) 
and time (10–48 h) (Table 6). The crude reaction mixtures were analyzed and the ratios between 
the mono- and disubstituted products as well as unreacted starting material were determined by 
mass spectrometry (MS).  
Table 6. Reaction optimization for the coupling of 3-bromo-5iodobenzoic acid. 
 







1 RuPhos-Pd G3 (10) 60/24 Dioxane/water 
(1:1) 
8: 10: 10 nd 
2 RuPhos-Pd G3 (5) 60/24 Dioxane/water 
(1:1) 
10: 6: 0.3 nd 
3 XantPhos-Pd G3 (5) 60/48 Dioxane/water 
(1:1) 
10: 1: 0 nd 
4 XantPhos-Pd G3 (5) 40/24 Dioxane/water 
(1:1) 
10: 1: 3 70a 
5 Pd2(dppf)Cl2 60/24 Dioxane/water 
(1:1) 
10: 1: 3 80a 
6 Xphos-Pd G2 (1) 60/24 Dioxane/water 
(1:1) 
10: 7: 1 nd 
7 SPhos-Pd G3 (5) 60/24 Dioxane/water 
(1:1) 
10: 2: 0 40 
8 Pd2(dba)3.CHCl3/SPhos 
1:1  (10) 
60/24 Dioxane/water 
(1:1) 
10: 1: 0.4 55 
9 Pd2(dba)3.CHCl3/SPhos 
1:1  (10) 
40/24 n-BuOH 10: 4: 4 nd 
10 Pd2(dba)3.CHCl3/SPhos 
1:1  (10) 
80/24 Dioxane/water 
(1:1) 
10: 1: 0.3 55 
11 Pd2(dba)3.CHCl3/SPhos 
1:1  (10) 
40/20 Dioxane/water 
(1:1) 
10: 1: 3 65 
12 Pd2(dba)3.CHCl3/SPhos 
1:1  (10) 
60/10 Dioxane/water 
(1:1) 
5: 4: 10 nd 
14 Pd2(dba)3.CHCl3/SPhos 
1:1  (10) 
60/48 Dioxane/water 
(1:1) 
10: 4: 1 nd 
15 Pd2(dba)3.CHCl3/SPhos 
1:1  (10) 
60/24 Dioxane/water 
(1:1) 

























        *nd= not determined, a= mixture of PI-int40 and PI-38. 
 
Among the tested catalysts, XantPhos-Pd G3, Pd2 (dppf)Cl2 and SPhos/Pd2 (dba)3 showed the 
best selectivity for the aryl iodide when the reaction was performed with K3PO4 as the base in 
dioxane/water at 60 °C for 24 h (Table 6, entries 3, 8, 15). The mono-substituted intermediate 
PI-int40 was obtained as the main product using SPhos/Pd2 (dba)3, only small amounts of the 
disubstituted by-product (8–10%) were observed. Careful purification to remove any traces of 
the disubstituted compound provided PI-int40 in a moderate yield (45%). The mono-
substituted product was then subjected to a second coupling with (3-acetamidophenyl)boronic 
acid using XPhos-Pd G2 (5 mol%) as a catalyst to provide the unsymmetrical 3,5-disubstituted 
benzoic acid (Table 7, PI-40) in a high yield (90%). 
The inhibitory activity of the disubstituted compounds against OXA-48 was evaluated 
and compounds PI-36, PI-37 and PI-40 (IC50 (µM)/LE: 2.9/ 0.27, 48/0.21 and 2.9/0.27) 
showed better inhibition activity in comparison to their corresponding mono-substituted 
fragments PI-21a, PI-21b and PI-28 (IC50 (µM)/LE: 35/0.33, 450/0.26, 240/0.3). The best two 
fragments were the symmetrical 3,5-disubstituted benzoic acid PI-36 and the unsymmetrical 
3,5-disubstituted benzoic acid PI-40 with IC50 values of 2.9 µM and LE of 0.27 (Table 7). 
Crystal structures of fragments PI-36 and PI-40 were obtained. They emphasized that the 
interactions exhibited by the individual fragments were also preserved in the merged structure. 
Table 7. Inhibitory activity of 3,5-disubstituted benzoic acid analogues against OXA-48 (IC50, Kd, LE). 
 
ID (Paper I) Ar1 Ar2 IC50 (µM) Kd (µM) LE 
PI-36 
  
2.9 20 0.27 
PI-37 
  
48 70 0.21 
PI-38 
  























100 70 0.22 
PI-40 
  
2.9 49 0.27 
 
4.5 Additional results not included in Paper I 
Attempts to synthesis the third fragment suggested from the merging approach compound PI-
41 (Figure 17). The strategy was based on using 3-(pyridin-2-yl)benzoic acid (Scheme 32, PI-
35) and 4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Scheme 32, PI-26b). In order 
to synthesize 3-bromo-5-(pyridin-2-yl)benzoic acid (PI-41), two synthetic strategies were 
considered. The first strategy was SMC of 3-bromo-5-iodobenzoic acid and pyridin-2-
ylboronic acid followed by a second SMC with (4-cyanophenyl)boronic acid. The resulting 
coupled product would then be submitted to a tetrazole formation step (Scheme 33, S1). The 
other strategy was to conduct the second coupling and install the tetrazole group first then 
submit the product to SMC with 2-pyridinylboronic acid (Scheme 33, S2).  
 
 
Scheme 32. Promising fragment based on overlay structures from paper I. 
In both synthetic strategies coupling with 2-pyridinylboronic acid or ester was not accessible. 
This might be due to the low reactivity of pyridine boronic acid. It is known that pyridine 
boronic acids tend to have a slow transmetalation rate due to the electron-deficiency of the 
pyridine ring. Thus, they require higher temperatures and longer reaction times.198  
The SMC with (4-cyanophenyl)boronic acid resulted in a mixture of mono- and di-
substituted benzoic acids in 60% and 25% yield, respectively. The compounds were submitted 
for the tetrazole formation and the symmetrical 3,5-di-(4-1H-tetrazolyl)phenyl benzoic acid 
































the compounds killed the bacteria at 250 and 500 µM concentrations. Therefore, the compounds 
were not further evaluated as inhibitors. 
 
Scheme 33. Two synthetic strategies to synthesize fragment PI-41. 
4.6 Conclusion from paper I 
In summary, the Suzuki-Miyaura cross-coupling was a successful approach to access a 
fragment library of 49 candidates of 3-substituted boronic acids. The crystal structures of 33 
fragments of the fragment library gave a closer insight into the possible interactions in the 
binding site R2 and the preferred binding site R1. The most efficient binders were selected to 
design a small fragment library based on the merging approach. Five fragments of both 
symmetrical and unsymmetrical 3,5-disubstituted benzoic acids were synthesized and tested for 
their inhibition activity. Selective Suzuki-Miyaura cross-coupling was applied to obtain the 
mono-substituted intermediate PI-int40 in a moderate yield of 45%. The best inhibitors with 
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2- Dibutyline oxide 
(0.2 equiv)
TMSA (2 equiv)
MW 150 oC, 1h
2- Dibutyline oxide 
(0.2 equiv)
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5. Development of carbonylative C-C couplings for the 
synthesis of VIM-2 inhibiting fragments (Paper II)  
5.1 Paper II background  
The group of our collaborator Prof. Leiros has previously identified novel fragments inhibiting 
the metallo-β-lactamase VIM-2.13 The study involved an orthogonal screening approach based 
on a surface plasmon resonance (SPR) assay combined with an enzyme inhibition assay of a 
library of 490 fragments. The identified fragments were submitted for characterization by 
determining the Kd, LE, and IC50 values. The IC50 ranged from 14 to 1500 µM and the LE 
ranged from 0.48-0.23 kcal/mol per heavy atom. 
Fragment 1 (IC50/LE= 14/0.38) shows two important interactions with the residues in 
the binding site (Figure 18). The carboxyl group displayed two types of interactions, it interacts 
with Zn2 in the binding site and also forms hydrogen bonds with two water molecules (W1 and 
W2). The other carbonyl group participated in two interactions, weak chelation with Zn1 and 
hydrogen bond with Asn233. In addition, the phenyl ring on both sides shows parallel π−π 
stacking with His263 and a T-shaped π−π stacking with Tyr67. The side chain of Arg228 
showed high mobility with different conformations partly forming a hydrogen bond with the 
carboxyl group in the fragment. 
 
Figure 18. X-ray structure of fragment 1 bound to the active site of VIM-2. Hydrogen bonds are shown as red 









Additional hydrophobic interaction of the fluorine substituted phenyl group with Phe61 and 
Trp87 stabilize the fragment binding. Furthermore, the carbonyl group favors the coplanar 
orientation of the two phenyl groups that enables the hydrophobic interactions with His263, 
Tyr67, Phe61, and Trp87. Based on the structural information in hand we used fragment 1 as 
the starting point for paper II. 
5.2 Initial work and research focus of paper II 
According to the previously reported observation and the information from the crystal 
structures, we used fragment 1 as a starting point for a fragment library. The 2-benzoylbenzoic 
acid system (Figure 19, B), where both the carbonyl group and the carboxylic acid are adjacent 
to each other is necessary for the binding. Phenyl rings could be changed to other heterocycles 
or substituted phenyl rings in order to keep the possibility of the π−π stacking.  
 
Figure 19. Structure model based on fragment 1 (A) & (B). Red; moieties targeting Zn ions. Blue; substituted 
aromatic rings for π−π stacking and different ionic and hydrophilic interactions. 
In order to synthesize a library of these fragments, several synthetic routes were evaluated to 
develop a general strategy that would provide a wide range of functionalized 2-aroylbenzoic 
acids without increasing the number of reaction steps. Our initial attempts to synthesize 2-
aroylbenzoic acids and derivatives were based on the most common methods such as the 
reaction of phthalic anhydride with organometallic reagents199 (Scheme 34, B) or Friedel-Craft 
acylation with aromatic nucleophiles (Scheme 34, C).154 Although we could obtain a small 
library of fragments (Chapter 5.5, Table 8, Fragment 1-7) using these methods, we found that 









π-π stacking and other type of bindings








compounds. Many functional groups were not tolerated in these reactions due to the harsh 
conditions and the use of excess Lewis acids.  
Simpler systems such as biaryl ketones have been synthesized by transition metal-
catalyzed carbonylative cross-couplings of organometallic reagents and aryl electrophiles174, or 
by the non-decarbonylative coupling of acyl electrophiles.200–202Although there are a number 
of reports describing the synthesis of biaryl ketones in general, only a few methods have proven 
to be applicable for the formation of 2-aroyl benzoic acid derivatives (Scheme 34. D-F).  
 
Scheme 34. Possible approaches towards 2-aroyl benzoic acid derivatives. 
For instance, Pd-catalyzed ortho-C–H activation of benzoic acids followed by decarboxylative 
coupling with α-oxocarboxylic acids (Scheme 34, E) showed several limitations regarding 
reaction conditions and substrate scope.156 This reaction was performed under harsh conditions 
in DME for 24-48h at 150 oC. In addition, the reaction might provide poor regioselectivity of 
the desired ortho position to the carboxylic group as there are several competing reaction sites. 
Although the reaction provided the 2-aroyl benzoic acid derivatives, it was not compatible with 
a wide range of functional groups, especially electron-withdrawing functional groups such as 
nitro groups, nitrile groups, amides, and aldehydes. The scope did not include highly substituted 








































































heterocyclic substrates as the coupling partner on both the benzoic acid side and/or the α-
oxocarboxylic acids.156 
Pd-catalyzed ortho-C–H activation of aryl amides followed by coupling with aryl 
aldehydes (Scheme 34, F) is another possibility to access 2-aroyl benzoic acid derivatives.155 
The reaction includes directed C–H activation, ortho-acylation of the aryl amide, then ring 
closure of the five-membered hydroxyl isoindolone. The five-member ring is then opened to 
give the biaryl imino carboxylic acid. The imine is then subjected to concentrated HCl in order 
to hydrolyze it to the keto form and eventually obtain the biaryl imino/keto carboxylic acids.155 
Regarding the substrate scope, the reaction shares the same limitations with the Pd-CH 
activation and decarboxylative coupling.  
Another possible approach is the Pd-catalyzed coupling of 2-iodobenzoates with 
aldehydes (Scheme 34, D). The advantages of this method are that it does not require any 
directing group assistance or in situ enamine formation and it prevents the use of CO.203 
However, it showed poor tolerance of substituted benzaldehydes with electron-withdrawing 
groups such as nitro or nitrile groups. In addition, the yield ranged from low to moderate 
throughout the whole substrate scope, while it was unsuccessful with amides and heterocyclic 
aldehydes.203 
5.3 Discussion of the results of Paper II 
Based on the analysis above, we decided to develop an alternative route to functionalized 2-
aroylbenzoic acids using palladium-catalysed carbonylative C-C couplings using CO as the 
carbonylating agent as key step. In particular we hoped to develop an approach that gave access 
to functionalized 2-aroyl benzoic acid derivatives where R2 = OH, NHR or other 
functionalisable handles. 
Based on a literature research, carbonylative C-C couplings the reaction showed 
widespread application in the synthesis of biaryl ketones. The vast majority of the studies 
reported carbonylative Suzuki-Miyaura couplings using aryl iodides with boronic acids, while 
few of them addressed the use of less reactive aryl bromides.129,153,152,204 Only a few reports 
discussed the challenging ortho-substituted systems, especially the electron-deficient 
substituted substrates on both coupling partners, the aryl bromide and the boronic acid.204,129 
Despite the hazard related to the toxic CO gas, we could use it in a safe fashion to avoid the 






We addressed two possible routes towards 2-aroylbenzoate esters as illustrated in Scheme 35. 
The aim was to identify a route with a high degree of functional group compatibility that could 
be used to establish a VIM-2 fragment library of analogues of fragment 1.  
 
Scheme 35. Two possible routes towards 2-aroylbenzoate esters. 
Route A 
The first route (Scheme 35, route A) comprises a carbonylative Suzuki-Miyaura coupling of 2-
bromoiodobenzene with phenyl/hetero-boronic acids via carbonylative Suzuki-Miyaura, 
followed by Pd catalyzed hydroxy- or alkoxycarbonylations of the 2-bromo functionalized 
biaryl ketones to obtain the 2-aroylbenzoic acids derivatives. The initial attempts of step 1 in 
route A indicated the high impact of the competing non-carbonylative SMC reaction on the 
results. The product of the competing direct coupling (bi-aryl) was always observed in a 
considerable amount together with the desired carbonylated product (bi-arylketone). The 
maximum obtained yield under the optimized conditions was 60 % of the carbonylated product. 
The competing SMC reaction is a common challenge concerning carbonylative SMC. It is 
known that in some cases the increase of the CO pressure, temperature and the catalyst loading 
could enhance the reaction in favor of the desired carbonylative SMC.128,130-132,133 However, in 
our hands increasing the temperature and catalyst loading decreased the yield and favored the 
direct coupling. High CO pressure would require special equipment and is associated with a 
risk of faster formation of the inactive palladium black when compared to reactions closer to 
atmospheric CO pressure.134 
Thus, we focused on finding conditions that enhanced the carbonylative SMC. First, we 
thought that making the CO available for the reaction before the transmetalation reagent may 

















1: R1 = H
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attempted as it could help to enhance the rate of the CO insertion. However, having the boronic 
acid readily available for the reaction would not allow the CO insertion to occur faster than the 
transmetalation and the reductive elimination steps. As already known, the transmetalation and 
the reductive elimination steps are faster than the CO insertion.133 Accordingly, slowing down 
the transmetalating agent from reaching the metal center might allow the CO insertion step to 
occur first. Introducing the boronic acid slowly into the reaction mixture after the complete 
release of the CO was an attractive approach to the test. Slow addition of the boronic acids was 
envisioned to enhance the reaction rate in favor of the desired carbonylative SMC. By adding 
the boronic acid slowly over 2-3h, the yield increased from 60% to 80%. This improvement 
encouraged us to proceed with the reaction scope, while applying the slow addition. The 
reaction was compatible with both electron-rich and electron-deficient aryl boronic acids giving 
moderate to high yields. In addition, electron-rich heterocycles and ortho-substituted boronic 
acids were also tolerated under the reaction conditions. However, some heterocyclic boronic 
acids (e.g. 2-furanyl boronic acid), hydroxy and N-acyl substituted aryl boronic acids were not 
tolerated and favored direct coupling instead of the carbonylative alternative.  
To emphasize the effect of the slow addition, selected substrates were tested applying slow 
addition and normal addition. The yield of the carbonylative coupling products were higher, 
which concludes slow addition can impact the reaction result in favor of the carbonylative 
coupling. 13 examples of substituted 2-bromobiaryl ketones were synthesized in low to high 
yields (Scheme 36). 
 
Scheme 36. Route A, 1) PdCl2 (1 mol%), C2CO3 (3 equiv), COgen (2 equiv) in anisole. 2) PdCl2 (1 mol%), 
Xantphos (2 mol%), C2CO3 (3 equiv), COgen (2 equiv) in anisole: n-BuOH (2:1). 
The second step of route A (Scheme 36, 2) was hydroxy- or alkoxy-carbonylation of the 
obtained 2-bromo functionalized biaryl ketones. Our initial attempts to directly obtain 
carboxylic acids by hydroxycarbonylation using SilaCOgen were unsuccessful. This might be 
due to steric hindrance at the ortho position of the ketone. However, we intended to try 
alkoxycarbonylation on 2-bromo-4-methoxybenzophenones as a test substrate. We tested 






















and solvents. Few reaction conditions gave access to the desired alkyl 2-(4-
methoxybenzoyl)benzoate. The best result was obtained with PdCl2 (1 mol%) and Xantphos (2 
mol%), n-BuOH, and K2CO3 in anisole (Scheme 36, 2). The desired butyl 2-(4-
methoxybenzoyl)benzoate was obtained with a 65% yield. Applying these conditions to a 
number of 2-bromobenzophenone derivatives from step 1, we found that the reaction is 
substrate-dependent. Thus, we concluded that this approach is limited and not suitable for 
synthesizing a larger library of 2-aroyl benzoic acid derivatives.  
 
One-pot approach to synthesize 2-aroylbenzoic ester 
The two steps of route A seemed to be feasible in one pot. The reagents required for the 
alkoxycarbonylation step such as the ligand and the nucleophile can be added later after 18 
hours from the first step. In this case no excess of catalyst or COgen is required (Scheme 37). 
Unfortunately, our initial attempts of a one-pot synthesis of 2-aroylbenzoic ester were not 
successful. Introducing extra fresh catalyst to the second step did not prove to be beneficial. 
We obtained several products after the second step including the biaryl ketone 88, the biphenyl 
coupled product 93 as a byproduct from the first step, the desired biphenyl keto ester 90 and 
the biaryl ketone without the bromide 94 (Scheme 37). Palladium black formation was always 
observed in the first step, which could be a reason that hindered the second step and decreased 
the activity of the freshly added PdCl2. Despite the addressed limitations of the one-pot 
approach, we could still observe some of the biaryl keto esters, which indicated that the reaction 
could be further developed to obtain the desired activity. We were therefore interested to study 
the reaction from another direction to learn about the sequence influence on the reaction 
reactivity, so the second route was evaluated. 
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In route B, we started from commercially available 2-bromo substituted benzoate esters as 
starting material for the carbonylative SMC. 2-Bromobenzoate was submitted to a range of 
experimental conditions including different palladium and Ni sources and ligands such as 
(Pd(acac)2 or Pd(OAc)2/CataCXium A or A·HI, Pd(OAc)2 or PdCl2/Xantphos, Ni(COD)/dcype) 
and others to find the best conditions for the reaction (Paper II, Table ESI-6). Our observations 
mainly concluded the dominance of the undesired non-carbonylative coupling pathway. Only 
the Pd(IPr)-based catalytic systems showed promising results as it could accomplish the 
carbonylative SMC. In the carbonylative coupling of methyl 2-bromobenzoate with 4-
methoxyboronic acid, PEPPSI-IPr (3 mol%) as catalyst precursor, Cs2CO3 as a base in 
chlorobenzene or anisole as solvent proved to be the best system, providing the desired product	
in 63% yield (paper II,S 4, 2aa). In order to enhance the yield, we tested the slow addition of 
the boronic acid to the reaction mixture over 2-3h. This approach showed great influence on 
the SMC in route A, so it was expected to give relatively similar results in route B. The yield 
was further increased to 80% by slow addition of the boronic acid. The reaction showed very 
good compatibility with different functional groups on both coupling partners including 
electron-withdrawing, electron-donating, and heterocyclic boronic acids (Scheme 38). Boronic 
acids with electron-donating groups such as -OMe, -SMe, and heterocyclic boronic acids such 
as thiophene and benzothiophene gave moderate to high yields. Boronic acids with electron-
withdrawing groups such as -CN, -F, -COOMe gave low to moderate yields. Sterically hindered 
ortho-substituted boronic acids were also compatible under the reaction conditions and gave 
acceptable yields. Aryl bromides with both electron-withdrawing and electron-donating groups 
were tolerated and gave moderate yields (Paper II, Scheme 4, 5).  
 
Scheme 38. Route B, Suzuki–Miyaura coupling of methyl 2-bromobenzoate. 
Scope limitations and general findings 
The paper aimed to establish a general method to synthesize a wide range of 2-aroylbenzoic 
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groups on both aryl rings (Scheme 38, R1 and R2) with a potential binding ability to the VIM-
2 binding site. Functional groups such as -OH, -NH2, -CONHR, NO2 could act as hydrogen 
bond donors and/or acceptors in the binding site. In addition, the fragments were also 
envisioned to contain functional groups that allow for late-stage functionalization of both aryl 
rings. Unfortunately, substituents such as hydroxy, amines, and amides could not be introduced 
with the developed method. Moreover, the solubility of the reagents including boronic acids or 
acid derivatives in the reaction solvent can impact the success of the reaction. As we developed 
the slow addition method, we introduced the boronic acid/anisole solution to the reaction 
mixture over 2-3h. Boronic acids with a low solubility in anisole were challenging substrates 
and thus were incompatible under reaction conditions. However, the strategy has good potential 
for further optimization. Therefore, an extended study to find a better system to overcome the 
scope limitations and allow for a wider range of VIM-2 inhibitors is an attractive research point 
for the future. 
5.4 Conclusion from paper II 
In conclusion, two routes for accessing 2-aroylbenzoate esters have been evaluated. This 
evaluation suggests that the second route (B), which employed a carbonylative Suzuki-Miyaura 
coupling of 2-bromobenzoate esters, could be a better strategy than route (A). Although the 
suggested slow addition of the boronic acids is dependent on the solubility of them in the 
reaction solvent, it is considered to be a finding of general value as it allowed us to enhance the 
reaction reactivity to favor carbonylative over non-carbonylative processes in Suzuki-Miyaura 
couplings. A range of diversely substituted 2-aroylbenzoate esters that share the same structure 
core as our targeted structure model (Figure 18, Fragment 1) was prepared and sent for 
biological testing at Nordstruct. The fragments were lacking some promising functional groups 
such as OH, NO2, NH2, etc. These types of substituents on both aryl rings could enhance the 
binding of the fragments with the active site via hydrogen bonding, ionic or covalent 
interactions. Due to the lacking of such functional groups, further optimization to find better 
reaction conditions including the solvent and the catalytic system is suggested in paper III.  
5.5 Additional results not included in Paper II 
The initial trials of preparing 2-aroylbenzoic acids by reacting phthalic anhydride with 
organometallic reagents or by Friedel-Craft acylation of aromatic nucleophiles resulted in a 






VIM-2 and IC50 values were obtained. None of these fragments showed improved inhibition 
activity when compared to fragment 1 (IC50/LE= 14/0.38). 
Fragments obtained via carbonylative Suzuki-Miyaura coupling were also tested against VIM-
2 and IC50 values were obtained (Table 8, Fragments F8-F20). All the tested fragments showed 
inhibition in the µM range. Two fragments (Table 8, Fragments F9 and F13) showed inhibition 
activity comparable to fragment 1 with LE of 9.96 and 10.77, respectively. Fragment F20 
showed the best ligand efficiency with LE of 0.43. The obtained results can be used as a starting 
point for further optimization towards better hits against VIM-2. 
Table 8. Biological data of tested fragments against VIM-2. 































































































































































6. Development of carbonylative C-C, C-N, C-O 
couplings using renewable solvents  
6.1 Paper III background 
As the method developed in paper II still showed limitations with regard to substituents such 
as -OH, -NH2, -NHR and -NO2, we continued our efforts to improve the carbonylative SMC of 
aryl bromides with aryl boronic acids. In paper III, an alternative method for carbonylative 
SMC in green solvents is described. 
Renewable solvents have been described to be suitable medium for several chemical 
transformations including classical condensation reactions and transition-metal (TM)-catalyzed 
cross-couplings.211-213 including biphasic reactions such as metal catalyzed carboxylation 
reactions using CO2.190 However, carbonylative reactions have not been studied in renewable 
solvents. In addition, we extended the study to investigate the efficiency of green solvents in 
alkoxycarbonylation that showed carbonylative couplings of aryl bromides with amines and 
alcohols, both reactions that were investigated during the work leading to paper II. For the latter 
two, we focused on catalytic systems that have already proven to be suitable systems for Pd-
catalyzed carbonylation reactions.153,176,171 
6.2 Paper III results and discussion  
Solvent properties  
In general, liquids that are available form biomass and CO2 derived chemicals have a great 
potential to replace non-renewable solvents that are frequently utilized in organic 
synthesis.188,205,206,187,181 In this study, we examined both known renewable solvents and some 







Figure 20. Structure of the renewable solvent used in paper III. 
The polarity of the solvents was estimated based on their dielectric constant. Solvents with 
dielectric constant higher than 5 are considered to be polar, while solvents with dielectric 
constant below 5 were considered as non-polar (Table 9). Thus, the solvents could roughly be 
grouped into non-polar hydrocarbons (a-pinene, g-terpinene, limonene, p-cymene), non-polar 
ethers (diethoxymethane (methylal), dimethoxymethane (ethylal), 1,1-diethoxyethane (acetal), 
rose oxide, eucalyptol) and carbonates (dimethylcarbonate (DMC), diethylcarbonate (DEC)), 
and polar ethers (dimethyl isosorbide, 2-methyltetrahydrofuran (2MeTHF)) comparable to e.g. 
THF and highly polar esters and carbonates (g-valerolactone (GVL), propylenecarbonate (PC), 




































non-polar        
a-Pinene 136.24 156 2.18 hydrocarbon 50 97 93 
g-Terpinene 136.24 174 2.27207 hydrocarbon 50 94 93 
(+)-Limonene 136.24 178 2.37 hydrocarbon 80 99 56 
p-Cymene 134.22 177 2.25208 hydrocarbon 75 97  
Toluene 92.14 111 2.38 hydrocarbon 90153 97176  
Diethoxymethane 
(ethylal) 
104.15 87 2.53209 ether  62 64 
Dimethoxymethane 
(methylal) 
76.10 42 2.64 ether 50  45 
Diethoxymethane 
(ethylal) 
104.15 87 2.53209 ether  62 64 
Diethylcarbonate 
(DEC) 
118.13 126 2.82 carbonate  94 45 
Dimethylcarbonate 
(DMC) 
90.08 90 3.13210 carbonate 16 97 93 
1,1-Diethoxyethane 
(acetal) 
118.18 102 3.80 ether  62 55 
(+)-Rose oxide 154.25 86/20 mmHg  ether 33 78 36 
Eucalyptol 154.25 176 4.57 ether  89 82 
polar aprotic        
Dimethyl isosorbide 174.20 
94/0.1 
mmHg 
6.20211 ether  89 30 
2-MeTHF 86.13 79 6.97212 ether 30 83 91 
Tetrahydrofuran (THF) 72.11 65 7.52213 ether   88171 
g-Valerolactone (GVL) 100.12 207 36.47 ester  74 64 
Propylenecarbonate 
(PC) 
102.09 242 66.14 carbonate  80 60 
Ethylenecarbonate 
(EC) 
88.06 261 92.8 carbonate   30 
1 Values obtained from CRC Handbook of Chemistry and Physics (85th ed.) unless mentioned otherwise. 








Carbonylative SMC (C-C) 
The reaction of 3-bromoanisole with m-tolylboronic acid was used as a model reaction for the 
screen. The reaction conditions were based on a catalytic system, which is originally developed 
in the group of Skrydstrup.153 The catalytic system relied on using Pd(acac)2 and di(1-
adamantyl)-n-butylphosphine hydroiodide (cataCXium AHI) as a ligand. The original method 
relied on using boronic acid derivatives such as diethanolamine-complexed heterocyclic 
boronic acids (DABO boronates) or aryl trihydroxyborates in toluene/H2O (10:1) or pure 
toluene as a solvent.153 When repeating the original reaction using aryl trihydroxyborates, we 
could obtain comparable result and the desired product was achieved in 83% yield (see paper 
III ESI, Table S1, entry 3). However, we found that the extra step of preparing the aryl 
trihydroxyborates was not needed. We were able to simplify the method by generating the aryl 
trihydroxyborates in situ by adding 1M NaOH (aq) instead of preparing the organoborates 
separately. 
We tested a range of renewable solvents using the model reaction of 3-bromoanisole 
with m-tolylboronic acid under the developed method. Non-polar ethers, like rose oxide and 
methylal, carbonate like DMC and polar ethers, like 2-MeTHF, gave the carbonylated product 
in low to moderate yield (16-50%) and favored direct coupling over the carbonylated product. 
On the other hand, non-polar hydrocarbons such as limonene, p-cymene, γ-terpinene, α-pinene 
gave better yields (80%, 75%, 50%, 50%, respectively) in correlation with the use of toluene 
in the original conditions. Limonene favored the carbonylative coupling reaction over the direct 
coupling and provided the desired biaryl ketone in 80%. Although limonene has a terminal no 
side product related to the Heck-type arylation of the solvent was observed under reaction 
conditions neither with rose oxide, γ-terpinene, α-pinene.  
We tested the scope of the reaction to check the generality of the carbonylative SMC in 
limonene. We examined a wide range of boronic acids and aryl bromides, which have shown a 
good scope. As we are generating the trihydroxyborates in situ, this allowed us to use a wide 
range of boronic acids and avoid the limitations associated with isolation of unstable 
trihydroxyborate salts. The reaction showed excellent compatibility with electron-rich, 
electron-deficient and heterocyclic boronic acids and gave high to excellent yields (71-95%). 
Moreover, electron-rich, electron-deficient and heterocyclic aryl bromides were successfully 






that the reaction still shows limitation regarding sterically hindered, electron-withdrawing 
group aryl bromide such as methyl 2-bromobenzoate, which gave the product in moderate yield 
(40%). The scope of the reaction allowed for 16 examples of substituted biaryl ketones in 
moderate to excellent yields (Scheme 39). We can conclude that the obtained yields were in 
correlation with original reports using non-renewable solvents such as toluene. This emphasizes 
that limonene is a renewable alternative for carbonylative SMC and can replace the commonly 
used non-renewable solvents such as toluene, dioxane, chlorobenzene, DMF.131,134,137,156,181,155  
 
 
Scheme 39. Carbonylative SMC of aryl boronic acids with boronic acid in limonene. 
Aminocarbonylation (C-N) 
For aminocarbonylation we used the catalytic system developed by Buchwald and coworkers, 
where they used Pd(OAc)2, Xantphos and triethylamine as base in toluene. The Pd-catalyzed 
aminocarbonylation of 4-bromobenzonitrile and N-methylaniline was used as model reaction 
for the solvent screening.176 The aminocarbonylation reaction in sustainable solvents gave 
yields comparable to the result under original conditions in toluene, and even better in some 
cases.176 Non-polar hydrocarbons such as limonene, p-cymene, γ-terpinene, α-pinene gave 
excellent yields (99, 97, 94, 97%, respectively), which was not surprising given that these 
solvents can be expected to have similar properties as toluene.176 However, the performance of 
non-polar carbonates (DMC, DEC) was also excellent and the products were obtained in 97% 
and 94% yield, respectively. The performance of polar carbonates (PC, GVL) and polar/non-
polar ethers (2-MeTHF, rose oxide, acetal, etc.) was less good than the other solvents but the 
product was also here obtained in moderate to high yields (62-89%). Under the reaction 
conditions, no sign of side reaction such as hydroamination or Mizoroki-Heck coupling for 
solvents possessing double bonds was observed. As we obtained excellent results in many of 
the tested solvents, we performed several experiments in the best 3 solvent candidates 
(limonene, DMC, α-pinene) to check their scope tolerance. We found that limonene, DMC gave 
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pinene, which showed high substrate dependence (Paper III, Scheme 2). Among other 
renewable solvents DMC is described to be less toxic, cheaper and more viable replacement for 
toluene.216–219 Thus, we tested the reaction scope to check the generality of the reaction in DMC. 
The renewable solvent DMC showed excellent performance throughout the tested scope and 
showed tolerance for many functional groups on both coupling partners. In general, aryl 
bromides with electron-withdrawing groups provided the product in high to quantitative yields 
(81-99%). However, electron-rich aryl bromides were obtained from low to moderate yields 
(16-64%). Different amines were also tested and both electron-rich or electron-deficient 
primary and secondary amines were well tolerated and the desired products were obtained in 
high to excellent yields (85-94%). In addition, we could synthesize commercial drugs such as 
Trimetozine,220,221 which is used as a sedative and analogue of Itopride,222–224 which is used for 
treatment of gastrointestinal symptoms in excellent yields (Paper III, Scheme 2). The scope of 
the reaction allowed for 20 examples of primary and secondary substituted amides (Scheme 40) 
and the results were in correlation with reports of aminocarbonylation in non-renewable 
solvents. We therefore conclude that renewable solvents such as limonene and DMC can 
efficiently replace toluene, THF or dioxane that are usually used in Pd-catalyzed 
aminocarbonylation reactions.139,158,159,163,166,176  
 
Scheme 40. Aminocarbonylation in dimethyl carbonate. 
Alkoxycarbonylation (C-O) 
Similarly, in case of alkoxycarbonylation, we preliminary tested the renewable solvents on a 
model reaction of 2-bromonaphthalene with sodium tert-butoxide and CO using the catalytic 
system based on Pd(dba)2 as catalyst precursor and 1,1′-bis(diisopropylphosphino)ferrocene 
(dippf) as ligand in THF that was first developed in the Skrydstrup group.171 As expected, 2-
MeTHF gave excellent results (91%). Non-polar ethers like methylal, ethylal, acetal, rose oxide 
and eucalyptol and carbonates like DEC showed moderate efficiency and the product was 
obtained in 45, 64, 55, 36, 82 and 45% yield. Polar solvents such as PC, EC, GVL and dimethyl 
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64%). In case of non-polar carbonate DMC, the alkoxycarbonylation worked well, but we 
obtained methyl ester in 93% isolated yield instead of tert-butyl ester. DMC played a dual role 
in the reaction where it worked as the reaction medium and as a reagent, which allowed for a 
transesterification step on the tert-butyl ester. However, the non-polar hydrocarbons γ-terpinene 
and α-pinene gave also excellent yields of 93%. 
As several solvents showed good performance in tert-butoxycarbonylation, we tested 
the best 3 candidates (2-MeTHF, γ-terpinene, α-pinene) with several substrate to check their 
scope tolerance. The experiments showed that the performance of the solvent depends on the 
substrate. However, α-pinene showed good general tolerance with the tested substrates. Then 
we tested the reaction scope to evaluate the generality of tert-butoxycarbonylation in α-pinene. 
Electron-rich aryl bromides could be transformed to the corresponding tert-butyl ester in 
moderate to excellent yields (80-93%), while electron-deficient aryl bromides were less 
reactive and the products were obtained in low to moderate yields (25-51%). The scope resulted 
in 10 examples and the yields are comparable original reported results in THF.171 Therefore, 
we suggest that renewable solvents such as 2-MeTHF, α-pinene and γ-terpinene can replace 
non-renewable solvents (DMSO, THF, TEA, etc.) that are usually used for alkoxycarbonylation 
reactions.170-173 
 
Further studies on the renewable solvent DMC 
As mentioned before (Chapter 3.3.1) Pd-catalyzed alkoxycarbonylation of aryl bromides are 
mainly based on using bulky alcohols, phenols or corresponding alkoxides.168,169,134,170,171,172,173 
Alcohols containing α-hydrogens were found to be challenging due to the side reactions they 
can undergo, such as  b-hydride elimination. Moreover, low boiling point alcohols e.g; 
methanol could be challenging. Thus, we were encouraged to investigate the scope of the 
observed methoxycarbonylation in (Paper III, Scheme 4). Electron-rich aryl bromides gave 
excellent yields, while electron-deficient aryl bromides were less reactive and gave only 
moderate yields. Traces of tert-butoxycarbonylation product were always observed with the 
main methoxycarbonylation product throughout the whole scope. 
We intended to perform a set of control experiments to gain closer overview of the 
possible products of the reaction and to confirm that obtaining the methyl ester occurs after the 
initial installation of the tert-butyl ester resulted from the tert-butoxycarbonylation mechanism 






when treated with NaOtBu in DMC. According to the experimental results, the 
transesterification happens both with and without the Pd-catalyst (Scheme 41). However, when 
testing methoxycarbonylation of 2-bromonaphtalene using MeONa as a nucleophile in DMC, 
the corresponding methyl ester resulted in 67% yield (Scheme 42, c). While the same reaction 
in α-pinene resulted in no product and the starting material was recovered (Scheme 42, d). 
 
Scheme 41. Control experiment on tert-butyl 2-naphthoate. 
These results indicate that the observed methoxycarbonylation can be a result of two 
simultaneous pathways. In one pathway, the tert-butyl ester is installed on the aryl bromide via 
Pd-catalyzed alkoxycarbonlyation followed by a transesterification with sodium methoxide 
generated in situ from the reaction of the excess sodium tert-butoxide with DMC. In the other 
pathway, in-situ generated sodium methoxide in involved in a Pd-catalyzed 
methoxycarbonylation. 
 
Scheme 42. MeONa initiated alkoxycarbonylation in DMC. 
6.3 Additional results not included in Paper III 
Column chromatography (C.C) and extraction are important means of purification. Common 
organic solvents used in these processes are heptane, DCM, MeOH, EtOAc, and many more. 
The amount of solvent needed for each synthesis until obtaining the pure product could reach 
couple of liters. Therefore, it is of high importance to find sustainable alternatives for the 
common solvents used in the purification process. The success of the renewable solvents as 
sustainable reaction medium in the reactions studied in paper III encouraged us to test them as 
a purification and isolation medium. Therefore, we attempted to replace the common non-polar 










































Therefore, we tested some non-polar hydrocarbons such as p-cymene (bp = 177 °C), 
careen (bp = 171 °C) and dipentene (bp = 170-180 °C) as the mobile phase in C.C to each model 
reaction of the three transformation - carbonylative SMC, aminocarbonylation and 
alkoxycarbonylation. In case of p-cymene as eluent, we faced difficulties with visualizing the 
compounds spots on the TLC plate and thus difficult separation. As p-cymene is a UV active 
solvent with high boiling point (177 °C), evaporating the TLC plate and detecting the spots was 
not successful. In case of carene and dipentene, we saw good separation on TLC. The product 
was separated with similar solvent system as for heptane-EtOAc mixtures. However, after 
evaporation of the pure fractions, we always noticed some remaining solvent together with the 
pure product. The solvent residues could not be removed using rotavap, high vacuum pump or 
overnight freeze drying. Thus, with the time available, we were not able to provide a green CC 
system. However, among the introduced sustainable solvents and other new candidates there 
might be some solvent that could replace common organic solvent in purification processes. 
Finding green CC systems is an important goal that should gain research interest. The field of 
green chemistry is a wide field and the development of greener methods including finding new 
sustainable solvents and testing them for application is interesting and useful environmental 
wise.  
6.4 Conclusion from Paper III 
The goal of this study was to determine green solvents for Pd-catalyzed carbonylative C-C, C-
N, and C-O bond forming reactions. A sub-goal was to find conditions that could be used in the 
synthesis of VIM-2 inhibitory fragments. We have found several renewable solvents, which 
can successfully substitute traditional non-renewable solvents for three types of palladium 
catalyzed cross-coupling transformations. Our investigation regarding carbonylative coupling 
reactions has proven that limonene and its derivatives (γ-Terp, α-Pin, Cym) can replace non-
polar petroleum solvents such as toluene, dioxane in both carbonylative SMC, 
aminocarbonylations and alkoxycarbonylations.  
Another stream of sustainable solvents including new candidates such as acetaldehyde diethyl 
acetal - readily available from ethanol;	eucalyptol - from Eucalyptus oil; rose oxide - from rose 
oil has been introduced. However, they showed weaker performance in comparison to the other 
solvent candidates. We also reported the behavior of CO2 derived solvents (DMC, DEC, PC) 






solvents was found to be good. Especially DMC was an excellent media for aminocarbonylation 
and alkoxycarbonylation. In addition, DMC can be used in methoxycarbonylation reaction 
instead of using the low boiling point methanol to avoid associating problems such as 
evaporation or side reactions as b-hydride elimination. It also could serve as transesterification 
agent to obtain methyl ester in late stage optimization.  
With regard to the synthesis of VIM-2 inhibitory fragments, more experiments are 
needed to evaluate if the procedures described in paper III will give excess to a broader 



























The aim of the thesis was to develop methods for the synthesis of carbapenemase inhibitors 
targeting OXA-48 and VIM-2 using a fragment based approach based on previous work in our 
group13–15,107 and to apply the methods to the synthesis of inhibitory fragments or inhibitors. 
 In chapter 4, a synthesis of a range of symmetrical and unsymmetrical 3,5-disubstituted 
benzoic acids using selective Suzuki-Miyaura coupling was developed. The synthesis of 3,5-
disubstituted benzoic acids was according to the merging approach of the promising mono-
substituted benzoic acids targeting OXA-48 reported in paper I. The synthesized di-substituted 
benzoic acid fragments were evaluated and their inhibition activity was found to be better than 
the mono-substituted benzoic acids. Crystal structures of the tested fragments were obtained 
and provided us with further knowledge about the active site of OXA-48 to be used for further 
development. 
In chapter 5, I developed a method for the synthesis of 2-aroylbenzoic acids and 
derivatives via carbonylative SMC using CO gas in a safe fashion. Challenges found upon 
synthesizing 2-aroylbenzoic acids were also discussed together with suggested solutions. In 
addition, I discovered the importance of slow addition of the boronic acid to suppress the 
competing SMC and to favor the carbonylative SMC. The developed method resulted in a range 
of 2-aroylbenzoic acids that were tested and evaluated against the carbapenamase VIM-2. The 
tested fragments gave IC50 values in the µM range. However, we were not able to expand the 
fragment library to include specific groups such as OH, NH2, NHR, etc. Accordingly, an 
expanded study to find a better system to include more challenging substrate was carried out. 
 In chapter 6, I tried to extend our study to find better reaction conditions to cover the 
scope limitations in paper II. In addition, I aimed to synthesize a larger fragment library to test 
against VIM-2. During the study, we found that sustainable solvents are efficient in Pd-
catalyzed coupling reactions and a wide range of sustainable solvents was tested to evaluate 
their impact on Pd-catalyzed couplings. The effect of sustainable solvents in the challenging 
carbonylative SMC, alkoxycarbonylation and aminocarbonylation was investigated. The tested 
sustainable solvents showed very good results in all the aforementioned reactions. Due to time 






 The work presented in the thesis could be a starting point towards the synthesis of 
inhibitors against VIM-2, OXA-48, and maybe other carbapenemases. The developed synthetic 
methods could also be applied in many other research projects where selective SMC and Pd-
catalyzed carbonylation reactions are employed. The sustainability approach that we addressed 
in this work is a valuable approach to consider, while running organic chemical reactions. The 
promising results obtained with Pd-catalyzed carbonylations using sustainable solvents are very 
encouraging to be taken further and to be tested in many other chemical transformations. 
Therefore, our research recommends including sustainability considerations as a priority in the 
future studies. The addressed research points in paper I, II, III are of high interest for further 




































8. Future direction 
 
The ultimate goal of my thesis was to use fragment optimization approaches to improve 
previously identified fragments into drug like compounds with better binding affinity against 
carbapenemases VIM-2 & OXA-48. This goal is part of a larger goal to discover new inhibitors 
that can reach clinical trials and can be used in combination therapy with carbapenem in order 
to save the last resort antibiotic class carbapenems.  
I focused on developing synthetic strategies to prepare 3,5-symmetrical and 
unsymmetrical disubstituted benzoic acids as extended fragments targeting OXA-48. These 
types of compounds were designed to reach the two identified binding sites. The future goal of 
this project is to further investigate the synthesis of the third fragment suggested by the merging 
approach PI-41.  
In silico optimization study performed by Sundus Akhter suggested that growing the 
fragment in the 2-ortho position might favor binding in the inner binding pocket instead of 
pointing out to the solvent. Therefore, we intended to extend the fragments in the 2-ortho 
position instead of 3-meta position. I supervised a master student, Harald Magnussen, that was 
responsible of preparing a library of 2,5-disubstituted benzoic acids from methyl 2-amino-5-
bromobenzoate. The synthesized fragment (Scheme 43, Fragment 32H) was submitted for 
biological testing. The fragment showed comparable IC50 (3.275 µM) to fragment PI-40. 
However, the LE of fragment 32 (0.24 kcal/(mol atom) was slightly lower than fragment PI-40 
(0.27 kcal/(mol atom). In the future a crystal structure of fragment/OXA-48 complex is a logical 
step in order to identify the binding modes of 2,5-disubstituted fragments assembled in 
fragment 32.  
 
























In paper II, I developed a method to synthesize a range of sterically hindered 2-
aroylbenzoic acid derivatives from simple boronic acids via carbonylative SMC. Applying slow 
addition of boronic acid to the reaction is a promising approach to suppress the undesired direct 
SMC coupling. This work was continued in Paper III and the choice of the renewable solvents 
showed great impact on the tested Pd-catalyzed carbonylation reactions. Limonene showed 
good performance in carbonylative SMC and it favored the carbonylation product over the 
direct coupling product without applying the slow addition. In future work, it would be 
interesting to combine the findings of paper II and III - slow addition of boronic acid and the 
use of renewable solvent. The future goal regarding this project is to test carbonylative coupling 
to synthesize the challenging substrates, which contain functional groups such as phenols, 
amides, amines, and strong electron-withdrawing groups such as nitro, nitrile, which can allow 



























This chapter includes additional experimental procedures and spectral data for compounds not 
included in paper II and presented in Table 8, entry 1-7. 
9.1 Experimental  
9.1.1  General methods 
 
All purchased chemicals were used as received without further purification. Solvents were dried 
according to standard procedures. Automated reverse-phase flash chromatography was 
performed using pre-packed C18-modified silica columns. The chemical shifts are reported in 
ppm relative to the solvent residual peak. NMR spectra were obtained on a 400 MHz Bruker 
Avance III HD equipped with a 5 mm SmartProbe BB/1H (BB = 19F, 31P-15N). Data are 
represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet), coupling constant (J, Hz) and integration. Chemical shifts (δ) are 
reported in ppm relative to the residual solvent peak (CDCl3: δH 7.26 and δC 77.16; Methanol-
d4: δH 3.31 and δC 49.00; Deuteriumoxide: δH 4.79; DMSO-d6: δH 2.51 and δC 39.52). The raw 
data was analysed with MestReNova (Version 10.0.2-15465). Positive ion electrospray 
ionization mass spectrometry was conducted on a Thermo electron LTQ Orbitrap XL 
spectrometer. The data was analysed with Thermo Scientific Xcalibur software.  
9.1.2 Experimental details 
 
1- 2-(4-fluorobenzoyl)benzoic acid 
  
Anhydrous AlCl3 (91 mg, 0.68 mmol) was suspended in fluorobenzene (20 ml) before phthalic 
anhydride (50 mg, 0.34 mmol) was added in portions to the reaction mixture at 0 oC while 
stirring. Upon complete addition of the phthalic anhydride, the reaction mixture was submitted 
to reflux for 3h. The reaction was quenched by adding ice-cold HCl (50%, 100 mL). The 
reaction mixture was concentrated on a rotavapor. The precipitate was dissolved in sodium 






the solid product was filtered and submitted for further purification by reverse phase flash 
chromatography using 30% acetonitrile: H2O. The pure product was obtained (50 mg, 60%) as 
a white powder. 1H NMR (400 MHz, CDCl3) δ 10.22 (bs, 1H), 8.09 (d, J = 7.6 Hz, 1H), 7.80 – 
7.71 (m, 2H), 7.69-7.65 (m, 1H), 7.59-7.55 (m, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.08 (t, J = 8.6 
Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 195.6, 170.9, 165.9 (d, J = 255.3 Hz), 142.4, 133.6 (d, 
J = 2.9 Hz), 133.5, 132.1 (d, J = 9.4 Hz), 131.1, 129.8, 127.8, 127.7, 115.9, 115.7, 77.5, 77.4, 
77.2, 76.8. HRMS (ESI): Calcd. for C14H9FNaO3 [M+H]+ 267.0428; found 
C14H9FNaO3 267.0428.  
 
2- 2-(4-methylbenzoyl)benzoic acid226,227 
  
Anhydrous AlCl3 (91 mg, 0.68 mmol) was suspended in toluene (20 ml) before phthalic 
anhydride (50 mg, 0.34 mmol) was added in portions to the reaction mixture at 0 oC while 
stirring. Upon complete addition of the phthalic anhydride, the reaction mixture was submitted 
to reflux for 3h-6h. The reaction was quenched by adding ice-cold HCl (50%, 100 mL). The 
reaction mixture was concentrated on a rotavapor. The precipitate was dissolved in sodium 
carbonate solution and then filtered. The resulted filtrate was acidified with aqueous HCl and 
the solid product was filtered and submitted for further purification by reverse phase flash 
chromatography. The pure product was obtained (71 mg, 87%) as a white powder. 1H NMR 
(400 MHz, CDCl3) δ 8.06 (d, J = 7.6 Hz, 1H), 7.66-7.62 (m, 3H), 7.54 (t, J = 7.6 Hz, 1H), 7.35 
(d, J = 7.6 Hz, 1H), 7.20 (d, J = 7.8 Hz, 2H), 5.86 (bs, 1H), 2.39 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.4, 144.2, 142.9, 134.6, 133.1, 130.9, 129.7, 129.5, 129.3, 128.2, 127.7, 21.8. 
HRMS (ESI): Calcd. for C15H12NaO3 [M+H]+ 263.0679; found C15H12NaO3 263.0680.  
 
3- 2-(3,4-dimethoxybenzoyl)benzoic acid228 
1,2-dimethoxybenzene (47 mg, 34 mmol) and phthalic anhydride (50 mg, 0.34 mmol) were 
added to a suspension of AlCl3 (91 mg, 0.68 mmol) in DCM (20 ml) at 0 °C. The reaction was 









The organic layer was collected and dried over MgSO4. The organic phase was concentrated 
on a rotavapor and the residue was triturated with diethyl ether. The product was submitted to 
reverse phase flash chromatography resulting in pure product (44 mg, 45%) as a yellowish 
solid. 1H NMR (400 MHz, DMSO-d6) δ 13.03 (s, 1H), 7.93 (d, J = 7.4 Hz, 1H), 7.72 – 7.54 (m, 
2H), 7.35 (d, J = 12.3 Hz, 2H), 6.95 (s, 2H), 3.76 (s, 6H). 13C NMR (101 MHz, DMSO-d6) δ 
204.40, 176.45, 162.56, 158.23, 150.96, 141.65, 139.53, 139.38, 139.17, 139.02, 136.98, 
134.22, 120.21, 119.60, 65.26, 64.95. HRMS (ESI): Calcd. for C16H14NaO5 [M+H]+ 309.0739; 
found C16H15NaO5 309.0737.  
 
4- 2-benzoylbenzoic acid226,227 
  
Anhydrous AlCl3 (91 mg, 0.68 mmol) was suspended in benzene (20 ml) before phthalic 
anhydride (50 mg, 0.34 mmol) was added in portions to the reaction mixture at 0 oC while 
stirring. Upon complete addition of the phthalic anhydride, the reaction mixture was submitted 
to reflux for 5h. The reaction was quenched by adding ice-cold HCl (50%, 100 mL). The 
reaction mixture was concentrated on a rotavapor. The precipitated product was dissolved in 
sodium carbonate solution and then filtered. The resulted filtrate was acidified with aqueous 
HCl and the solid product was filtered. The pure product was collected without further 
purification (69 mg, 90%) as white powder.1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 7.8 Hz, 
1H), 7.72 (d, J = 7.6 Hz, 2H), 7.69-7.65 (m, 1H), 7.59-7.52 (m, 2H), 7.45-7.35 (m, 3H), 5.07 
(bs, 1H). 13C NMR (101 MHz, CDCl3) δ 197.5, 170.5, 143.0, 137.4, 133.6, 133.6, 131.3, 123.0, 
129.9, 128.9, 128.4, 128.2, 77.8, 77.7, 77.5, 77.2. HRMS (ESI): Calcd. for C14H10NaO3 [M+H]+ 
249.0522; found C14H10NaO3 249.0527.  
 







Phthalic anhydride (500 mg, 3.4 mmol) was added to the pyridine-2-amine (390 mg, 4.1 mmol) 
in DCM (20 mL) and the reaction mixture was left stirring for 18h at room temperature. The 
product was recrystallized in DCM, the pure product was obtained by vacuum filtration in (710 
mg, 85%) yield.1H NMR (400 MHz, MeOD) δ 8.24-8.20 (m, 1H), 7.93-7.91 (m, 1H), 7.81-7.78 
(m, 1H), 7.69-7.65 (m, 1H), 7.62-7.50 (m, 2H), 7.12-7.09 (m, 1H), 6.78 (d, J = 8.7 Hz, 1H), 
6.70 (t, J = 6.5 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 158.6, 154.2, 147.8, 146.6, 144.7, 
137.0, 136.2, 135.9, 133.9, 126.2, 121.2, 118.8, 118.0, 54.9, 54.6, 54.4, 54.2, 54.0, 53.7, 53.5. 
HRMS (ESI): Calcd. For C13H11O3N2 [M+H]+ 243.0770; found C13H11O3N2 243.0771.  
 
6- 2-(7-bromo-1H-indole-3-carbonyl)benzoic acid 
  
Anhydrous AlCl3 (91 mg, 0.68 mmol) was suspended in DCM (20 ml) before phthalic 
anhydride (50 mg, 0.34 mmol) and 7-bromoindole (67 mg, 34 mmol) were added in portions to 
the reaction mixture at 0 oC while stirring. Upon complete addition of the phthalic anhydride, 
the reaction mixture was submitted to reflux for 6h. The reaction was quenched by adding ice-
cold HCl (50%, 100 mL). The reaction mixture was concentrated on a rotavapor. The 
precipitated product was dissolved in sodium carbonate solution and then filtered. The resulted 
filtrate was acidified with aqueous HCl and extracted with EtOAc. The organic phase was 
collected, dried over Na2SO4 and concentrated on a rotavapor. The product was submitted for 
to reverse phase flash chromatography using 30-50% acetonitrile: H2O. The pure product was 
obtained (78 mg, 67%) as a gummy solid. 1H NMR (400 MHz, MeOD) δ 8.18 (d, J = 7.9 Hz, 
1H), 8.05 (d, J = 7.7 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.49 (d, J = 7.4 
Hz, 1H), 7.44 (d, J = 7.7 Hz, 2H), 7.15 (t, J = 7.8 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 
194.6, 169.5, 144.1, 137.1, 136.9, 133.1, 131.4, 130.6, 128.9, 127.2, 124.5, 122.2, 119.8, 105.9. 









7-  2-(phenylcarbamoyl)benzoic acid229 
Phthalic anhydride (500 mg, 3.4 mmol) was added to the aniline (380 mg, 4.1 mmol) in 
DCM (20 mL) and the reaction mixture was left stirring for 6h at room temperature. The 
product was obtained by vacuum filtration. The precipitate was recrystallized in DCM-
heptane mixture. The pure product was obtained (76 mg, 92%) a white solid. 1H NMR (400 
MHz, MeOD) δ 8.02 (d, J = 7.5 Hz, 1H), 7.65-7.63 (m, 3H), 7.57-7.55 (m, 2H), 7.33 (t, J 
= 7.7 Hz, 2H), 7.12 (m, 2H), 6.77-6.70 (m, 2H). 13C NMR (101 MHz, MeOD) δ 171.1, 
169.3, 140.3, 140.1, 133.2, 131.4, 130.6, 130.1, 129.7, 128.8, 125.4, 121.7, 119.9, 117.1, 
49.6, 5.4, 49.2, 49.0, 48.8, 48.6, 48.6. HRMS (ESI): Calcd. for C14H11NNaO3 [M+H]+ 









































111-6D_180907162546 #1-5 RT: 0.00-0.11 AV: 5 NL: 7.16E7
T: FTMS + p ESI Full ms [200.00-500.00]



















































ABAI_1 #1-5 RT: 0.01-0.13 AV: 5 NL: 8.63E6
T: FTMS + p ESI Full ms [100.00-500.00]































































1,2 dimeth biotag 2 #1-5 RT: 0.01-0.12 AV: 5 NL: 5.54E6
T: FTMS + p ESI Full ms [200.00-500.00]
























































ABAI-1-6 #1-5 RT: 0.00-0.11 AV: 5 NL: 1.08E7
T: FTMS + p ESI Full ms [150.00-500.00]





























































ABAI-1-5-2 #1-5 RT: 0.01-0.14 AV: 5 NL: 1.02E6
T: FTMS + p ESI Full ms [150.00-500.00]



























































abai_9_7bro #1-5 RT: 0.01-0.12 AV: 5 NL: 3.84E6
T: FTMS + p ESI Full ms [150.00-500.00]




























































anil test pow #1-5 RT: 0.01-0.16 AV: 5 NL: 1.02E6
T: FTMS + p ESI Full ms [150.00-500.00]
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a b s t r a c t
b-Lactam antibiotics are of utmost importance when treating bacterial infections in the medical com-
munity. However, currently their utility is threatened by the emergence and spread of b-lactam resis-
tance. The most prevalent resistance mechanism to b-lactam antibiotics is expression of b-lactamase
enzymes. One way to overcome resistance caused by b-lactamases, is the development of b-lactamase
inhibitors and today several b-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is
the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly
identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely
substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48 for useful enzyme-
inhibitor interactions. In the presented study, a focused fragment library containing 49 3-substituted
benzoic acid derivatives were synthesised and biochemically characterized. Based on crystallographic
data from 33 fragment-enzyme complexes, the fragments could be classified into R1 or R2 binders by
their overall binding conformation in relation to the binding of the R1 and R2 side groups of imipenem.
Moreover, binding interactions attractive for future inhibitor design were found and their usefulness
explored by the rational design and evaluation of merged inhibitors from orthogonally binding frag-
ments. The best inhibitors among the resulting 3,5-disubstituted benzoic acids showed inhibitory po-
tential in the low micromolar range (IC50¼ 2.9 mM). For these inhibitors, the complex X-ray structures
revealed non-covalent binding to Arg250, Arg214 and Tyr211 in the active site and the interactions
observed with the mono-substituted fragments were also identified in the merged structures.
© 2018 Elsevier Masson SAS. All rights reserved.
1. Introduction
Years of overuse of antibiotics have selected for antibiotic
resistant strains [1], and today medical personnel are frequently
forced to administer last-resort antibiotics. However, the number
of cases where last-resort antibiotics fail in treatment are
increasing [2] and deaths due to antibiotic resistant infections are
expected to surpass cancer deaths by 2050 [3]. Bacterial resistance
towards clinically important b-lactam antibiotics [4] like penicil-
lins, cephalosporins and carbapenems originates most often from
the occurrence of b-lactam-hydrolysing enzymes e the b-
lactamases.
The b-lactamase enzymes are of ancient origin [5] and today
over 2600 enzymes spanning four classes of b-lactamases are
known [6e8]. b-Lactamases are grouped into two super families
based on the enzyme mechanism for b-lactam hydrolysis: the
serine dependent b-lactamases (SBLs; Amber class A, C, and D) and
metallo-b-lactamases (MBLs; Amber class B) [7,9]. SBLs are char-
acterized by a serine residue in the active site, while MBLs require a
metal co-factor, usually one or two zinc ions, for enzyme activity.
This work focuses on the class D SBLs e also called oxacillinases
(OXAs) e and in particular on the oxacillinase-48 (OXA-48).
Abbreviations: DMSO, dimethyl sulfoxide; OXA, oxacillinase; IC50, half maximal
inhibitory concentration; LE, ligand efficiency; MBL, metallo-b-lactamase; NMR,
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The class D SBLs are characterized by a hydrophobic environ-
ment in the active site, that facilitates the carboxylation of a lysine
residue. The N-carboxylated lysine plays a critical role in the sub-
strate hydrolysis [10]. Originally, the OXAs were believed to have a
limited substrate profile only hydrolysing penicillins, but with the
emergence of carbapenem-hydrolysing OXA variants, e.g. OXA-23,
OXA-24 and OXA-48, their clinical relevance has increased [11].
OXA-48 was reported for the first time in 2001 and has since then
spread rapidly across the world [11]. It is commonly identified in
Escherichia coli and Klebsiella pneumoniae.
One strategy to circumvent resistance in b-lactamase producing
pathogens is the use of b-lactamases inhibitors [4,12] in combina-
tion with the b-lactam antibiotic. Inhibitors of class A SBLs like
clavulanic acid, sulbactam and tazobactam became clinically
available from the 1980s [13], but only a few class D b-lactamases
are inhibited by these b-lactamase inhibitors e.g. OXA-2 and OXA-
18 [14]. In 2015, a new SBL inhibitor, avibactam, targeting class A,
C and some class D SBLs, including OXA-48, was approved by the
FDA for treatment of complicated urinary tract and intra-
abdominal infections [15]. However, the inhibition level of
different class D b-lactamases by avibactam varies [16,17]. With the
first reports of resistance to avibactam published [18], one can
speculate that it will only be a matter of time before class D b-
lactamases show resistance to avibactam as well.
The development of new OXA inhibitors, either with a different
enzyme-inhibition profile compared to existing inhibitors, or as
alternative when resistance to existing inhibitors arises, is of
importance. We have previously reported a fragment-based
screening approach to identify weak inhibitors of OXA-48 [19].
The most interesting hit was 3-(pyridin-4-yl)benzoic acid 1 with
an IC50 of 250 mM and a ligand efficiency (LE) of 0.32. Crystallo-
graphic data from enzyme-fragment complexes indicated two
overlapping binding conformations of the fragment. Merging of
the two conformations of 1 into one molecule 2 (Fig. 1) gave a 10-
fold increase in binding affinity improving the IC50 from 250 mM to
18 mM [19].
In this study, we describe the use of small mono-substituted
fragments - analogues of fragment 1 - as probes to explore the
OXA-48 binding site. The aim was to identify fragment-enzyme
interactions in the two alternate binding pockets of the active site
of OXA-48, which could be of general interest for the design of OXA-
48 inhibitors. Wewanted to exploit the ability of small fragments to
efficiently explore the binding pocket as they are less restricted by
size and more flexible compared to more elaborated inhibitors.
Moreover, the smaller fragments generally have the advantage of
being more easily prepared making the discovery process more
work-efficient. Furthermore, wewanted to translate the knowledge
gained into the rational design of di-substituted inhibitors related
to compound 2 circumventing the laborious preparation of a large
library of elaborated inhibitors.
Towards this goal, we prepared a focused fragment library
containing 3-aryl benzoic acids decorated with a wide range of
polar groups and a number of 3-heteroaryl benzoic acid derivatives.
In total 49 fragments were tested for inhibitory activity against
OXA-48 and the binding conformations of 33 fragment-enzyme
complexes were analyzed by X-ray crystallography. Based on the
structural information, fragments could be classified according to
their preferred binding pocket and useful fragment-enzyme in-
teractions e.g. hydrogen bonds were identified. Moreover, several
new orthogonally binding fragments were found leading to the
design of symmetrically and unsymmetrically di-substituted in-
hibitors with improved IC50 in the low micromolar range. The
structural data from enzyme-inhibitor complexes was compared
with enzyme-fragment complexes.
2. Results and discussion
2.1. Synthesis
2.1.1. Synthesis of 3-substituted benzoic acids
A fragment library containing 49 3-substituted benzoic acid
analogues 3ae35 was prepared (Table 1). The fragments generally
fulfilled the demands of libraries for fragment-based ligand design
(MW< 300, clogP< 3, hydrogen bond acceptor/donors< 3) [20].
For the synthesis, a strategy based on the Suzuki-Miyaura (SM)
cross-coupling reaction to join two sp2ehybridized carbons was
employed [21]. Two alternate coupling strategies were successful
starting with either 3-bromobenzoic acid (Table 1, strategy A) or 3-
carboxyphenylboronic acid pinacol ester (Table 1, strategy B) as
starting materials allowing for the utilisation of a wide range of aryl
boronic acids or aryl bromides to introduce diversity in the library.
Many of the required aryl boronic acids and bromides were
commercial available, while the aryl bromides used as starting
materials for fragments 17e20, 24, 29 and 30 were prepared ac-
cording to standard acylation and sulphonylation protocols. The
NH-tetrazol-5-yl-substituted arylbromides (starting material for
fragments 26a and 26b) were prepared by a [3 þ 2] intermolecular
cycloaddition of 3- or 4-bromobenzonitrile with trimethyl silyl
azide in the presence of dibutyltin oxide in anhydrous 1,4-dioxane.
The reaction mixture was subjected to microwave irradiation in a
tightly sealed vessel for 50 min at 150 #C to afford 3- or 4-
bromobenzotetrazole in 86% and 82% yield, respectively.
In general, couplings under standard aqueous conditions using
PdCl2(PPh3)2 as catalyst (5e10mol%), K3PO4 as base (5 equiv.) in
dioxane/water gave good yields. The couplings leading to frag-
ments 9, 17e20 and 22e24 were not successful under these stan-
dard conditions. More efficient catalysts (XPhos-Pd G2 or
PdCl2(dppf)) and water-free conditions (anhydrous THF instead of
dioxane/water) were successfully employed to solve reactivity and
solubility problems and to prevent hydrolysis for base sensitive
products (9 and 24). However, for some products (19a, 19b and 20)
the yields were still low (<20%). Generally, the reactions were easily
purified by automated C18 flash chromatography to provide com-
pounds of high purity (>95% as determined by UHPLC). For some
compounds (15, 16, 19, 23, 24, 32 and 34), additional silica flash
chromatography was necessary to provide sufficiently pure
products.
2.1.2. Synthesis of 3,5-disubstituted benzoic acid derivatives
To study inhibitor properties like activity and enzyme in-
teractions of merged fragments, a small series of symmetrical and
unsymmetrical 3,5-disubstituted benzoic acids was designed (vide
infra) and prepared. The synthesis of symmetrical 3,5-disubstituted
compounds 36 and 38 was achieved under the conditions estab-
lished for the coupling of mono-substituted fragments using Pd2
(dba)3/XPhos or XPhos-Pd G2 as catalysts (Scheme 1) [19]. The di-
substituted coupling products 36 and 38 were obtained from 3,5-
dibromobenzoic acid as starting material and an increased
amount of the boronic acid derivative (2 equiv.) in 54% and 65%
yield, respectively. Compound 37 was isolated in 11% yield as by-
product in an attempt to selectively mono-substituted 3,5-
dibromobenzoic acid (vide infra).
For the synthesis of unsymmetrical 3,5-disubstituted benzoic
acids 39, the sequential addition of two different aryl boronic acids
under the previously established conditions gave only 15% isolated
yield (Scheme 2). In addition, the procedure involved tedious HPLC
purifications as the reaction mixture was difficult to purify due to
occurrence of symmetrical by-products with similar properties. To
improve the selectivity of the reaction, we changed the starting
material from 3,5-dibromobenzoic acid to 3-iodo-5-bromobenzoic
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acid in order to take advantage of the faster coupling reaction of
aryl iodides when compared with aryl bromides and thereby to
prevent formation of symmetrical disubstituted by-products
(Scheme 2). Investigation of the chemoselective coupling of 3-
iodo-5-bromobenzoic acid with quinolin-6ylboronic acid pinacol
ester to form mono-substituted int-40 showed that a second, un-
wanted coupling was not easily prevented and a careful fine tuning
of catalyst (RuPhos-Pd G3, XantPhos-Pd G3, Sphos/Pd2 (dba)3,
Xphos/Pd2 (dba)3, SPhos-Pd G3, XPhos-Pd G2, Pd2 (dppf)Cl2), sol-
vent (toluene/water, anhydrous THF, dioxane/water, tert-butanol),
reaction temperature (40e80 #C) and time (10e48 h) was initiated
(Table SI1, see Supporting information). The composition of the
crude reaction mixtures with respect to mono- and disubstituted
products as well as unreacted starting material was determined by
mass spectrometry (MS). The most chemoselective catalysts were
XantPhos-Pd G3, Pd2 (dppf)Cl2 and SPhos/Pd2 (dba)3 showing good
selectivity for the aryl iodide when the reaction was performed
with K3PO4 as base in dioxane/water at 60 #C for 24 h (Scheme 2). At
this conditions with SPhos/Pd2 (dba)3 as catalyst, the mono-
substituted intermediate int-40 was obtained as main product
together with small amounts of the disubstituted by-product
(8e10%). Careful purification to remove any traces of the disubsti-
tuted compound provided int-40 in moderate yield (45%). The
mono-substituted int-40 was further subjected to a second
coupling with XPhos-Pd G2 (5mol%) as catalyst to provide 40 in
good yields (90%).
2.2. Evaluation of 3-substituted benzoic acids
2.2.1. Inhibitor activity of 3-substituted benzoic acids
The mono-substituted fragments 3e35 were initially investi-
gated for their inhibitory activity against OXA-48 in an enzymatic
assay and by SPR. Inhibition and binding data are given in Table 1
along with the associated ligand efficiencies (LE). The original hit
fragment 1 had an IC50 of 250 mM and an LE of 0.32. Most of the
fragments in this study showed inhibition at a similar level with
IC50> 200 mM and LE $ 0.30. Fragments 4a (IC50 (mM)/LE: 50/0.38),
18 (IC50 (mM)/LE: 60/0.24), 21a (IC50 (mM)/LE: 35/0.33), 26b (IC50
(mM)/LE: 36/0.30) and 35 (IC50 (mM)/LE: 35/0.42) showed an order
of magnitude stronger inhibition and were the most potent frag-
ments. Even though there are some discrepancies between the
inhibition and binding data, the same trends are maintained when
comparing similar compounds, indicating that the compounds
indeed bind specifically to one site of the enzyme.
2.2.2. Structural analysis of 3-substituted benzoic acids
To evaluate the binding poses of our fragments, enzyme-
fragment complexes for x-ray crystallographic analysis were pre-
pared. Rewardingly, 33 out of 49 fragments were successfully
soaked with OXA-48 and yielded crystal structures with resolution
high enough to warrant placement of the inhibitor in the electron
density (Table 1). In addition, a crystal structure of OXA-48 in
complex with the substrate imipenem was obtained to better un-
derstand substrate binding and to compare substrate and fragment
binding interactions.
The crystal structure of the acyl-enzyme complex of OXA-48
with imipenem (Fig. 2A) revealed a conformation close to previ-
ously observed conformations with OXA-13 (PDB-ID: 1h5x). In the
complex the ring-opened imipenem was bound to OXA-48 cova-
lently with continuous electron density from the hydroxyl group of
Ser70. There was an ionic bond from the carboxylate group of
imipenem to the guanidine group of Arg250. The carbonyl-group of
the now ring-opened b-lactam ring was positioned in the
oxyanion-hole forming hydrogen bonds to the main chain amides
of Tyr211 and Ser70. The 6a-hydroxyethyl group (R1) of imipenem
was positioned towards the hydrophobic residues Trp105, Val120
and Leu158 and in the following discussion this region will be
called the R1 site. The amidine group (R2) was situated in the cleft
defined by Ile102, Tyr211, Leu247 and Thr213 and this regionwill be
called the R2 site. The R1 and R2 side chains of imipenem (Fig. 2A)
had the same overall directions as the pyridinyl substituents in the
two overlapping binding conformations observed with our initial
hit 3-pyridin-4-ylbenzoic acid 1 [19].
In all our structures of OXA-48 in complex with fragments, an
ionic bond between the carboxylate group of the fragments and the
guanidine group of Arg250 was observed, which resembled the
interaction of the carboxylate group of imipenem or the sulfamate
group of avibactam with Arg250 [17,22]. In some cases, the
carboxylate group was oriented in such a way that also Thr209
(fragments 9b, 28, 35), Lys208 (fragment 34) or both (fragment
26a) participated in binding.
Another common feature found in almost all crystal structures,
except for fragments 21a and 26b, was a p-p stacking interaction of
the 3-aryl substituents attached to the benzoic acid scaffold with
Tyr211. This is consistent with the binding of imipenem, where the
R2 side chainwas oriented towards Tyr211 (Fig. 2C). The importance
of Tyr211 as a non-polar patch that contributes in binding substrate
side-chains has been recognised before [23]. We also observed this
interactionwith our unsubstituted pyridyl benzoic acids previously
[19].
The weaker binding fragments (3a, 3b, 4aec, 5, 6aec, 8aec, 9b,
11b, 12a, 13, 14, 17, 24) all bound in nearly the same conformation
with the ionic bond of the benzoic acid and Arg250 and the p-p
stacking interaction with Tyr211 as major interactions. In these
structures, the 3-aryl substituent on the benzoic acid was directed
towards the R2 pocket (Fig. 2C). Only minor conformational dif-
ferences were observed as described in the following. To help the
reader in the following discussion, we will describe the fragments
by the identity of the Ar groups (Table 1), as the structural differ-
ences of the fragments relate to this group i.e. 3-(2-methyl)
Fig. 1. The two alternate conformations of fragment 1 (light grey) in complex with OXA-48 (dark grey surface) (A and B), the merged compound 2 (pink) in complex with OXA-48
(dark grey surface) (C), and a schematic view of the merging approach described in previous work (D) [19]. (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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Table 1
Preparation strategy and inhibitor activities of a library of 3-substituted benzoic acids analogues against OXA-48 (IC50, Kd and LE).
Comp. ID Ar¼ Strateg. Yield IC50 (mM) KD (mM) LEd Comp. ID Ar¼ Strateg. Yield IC50 (mM) KD (mM) LEd
3a* B 78% 90 170 0.35 11b* A 97% 180 350 0.29
3b* B 67% 170 300 0.33 12a* A 82% 120 150 0.29
4a* A 94% 50 175 0.38 12b A 90% 380 361 0.25
4b* A 98% 110 110 0.35 13* B 35% 330 330 0.29
4c* A 39% 470 170 0.29 14* A 95% 390 220 0.27
5* A 84% 900 230 0.25 15a B 36% 600 800 0.27
6a* A 98% 250 123 0.30 15b B 86% 1400 550 0.23
6b* A 98% 360 226 0.28 16a B 15% 110 300 0.31
6c* A 86% 150 250 0.31 16b B 67% 1000 970 0.23
7 A 91% 400 1000 0.28 17* Ba, c 41% 370 100 0.24
8a* A 68% 130 170 0.34 18 Ba, c 65% 60 210 0.24
8b* A 98% 130 240 0.34 19a Ba, c 26% 110 110 0.26
8c* A 78% 360 312 0.30 19b Ba, c 10% 450 240 0.22
9a Aa, c 57% 210 200 0.27 20 Ba, c 11% 370 200 0.22
9b* A 54% 260 144 0.26 21a* A 98% 35 100 0.33
10 A 98% 380 280 0.27 21b* A 98% 450 290 0.25
11a A 98% 260 220 0.28 22 Ba, b 87% 130 130 0.27
23a Ba, c 46% 230 170 0.24 29 B 36% 170 130 0.33
23b Ba, c 34% 520 190 0.22 30 B 45% 800 900 0.29
(continued on next page)
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phenylbenzoic acid 3a will be described as 2-methylphenyl
substituted fragment.
The methylphenyl substituted fragments 3a (IC50 (mM)/LE: 90/
0.35) and 3b (IC50 (mM)/LE: 170/0.33) had similar conformations,
however, the 2-methyl group in 3a was facing towards the hydro-
phobic Cb of Ser244 explaining the more favourable binding.
Fragments 4aec (IC50 (mM)/LE: 50/0.38, 110/0.35 and 470/0.29,
respectively) also had very similar conformations, but againwe saw
that more favourable van der Waals interactions gave higher af-
finity for the 2-hydroxyphenyl substituted 4a. The 4-hydroxy iso-
mer 4c had an unfavourable solvent exposure of the hydroxyl
group. Adding a methylene bridge yielding 3-
hydroxymethylphenyl 5 (IC50 (mM)/LE: 900/0.25) did not lead to
any favourable interactions. The methoxyphenyl fragments 6aec
(IC50 (mM)/LE: 250/0.30, 360/0.28 and 150/0.31) shared the ca-
nonical R2 binding pose. Themethoxy group of the 2-substituted 6a
appeared more shielded from solvent exposure than in 6b and 6c,
yet the methoxy group did not seem to make any strong contacts.
The weak inhibition seen with methyl thioether 7 (IC50 (mM)/LE:
400/0.28) corresponded to the results observed with the methoxy
ethers 6. The fluorophenyl substituted 8aec (IC50 (mM)/LE: 130/
0.34, 130/0.34 and 360/0.30) had nearly identical binding poses.
The 4-substituted 8c gave the highest IC50 value, most likely due to
the solvent exposed fluorine. The 2-substituted 8a seemed more
favourable based on the decreased solvent exposure of the fluorine
atom, however, the difference to 8b was negligible only observed
by SPR.
The methoxyacetylphenyl esters 9a and 9b (IC50 (mM)/LE: 210/
0.27 and 260/0.26) showed no clear additional interactions in the
complex structures with OXA-48, and the methyl group appeared
to be unfavourably exposed to the solvent. The corresponding 4-
Table 1 (continued )
Comp. ID Ar¼ Strateg. Yield IC50 (mM) KD (mM) LEd Comp. ID Ar¼ Strateg. Yield IC50 (mM) KD (mM) LEd
24* Aa, b 34% 250 140 0.25 31 B 67% 350 113 0.28
25 B 15% 1300 ˃1000 0.20 32 A 6% 500 590 0.31
26a* B 98% 60 70 0.30 33 B 24% 800 900 0.31
26b B 98% 36 70 0.30 34 B 20% 310 400 0.27
27* B 67% 110 400 0.30 35* A 98% 35 159 0.42
28* B 87% 240 160 0.27
*X-ray structure of fragment-enzyme complex available. a Reaction in anhydrous THF instead of dioxane:water as solvent; b XPhos-Pd G2 as catalyst instead of PdCl2(PPh3)2; c
PdCl2(dppf) as catalyst instead of PdCl2(PPh3)2. d LE ¼ ð& 1:4 ' log10IC50Þ=HeavyAtomCount, with units kcal/(mol per heavy atom).
Scheme 1. Preparation of symmetrical 3,5-disubstituted benzoic acids. Reagents and
conditions: 36: 3-acetamidophenylboronic acid (1.5 equiv.), Pd2 (dba)3)CHCl3 (5mol%),
XPhos (5mol%), dioxane:water (1:1), 60 #C, 54%; 37: 4-acetamidophenylboronic acid
(0.75 equiv.), PdCl2(PPh3)2 (10mol%), dioxane:water (1:1), 95 #C, 11%; 38: quinolin-6-
ylboronic acid pinacol ester (2.0 equiv.), XPhos-Pd G2 (5mol%), tert-butanol, 60 #C,
65%.
Scheme 2. Preparation of unsymmetrical 3,5-disubstituted benzoic acids. Reagents and conditions: 39: i. X¼ Br, 3-acetamidophenylboronic acid (0.75 equiv.), PdCl2(PPh3)2 (10mol
%), dioxane:water (1:1), 60 #C; ii. pyridin-4-ylboronic acid (1.2 equiv.), PdCl2(PPh3)2 (10mol%), dioxane:water (1:1), 60 #C; int-40: X¼ I, quinolin-6-ylboronic acid pinacol ester (2.0
equiv.), Pd2 (dba)3*CHCl3 (5mol%), SPhos (5mol%), dioxane:water (1:1), 60 #C; 40: 3-acetamidophenylboronic acid (1.5 equiv.), XPhos-Pd G2 (5mol%), tert-BuOH, 60 #C.
S. Akhter et al. / European Journal of Medicinal Chemistry 145 (2018) 634e648638
acetylphenyl substituted 10 (IC50 (mM)/LE: 380/0.27) and carba-
moylphenyl substituted 11a and 11b (IC50 (mM)/LE: 260/0.28 and
180/0.29) gave generally weak inhibition indicating that a carbonyl
group attached to the aromatic ring was not contributing to bind-
ing. No complex structures are available for 10 and 11a, but the
complex structure of 4-carbamoylphenyl 11b was similar in
conformation to the esters 9a and 9b. Slightly tighter binding was
observedwith themeta-substituted sulfone 12a (IC50 (mM)/LE: 120/
0.29), which also shares the same overall conformation.
The 4-aminophenyl substituent of 13 (IC50 (mM)/LE: 330/0.30)
did not appear to make any interaction with the enzyme, and the
inhibition was weak. The complex structure of the corresponding
N,N-dimethyl-4-aminophenyl substituted 14 (IC50 (mM)/LE: 390/
0.27) showed that the two methyl groups are solvent exposed, and
this is reflected in the poor inhibition by this compound. Similar to
the complex structure of 14, the methyl 4-sulfonamidophenyl
group of 17 (IC50 (mM)/LE: 370/0.24) was seemingly pushed out of
the active site and appears completely exposed to the solvent. The
larger phenyl 4-sulfonamidophenyl substituted fragment 18 (IC50
(mM)/LE: 60/0.24) showed lower IC50 values probably driven by the
increase in hydrophobicity, and no complex structurewas obtained.
The corresponding 4-acetamidophenyl 21b (IC50 (mM)/LE: 450/
0.25) showed weak inhibition, likely due to the solvent exposure of
the hydrophobic methyl group. The 3-acetamidophenyl containing
fragment 21a (Fig, 3), however, showed a 10-fold increased inhi-
bition (IC50 (mM)/LE: 35/0.33). The complex structure of OXA-48
with fragment 21a revealed that the carbonyl of the acetyl
formed a hydrogen bond to the guanidine group of Arg214, which
directs the 3-acetamidophenyl substituent to the R1 site (Fig. 2B)
and lead to a T-shaped p-p-stacking interaction of the 3-
acetamidophenyl substituent with Trp105. The p-p stacking of
the 3-acetamidophenyl substituent to Tyr211 normally observed
with these fragments was not observed; instead Tyr211 interacted
with the benzoic acid by T-shaped p-p-stacking. The interaction of
an acetamide with Arg214 has been described previously for the
avibactam analogue FPI-1523 in complex with OXA-48 (PDB-ID:
5fas) [22].
Encouraged by the results for fragment 21a, we designed a se-
ries of fragments incorporating a hydrocarbon linker between the
phenyl ring and the amino, sulfonamido or acetamido groups of 13,
18 and 21. The amines 15 and 16, the sulfonamides 19 and 20, the
amides 22, 23a, 23b and the acetate 24 are more flexible, thus,
increasing the potential of hydrogen bonding. However, none of
these fragments showed substantially improved binding (IC50:
110e1000; LE: 0.19e0.30). Moreover, the crystal structures of the
amides 22, 23a, 23b and the acetate 24 (IC50 (mM)/LE: 230/0.24,
520/0.22 and 250/0.25) did not show any specific interactions for
the functional groups.
In fragments 26a and 26b NH-tetrazole substituted phenyl rings
were investigated as Ar substituents. Introducing the weakly acidic
tetrazol-5-ylphenyl substituent in either 3-position 26a (IC50 (mM)/
LE: 60/0.30) or 4-position 26b (IC50 (mM)/LE: 36/0.30) yielded good
binding for both fragments. However, the binding poses for the two
compounds were very different. The 3-tetrazol-5-ylphenyl
substituted 26a bound in two alternate positions. The p-p-stack-
ing with Tyr211 was maintained for both conformations, but the
tetrazoles appeared completely solvent exposed with no in-
teractions with the enzyme. The 4-tetrazol-5-ylphenyl substituted
26b formed a hydrogen bond with the guanidine group of Arg214
(Fig. 4), interrupting the p-p-stacking with Tyr211. Fragment 26b
occupied the R1 site rather than the more common R2 site.
A number of heterocyclic aryl substituents were also evaluated
(fragments 25, 28e35). With some exceptions of the pyridinyls 29
and 35 (IC50 (mM)/LE: 170/0.33 and 35/0.42) most of these frag-
ments showed only weak inhibition. The quinolin-7-yl substituted
fragment 28 (IC50 (mM)/LE: 240/0.30) did maintain the overall
conformation of the previous R2 binding fragments (Fig. 5), and so
did the corresponding naphtalen-2-yl substituted fragment 27 (IC50
(mM)/LE: 110/0.29). In the same manner the indol-5-yl substituted
fragment 34 (IC50 (mM)/LE: 310/0.27) did show acceptable binding,
yet no specific interaction except for the p-stacking with Tyr211. In
our previous paper, we investigated pyridin-4-yl and pyridin-3-yl
substituted fragments [19], and both inhibited OXA-48 with the
same potency (IC50 (mM)/LE: 250/0.32). The pyridin-2-yl
substituted fragments 35 (IC50 (mM)/LE: 35/0.41) showed a 10-
fold improvement in binding (Fig. 6A and B). In the crystal struc-
ture, two alternative conformations were observed (Fig. 6C). One
conformation was the canonical with p-stacking of the pyridinyl
ring with Tyr211 occupying the R2 site (Fig. 6E), but in the other
conformation the pyridinyl ring was orientated to the R1 site. The
second conformation showed a hydrogen bond from the proton-
ated N atom in the pyridine ring to the backbone carbonyl of Tyr117,
Fig. 2. The crystal structure of imipenem in complex with OXA-48 (A) shows that the two side chains of imipenem extends in separate directions. The carbapenem substrates of
OXA-48 have small R1 side chains. We were however able to fit larger groups in the R1 site like the N-acetamide substituted phenyl ring in compound 21a (B). Yet, most of the tested
3-substituted benzoic acids bind towards the larger R2 site, like the quinolin-7-yl substituted compound 28 (C).
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which represents a unique interaction for the fragments in the li-
brary (Fig. 6D). Only the protonated pyridinyl-nitrogen would be
able to form hydrogen bonds to the Tyr117 mainchain, which may
explain the slower on/off-rates observed for fragment 35 in the
SPR-experiments (Fig. 6B).
In the discussion above most fragments were identified as R2
binders with fragment 4a (IC50 (mM)/LE: 50/0.38) being the stron-
gest binder among them. For R2 binders, the edge-to-face p-p-
stacking with Tyr211 appears to be an important interaction in
accordance with previous analyses [23]. Fragment 35 showed the
best ligand efficiency (IC50 (mM)/LE: 35/0.42), but could not be
classified as a R1 or R2 binder as both binding pockets showed
useful interactions (Fig. 6CeE). Only two R1 binders e fragments
21a and 26b - were identified, both showing hydrogen bonds with
Arg214 as cause for the fragments orientation towards the R1 site.
2.2.3. NMR studies
In order to evaluate the fragment-enzyme binding in solution, a
13C NMR experiment for OXA-48 was developed based on previous
studies [24,25]. OXA enzymes can be selectively carbamylated with
bicarbonate at an active site lysine to provide the corresponding
carbamic acid [24,26,27]. For OXA-48 the carbamylated residue is
Lys73, which is situated in the R1 site (Fig. 2B). By using 13C-labeled
sodium bicarbonate (NaH13CO3), a13C atom was introduced in the
R1 site of OXA-48, which can be used as a reporter probe for frag-
ment binding in 13C NMR studies.
Fragments binding in the R1 site were expected to change the
local environment of the 13C labeled Lys73, which results in a
change of the 13C chemical shift of LyseNHe13CO2H, while ligands
binding in the R2 site are further than ~9 Å away from the Lys73
carbamic acid, and are therefore not expected to directly affect the
13C chemical shift.
NMR experiments were performed by equilibrating OXA-48
with 13C-labeled sodium bicarbonate followed by the addition of
inhibitor 2 and selected fragments 21a, 28 and 35 with known
binding modes from X-ray analysis. The results are shown in Fig. 7.
The 13C NMR spectrum of OXA-48 after equilibration with
NaH13CO3 showed the carbamate resonance at 163.95 ppm as a
broad signal (Fig. 7E), which is in good agreement with the reported
chemical shift for carbamylated OXA-48 [28]. In addition, two
unassigned signals were observed at 164.04 ppm similar to the
results reported for carbamylation of OXA-58 [27]. Here the authors
speculated that the unassigned signal may be related to a second
carbamylation site [27].
On addition of R1 binding fragment 21a and inhibitor 2, the 13C
chemical shifts of the carbamate signal were consistently deshiel-
ded in both experiments (d¼ 164.25, Dd¼ 0.28 ppm, Fig. 7E and F).
These findings support that the compounds bind competitively in
the active site. Moreover, the observed chemical shift perturbation
indicates that the compounds occupy the R1 site as found in the
crystal structures. The R2 binding fragment 28 showed a similar
deshielding of the carbamate signal though at a smaller amplitude
(d¼ 164.13, Dd¼ 0.16 ppm, Fig. 7D) supporting that the fragment
binds in the active site, while fragment 35, which was identified as
R1 or R2 binder, only slightly affected the chemical shift (d¼ 164.00,
Dd¼ 0.04 ppm, Fig. 7C). The observed chemical shift perturbations
for fragments 28 and 35may indicate that fragment 28 has an effect
on carbamylated Lys73, while fragment 35 do not interact with the
R1 site, which is not consistent with the X-ray structures. However,
a more detailed study of the NMR conformations would be needed
to be conclusive about the binding poses in solution.
The small amplitudes of the observed chemical shift
Fig. 3. Compound 21a was one of the most potent 3-substituted benzoic acid derivatives we found. The IC50-value (A) was determined to be 35 mM, while the Kd was found to be
100 mM (B). The crystal structure of the complex OXA-48:21awith an omit-type polder-map (2.5s) (C) and its 2D-representation (D) shows that the carbonyl of the acetamido-group
forms a hydrogen bond with the guanidine of Arg214. The interaction with Arg214 causes the B-ring to move away from Tyr211, introducing a new interaction with Trp105.
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Fig. 4. The IC50-value of compound 26b (A) was determined to be 36 mM, while the KD was found to be 70 mM(B). The crystal structure of the complex OXA-48:26b with an omit-
type polder-map (2.5s) (C) and a 2D-representation of the protein:compound complex interactions. (D).
Fig. 5. The IC50-value of compound 28 (A) was determined to be 240 mM, while the KD was found to be 160 mM (B). The crystal structure of the complex OXA-48:28 with an omit-
type polder-map (2.5s) (C) and a 2D-representation of the protein:compound complex interactions. (D).
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perturbations indicated that the effect is not caused by direct
hydrogen bonding of the carbamic carbonyl, for which a Dd of
several ppmwould be expected, even for a mMbinder [29]. This was
supported by the crystal structures of OXA-48 indicating that the
Lys73 carbamic acid was preoccupied in hydrogen bonding to
Trp157 and was not affected by ligand binding. The observed
consistent, but rather subtle, deshielding of the Lys73 carbamic acid
(d¼ 164.25, Dd¼ 0.28 ppm, Fig. 7E and F) for our R1 binding frag-
ments can possibly be explained by an anisotropic magnetic
deshielding by the edge of the aromatic rings of these fragments,
which were positioned roughly 5 Å away from the reporter carbon
for R1 binding fragments. Moreover, amplitude of the chemical shift
perturbation observed with R1 binding fragments 21a and inhibitor
2 (Fig. 7E and F) were in line with the reported changes observed
for OXA enzymes on coordination with inhibitors like b-hydrox-
yisopropylpenicillanates [24], cyclic boronates [25] and avibactam
[28].
2.3. Inhibitor activity and structural analysis of 3,5-disubstituted
benzoic acids
In an attempted to design more potent inhibitors from our
fragments, the mono-substituted benzoic acids were evaluated for
a merging approach (Fig. 8). By overlaying X-ray structures,
promising combinations showing orthogonal binding poses were
identified and some of the combined structures were prepared and
evaluated with good results.
An overlay of fragment 21a as well as 26b with several R2
binders identified the combinations of fragments 21a/28, 21a/1 and
26b/35 as interesting partners (Fig. 9). The combination 21a/1 and
21a/28 were synthetically feasible and gave compounds 39 and 40
(Scheme 2), respectively. In addition, the symmetrical 3,5-
disubstituted benzoic acids 36e38 representing the symmetrical
combinations of fragments 21a, 21b and 28 were included in this
Fig. 6. Compound 35 bound in the two alternate conformations. The IC50-value (A) was determined to be 35 mM, while the KD was found to be 159 mM (B). The crystal structure of
the complex OXA-48:35 with an omit-type polder-map (2.5s) (C) and a 2D-representation of the protein:compound complex interactions. (D for green colored conformation, E for
magenta colored conformation). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 7. 13C NMR of the buffer alone including 13C labeled bicarbonate (A); OXA-48
without 13C labeled bicarbonate (B), OXA-48 with 13C labeled bicarbonate and frag-
ment 35 (C); OXA-48 with 13C labeled bicarbonate and fragment 28 (D); OXA-48 with
13C labeled bicarbonate and fragment 21a (E); OXA-48 with 13C labeled bicarbonate
and 3,5-di (4-pyridinyl)benzoic acid 2 (F) and OXA-48 with 13C labeled bicarbonate and
no fragment (G). Two unassigned signals were observed at 164.1 ppm, and are believed
to originate in a second carboxylated site of OXA-48.
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study (Scheme 1).
The 3,5-disubstituted compounds 36e40 were evaluated for
their inhibitory activity against OXA-48 as measured by their IC50,
Kd and LE and complex structures with OXA-48 and compounds 36,
38 and 40 were obtained (Table 2). The merged compounds 37, 38
and 39 (IC50 (mM)/LE: 110/0.19, 48/0.21, 100/0.22) failed to
adequately maintain the binding interactions as the IC50 values
were at a similar level as the corresponding mono-substituted
fragments 28, 1 and 21a (IC50 (mM)/LE: 240/0.33, 250/0.32 and
35/0.33).When comparing the IC50 values of compounds 36, 37 and
40 (IC50 (mM)/LE: 2.9/0.27, 48/0.21 and 2.9/0.27) with the corre-
sponding fragments 21a, 21b and 28 (IC50 (mM)/LE: 35/0.33, 450/
0.26, 240/0.3), a 10-fold decrease of the IC50 value was observed.
Nevertheless, the improved binding was associated with a decrease
in LE showing that the fragment-enzyme interactions are less
efficient with themerged compounds. The reduction in LE probably
relates to the rigid structure of the merged compounds allowing for
little conformational freedom. Overall, the strongest inhibitors in
this study are compounds 36 and 40 with IC50 values of 2.9 mM and
LE of 0.27.
The structural analysis of the OXA-48 complexes with 36, 38 and
40 showed that the interaction of the carboxylic acid with Arg214 is
maintained. For compound 36, a near perfect overlay was obtained
with the complex structure of fragment 21a showing that all in-
teractions seen with the fragments were preserved in the larger
compound (Fig. 10). The second 3-N-acetamidophenyl group forms
a not previously observed hydrogen bond with Ser244. In the SPR
sensorgrams some concentration dependent aggregation was
observed [30].
Interestingly, the conformation of compound 38 in complex
with OXA-48 was changed compared with the mono-substituted
fragment 28. In the OXA-48:38 complex, one quinolinyl group
bound in the R1 site similar to fragment 21a. The other quinolinyl
group positions itself in a conformation similar to the alternative
conformation observed with fragment 35 (Fig. 6). No specific in-
teractions were observed, but this conformation shielded the hy-
drophobic quinoline ring from solvent exposure by burying the
compound deep in the hydrophobic cleft.
The complex structure of the unsymmetrical compound 40
(Fig. 11) that was composed of the quinoline ring of fragment 28
and the 3-N-acetamidophenyl substituent of fragment 13a shared
the key interactions of both mono-substituted fragments validating
our approach, with an IC50 of 2.9 mM.
3. Conclusion
A targeted fragment library consisting of 49 diversely 3-
substituted benzoic acid derivatives was prepared and biochemi-
cally analyzed for their inhibitory activity against OXA-48. Enzyme-
fragment complexes for crystallographic studies were obtained for
33 fragments. By systematically changing the substituent-groups of
the benzoic acid derivatives we were able to identify inhibitory
fragments with IC50< 40 mM (21a, 26b, 35). Based on the structural
information, fragments could be classified according to their
preferred binding pocket. Most fragments were orientated towards
the R2 site induced by a p-p-stacking with Tyr221. Unfortunately,
no further interactions in the R2 site could be identified from our
library. The strongest binding fragments 21a and 26bwere binding
in the R1 site due to a hydrogen bond to Arg214 and for fragment 35
a hydrogen bond to the carbonyl backbone of Tyr117 was observed.
By overlaying the complex crystal structures of fragments 1, 21a,
26b, 28 and 35, the design of five new 3,5-disubstituted inhibitors
evolved. The strongest 3,5-disubstituted inhibitors 36 and 40
showed IC50 values as low as 2.9 mM, thus have improved inhibitory
potential. The complex crystal structures of 36 and 40 revealed that
the interactions of the individual fragments were mainly retained
in the merged structures. In addition, for inhibitor 36 a previously
not observed hydrogen bond from the 3-N-acetamidophenyl group
in the R2 site to Ser244 was found, which is interesting as we
otherwise found few interactions in this region. Future work will
focus on the evaluation of fragments with increased flexibility e.g.
by introducing a CH2 or heteroatom linker bridging the aromatic
ring systems to further explore the active site.
Fig. 8. Strategy for substitution of the Ar1 and Ar2 groups in the focused fragment
library of 3-substituted benzoic acids analogues.
Fig. 9. Superimpositions of the binding poses observed for 21a/28 (A), 21a/1 (B, 1:
PDB-ID:5dva) and 26b/35 (C) showing some of the possible combinations for 3,5-
disubstituted benzoic acids.
Table 2
Inhibitor activities of 3,5-disubstituted benzoic acids analogues against OXA-48
(IC50, KD and LE).
Ar1 Ar2 ID IC50 (mM) KD
(mM)
LEa
36* 2.9 20 0.27
37 48 70 0.21
38* 110 70 0.19
39 100 70 0.22
40* 2.9 49 0.27
*X-ray structure of fragment-enzyme complex available.
a LE ¼ ð& 1:4 ' log10IC50Þ=HeavyAtomCount, with units kcal/(mol heavy atom).
S. Akhter et al. / European Journal of Medicinal Chemistry 145 (2018) 634e648 643
Fig. 10. Compound 36maintained the interactionwith Arg214 as we observed for the 3-substituted benzoic acid derivate. The IC50-value (A) was determined to be 2.9 mM, while the
KD was found to be 30 mM(B). For the higher concentrations of compound 36 some unspecific binding was observed. The crystal structure of the complex OXA-48:36 with an omit-
type polder-map (2.5s) (C) and its 2D-representation (D) shows one of the acetamide-groups interacted with the guanidine group of Arg214, while the other group was solvent
exposed.
Fig. 11. Compound 40maintained the interaction with Arg214 as we observed for the 3-substituted benzoic acid derivate. The IC50-value (A) was determined to be 2.9 mM, while the
KD was found to be 49 mM (B). The crystal structure of the complex OXA-48:40 with an omit-type polder-map (2.5s) (C) and its 2D-representation (D) shows that the acetamide-
group interacted with the guanidine group of Arg214, while the quinoline-ring was partially solvent exposed.
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4. Experimental
4.1. Synthesis
4.1.1. Synthesis of 3-substituted benzoic acids (complete data for all
procedures and compounds is found in the Supporting information)
4.1.1.1. General procedure A e aqueous conditions. The halo aryl (1.0
equiv) was dissolved in a mixture of water:dioxane (1:1). The
boronic acid or ester (1.5 equiv) and potassium phosphate (5.0
equiv) were added. The solution was degassed by vacuum/Argon
cycles (10 times) before addition of PdCl2(PPh3)2 (10mol%) and
further degassed (5 times). The resulting mixture was stirred at
95 #C under argon atmosphere for 16e20 h. The reaction mixture
was filtered through Celite and diluted with water (approx. 30mL)
before washing with chloroform (3 * 30mL). If not stated other-
wise, the aqueous phase was concentrated under reduced pressure
and applied to a C18 precolumn before purification on a 10 g or 60 g
C18 column with a gradient of acetonitrile in water (10e100%) to
yield the desired product.
4.1.1.2. General procedure B e anhydrous conditions. The halo aryl
(1.0 equiv) was dissolved in anhydrous THF. The aryl boronic acid or
aryl boronic ester (1.5 equiv) and inorganic base (5.0 equiv) were
added. The solution was degassed by vacuum/Argon cycles (10
times), before addition of a palladium catalyst (10mol%) and
further degassed (5 times). The resulting mixture was stirred at
75e90 #C under an inert atmosphere for 16e20 h. The reaction
mixturewas filtered through Celite and diluted with water (approx.
30mL) before washing with ethyl acetate (3 * 30mL). If not stated
otherwise, the aqueous phase was concentrated under reduced
pressure and applied to a C18 precolumn before purification on a
10 g or 60 g C18 column with a gradient of acetonitrile in water
(10e80%) to yield the desired molecule.
4.1.2. Screening of catalysts (for results see Table SI1)
4.1.2.1. General procedure. 3-Bromo-5-iodobenzoic acid
(0.03e0.06mmol, 1.0 equiv.) was dissolved in the indicated solvent
(0.5e1 mL/0.01mmol substrate). The boronic acid or ester (1.5
equiv.) and base (5.0 equiv.) were added. The solutionwas degassed
by vacuum/Ar cycles (10 times) before addition of the palladium
catalyst and further degassed (5 times). The resulting mixture was
stirred at the indicated temperature under an inert atmosphere for
the indicated reaction time. The crude reaction mixture was
analyzed by HRMS to determine the ratio of int-39: disubstituted
38: starting material. The reaction mixture was filtered through
Celite bed and diluted with water (approx. 30mL) before washing
with chloroform (3 * 30mL). The aqueous phase was concentrated
under reduced pressure and applied to a C18 precolumn before
purification on a 60 g C18 column with a gradient of acetonitrile in
water (0e5% over 15min) to yield the product.
4.1.3. Synthesis of symmetrical 3,5-disubstituted benzoic acid
derivatives
4.1.3.1. 3,5-Di(3-acetamidophenyl)benzoic acid 36.
3-Bromo-5-iodobenzoic acid (0.30mmol, 100mg, 1.0 equiv), 3-
acetamidophenylboronic acid (0.45mmol, 816mg, 1.5 equiv), po-
tassium phosphate (1.5mmol, 324mg, 5.0 equiv) were dissolved in
a mixture of water/dioxane (1:1). The solution was degassed by
vacuum/Ar cycles (10 times) before addition of Pd2(dba)3)CHCl3
(15mg, 5mol%), and XPhos (7.2mg, 5mol%) and further degassed
(5 times). The resulting mixture was stirred at 60 #C for 20e24 h.
The reaction mixture was filtered through Celite bed and diluted
with water (approx. 30mL) before washing with chloroform
(3 * 30mL). The aqueous phase was concentrated under reduced
pressure and applied to a C18 precolumn before purification on a
60 g C18 columnwith a gradient of acetonitrile inwater (0e5% over
15min) to provide 36 (60mg, 54%) as white powder. 1H NMR
(400MHz, methanol-d4) d 8.21 (s, 2H), 7.90 (t, J¼ 1.7 Hz,1H), 7.81 (t,
J¼ 1.7 Hz, 2H), 7.68 (d, J¼ 8 Hz, 2H), 7.43 (s, 1H), 7.49e7.46 (m, 2H),
7.43e7.39 (m, 2H), 2.16 (s, 6H). 13C NMR (101MHz, methanol-d4)
d 175.0, 171.8, 142.9, 142.3, 140.5, 132.2, 130.4, 128.2, 128.1, 123.9,
120.3, 119.7, 24.0. HRMS (ESI): Calcd. for C23H19N2O4 [M-H]-
387.1350; found 387.1342. UPLC: purity¼ 97.5%
4.1.3.2. 3,5-di(4-acetamidophenyl)benzoic acid 37.
3,5-Dibromobenzoic acid (1.01mmol, 300mg, 1.0 equiv), 3-
acetamidophenylboronic acid (0.81mmol, 178mg, 0.75 equiv),
potassium phosphate (3.76mmol, 0.80 g, 3.5 equiv) and
PdCl2(PPh3)2 (0.11mmol, 77mg, 10mol%) were stirred in a mixture
of water/dioxane (1:1) for 24 h at 95 #C under argon atmosphere.
The crude reaction mixture was filtered through Celite and diluted
with water (approx. 30mL) before washing with chloroform
(3 * 30mL). The aqueous phase was concentrated under reduced
pressure and applied to a C18 precolumn before purification on a
60 g C18 column with a gradient of acetonitrile in water (0e100%
over 12min). The fractions were analyzed by MS and fractions
containing 37were combined. The product was purified by reverse-
phase automated flash chromatography before being subjected to
purification by HPLC, to yield 37 (0.09mmol, 34mg, 11%) as a white
solid. 1H NMR (400MHz, methanol-d4) d 8.24 (s, 2H), 7.98 (d,
J¼ 7.8 Hz, 2H), 7.85 (d, J¼ 7.9 Hz, 2H), 7.68e7.66 (m, 2H), 7.63e7.60
(m, 2H), 7.57e7.53 (m, 1H), 2.16 (s, 6H). 13C NMR (101MHz, meth-
anol-d4) d 175.2, 171.7, 142.0, 140.2, 139.4, 137.9, 131.7, 128.4, 128.2,
127.6, 127.4, 123.3, 121.4, 116.2, 23.9. HRMS (ESI): Calcd. for
C23H19N2O4 [M-H]- 387.1350; found 387.1340. UPLC: purity >99.5%
4.1.3.3. 3,5-Diquinolin-6-ylbenzoic acid 38.
3,5-Dibromobenzoic acid (0.11mmol, 33mg, 1.0 equiv), 6-
quinolinylboronic acid pinacol ester (0.23mmol, 60mg, 2.0
equiv), potassium phosphate (0.58mmol, 125mg, 5.0 equiv) were
dissolved in tert-butanol. The solution was degassed by vacuum/Ar
cycles (10 times) before addition of XPhos-Pd G2 (5mol%, 5mg)
and further degassed (5 times). The resulting mixturewas stirred at
60 #C for 20e24 h. The reaction mixture was filtered through Celite
bed and diluted with water (approx. 30mL) before washing with
chloroform (3 * 30mL). The aqueous phase was concentrated un-
der reduced pressure and applied to a C18 precolumn before pu-
rification by C18 RP flash chromatography with a gradient of
acetonitrile in water (0e5% over 15min) to yield 38 (0.08mmol,
29mg, 65%) as white powder. 1H NMR (400MHz, methanol-d4)
d 8.87e8.86 (m, 2H), 8.52 (s, 1H), 8.50 (s, 1H), 8.46 (m, 2H), 8.38 (m,
2H), 8.29e8.26 (m, 3H), 8.18 (s, 1H), 8.16 (s, 1H), 7.61e7.58 (dd,
J¼ 8.3, 4.2 Hz, 2H). 13C NMR (101MHz, methanol-d4) d 174.4, 151.1,
148.0, 141.5, 140.5, 138.6, 130.6, 130.1, 129.5, 128.7, 126.9, 122.8.
HRMS (ESI): Calcd. for C25H15N2O2 [M-H]e 375.1139; found
375.1133. UPLC: purity¼ 99.1%
4.1.4. Synthesis of unsymmetrical 3,5-disubstituted benzoic acid
derivatives
4.1.4.1. 3-(30-Acetamidophenyl)-5-pyridin-4-ylbenzoic acid 39:
attempted synthesis from 3,5-dibromobenzoic acid.
3,5-Dibromobenzoic acid (1.01mmol, 300mg, 1.0 equiv), 3-
acetamidophenylboronic acid (0.81mmol, 178mg, 0.75 equiv),
potassium phosphate (3.76mmol, 0.80 g, 3.5 equiv) and
PdCl2(PPh3)2 (0.11mmol, 77mg, 10mol%) were stirred in a mixture
of water/dioxane (1:1) for 24 h at 95 #C under argon atmosphere.
The crude reaction mixture was filtered through Celite and diluted
with water (approx. 30mL) before washing with chloroform
(3 * 30mL). The aqueous phase was concentrated under reduced
pressure and applied to a C18 precolumn before purification by C18
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RP flash chromatography with a gradient of acetonitrile in water
(10e100% over 12min). The fractions were analyzed by MS and
fractions containing int-39 were combined and reacted with pyr-
idin-4-ylboronic acid (0.97mmol, 119mg, 1.2 equiv), potassium
phosphate (4.05mmol, 0.86 g, 5.0 equiv) and PdCl2(PPh3)2
(0.08mmol, 56mg, 10mol%). The product was purified by reverse-
phase automated flash chromatography before being subjected to
purification by HPLC, to yield 39 (0.12mmol, 39mg, 15%) as a white
solid. 1H NMR (400MHz, methanol-d4) d 8.22 (s, 1H), 7.92 (d,
J¼ 7.6 Hz, 1H), 7.76 (s, 2H), 7.68e7.60 (m, 3H), 7.46e7.33 (m, 4H),
2.14 (s, 3H). 13C NMR (101MHz, methanol-d4) d 175.3, 171.7, 143.0,
141.5, 140.4, 139.8, 130.3, 129.7, 129.3, 129.3, 128.9, 123.7, 120.1,
119.6, 23.9. UPLC: purity¼ 97.9%
4.1.4.2. 3-Bromo-5-(quinolin-6-yl) benzoic acid int-40.
3-Bromo-5-iodobenzoic acid (0.15mmol, 50mg, 1.0 equiv), 6-
quinolinylboronic acid pinacol ester (0.22mmol, 58mg, 1.5 equiv)
and potassium phosphate (0.76mmol, 162mg, 5.0 equiv) were
dissolved in a mixture of water/dioxane (1:1). The solution was
degassed by vacuum/Ar cycles (10 times) before addition of
Pd2(dba)3$CHCl3 (5mol%, 7.5mg), and SPhos (5mol%, 3.1mg) and
further degassed (5 times). The resulting mixture was stirred at
60 #C for 20e24 h. The reaction mixture was filtered through a
Celite bed and diluted with water (approx. 30mL) before washing
with chloroform (3 * 30mL). The aqueous phase was concentrated
under reduced pressure and applied to a C18 precolumn before
purification on a 60 g C18 column with a gradient of acetonitrile in
water (0e5% over 20min). Product int-40 (0.07mmol, 23mg, 45%)
was obtained as a white powder. 1H NMR (400MHz, methanol-d4)
d 8.92e8.91 (m,1H), 8.49e8.46 (m,1H), 8.35 (s,1H), 8.28 (s, 2H), 8.10
(s, 2H), 8.02e8.01 (m, 1H), 7.97e7.96 (m,1H), 7.59e7.56 (dd, J¼ 8.3,
4.2 Hz, 1H). 13C NMR (101MHz, DMSO-d6) d 166.6, 150.8, 147.2,
143.6, 140.6, 136.8, 136.5, 131.7, 131.1, 129.6, 128.5, 128.2, 127.4,
126.5, 125.8, 121.9, 121.7; HRMS (ESI): Calcd. for C16H979BrNO2 [M-
H]e 325.9822; found 325.9822.
4.1.4.3. 3-(30-Acetamidophenyl)-5-quinolin-6-ylbenzoic acid 40.
3-Bromo-5-(quinolin-6-yl) benzoic acid int-40 (0.039mmol,13mg,
1.0 equiv), 3-acetamidophenylboronic acid (0.55mmol, 10mg, 1.5
equiv) and potassium phosphate (0.20mmol, 0.42 g, 5.0 equiv)
were dissolved in tert-butanol. The solution was degassed by vac-
uum/Ar cycles (10 times) before addition of Xphos-Pd G2 (5mol%,
1.5mg) and further degassed (5 times). The resulting mixture was
stirred at 60 #C for 20e24 h. The reaction mixture was filtered
through Celite bed and diluted with water (approx. 30mL) before
washing with chloroform (3 * 30mL). The aqueous phase was
concentrated under reduced pressure and applied to a C18 pre-
column before purification on a 60 g C18 columnwith a gradient of
acetonitrile in water (0e5% over 20min). Product 40 (0.023mmol,
9mg, 90%) was obtained as white powder. 1H NMR (400MHz,
methanol-d4) d 8.87e8.83 (m, 1H), 8.56e8.45 (m, 1H), 8.41e8.39
(m, 1H), 8.35e8.20 (m, 3H), 8.18e8.11 (m, 1H), 8.08 (t, J¼ 1.8 Hz,
1H), 7.87e7.86 (m, 1H), 7.72e7.68 (m, 1H), 7.62e7.56 (m, 1H),
7.56e7.49 (m, 1H), 7.46e7.42 (m, 1H), 2.17 (s, 3H). 13C NMR
(101MHz, DMSO-d6) d 174.7, 171.8, 151.2, 148.2, 142.8, 142.5, 141.4,
140.8, 140.7, 140.5, 138.8, 130.8, 130.4, 130.3, 129.7, 128.6, 128.5,
128.5, 127.0, 123.9, 123.0, 120.3, 119.7, 23.9. HRMS (ESI): Calcd. for
C24H18N2O3 [M-H]- 381.1245; found 381.1243.UPLC: purity¼ 96.4%
4.2. Protein production
For the biochemical assay OXA-48 was expressed with the
native signal-peptide and purified from the periplasm as described
earlier [31]. For surface plasmon resonance assays, nuclear mag-
netic resonance and crystallization a His-tagged construct was used
[19].
4.3. Biochemical assay
All experiments were performed using a Spectramax M2e at
25 #C in 100mM sodium phosphate (pH 7.0) supplemented with
50mM NaHCO3 and 0.2mg/mL bovine serum albumin (BSA). Ve-
locities from the linear range were determined in the SoftMax Pro
software (Molecular Devices). All experiments were done with a
sample volume of 100 mL. IC50 values were determined for all
compounds in competition with 25 mM of the chromogenic sub-
strate nitrocefin. The log10 of the inhibitor concentrations to the
response with bottom and top constant based on controls were
fitted nonlinearly in GraphPad Prism 6 (GraphPad Software) to
determine the IC50 value.
4.4. Surface plasmon resonance
All SPR experiments were performed on a Biacore T200 at 25 #C.
The data were analyzed using Biacore T200 Evaluation Software 2.0
(GE Healthcare). The sensorgrams were double reference sub-
tracted using a reference surface and blank injections. The final
running buffer included 50mM HEPES pH 7.0, 50mMK2SO4, 0.5%
Tween-20, 50mM NaHCO3, and 2.5% DMSO. The enzyme, OXA-48,
was diluted to 25 mg/mL in 10mM MES pH 5.5. The enzyme was
immobilized to a level of around 5000 RU on a CM5 chip using
standard amine coupling.
Compounds were tested with 10 dilutions from 400 mM to
10.5 mM, with 30 s injection and 60 s dissociation time. Compounds
exhibiting kinetic behavior had the dissociation time extended to
300 s. Seven startup cycles with buffer were performed. Solvent
correction was performed every 48th cycle and a positive control
was included every 24th cyclewith 3.5-Di (4-pyridinyl)benzoic acid
as the control [19]. Affinities were calculated from the steady-state
affinity model with a constant Rmax adjusted by the control and the
molecular weight of the compound.
4.5. 13C nuclear magnetic resonance
A solution of NaH13CO3 in D2O (50mM) was prepared. The
NaH13CO3/D2O-mixture was added to 1mM OXA-48 in 50mM so-
dium phosphate and 50mM sodium bicarbonate pH 6.5 in a 1: 9
ratio of bicarbonate to enzyme. Compounds were diluted from a
150mM stock solution in 100% DMSO to a final concentration of
3.75mM (2.5% DMSO). Sample volumes of 500 mL were used. We
performed the experiment at 37 #C with a Bruker Avance III HD
with an inverse detected TCI probe with cryogenic enhancement
for 1H, 13C and 2H, operating at 599.90MHz for protons and
150.86MHz for carbon. 10 000 scans at 30# pulse angle with 2 s
relaxation delay were collected using 1D13C NMR with power-
gated decoupling of protons (zgpg30 using waltz16).
4.6. Crystallization and data processing
Crystals of OXA-48 was grown from hanging drops containing
0.1M HEPES pH 7.5, 8e11% PEG 8000 and 4e8% 1-butanol as pre-
viously described [17]. Compounds were diluted to 3.75mM in the
cryo solutionwith 0.1MHEPES pH 7.5, 10% PEG 8000, 5% 1-butanol,
and 25% ethanediol, usually overnight. The exception was the
crystal soaked in imipenem. Imipenem was added to saturation in
the cryosolution, and the crystal was just given a quick soak.
Crystals were flash cooled in liquid nitrogen. X-ray diffraction
data were collected at BL 14.1 and BL14.2 at BESSY (Berlin, Ger-
many) [32], and at ID23-1, ID23-2 and ID30B at ESRF (Grenoble,
France). In most cases the structures were solved by refining
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against the protein-atoms of previous structures (P212121 PDB ID:
5DVA and P21 PDB ID: 5DTK), but in cases where the unit cells were
to different PHASERwas usedwith chain A from PDB ID: 5dtk as the
search model for molecular replacement. In most cases images
were autoprocessed using the tools at the beamlines [33e37], but
in some cases we found it useful to reprocess using DIALS or XDS
together with AIMLESS [38e40].
The compounds were built into difference density maps after
initial refinement in phenix.refine [41], with waters deleted from
the active site. Restraints for the compounds were prepared using
the GRADE Web Server [42]. Omit maps were calculated using the
phenix.polder-tool which excludes bulk-solvent from the volume
surrounding the ligand [43]. Figures were made using PyMOL [44].
Ligand-interaction diagrams were prepared using the Maestro-
suite from Schr€odinger Release 2016-3 (Schr€odinger, LLC, New
York).
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All	 reagents	 and	 solvents	 were	 purchased	 from	 commercial	 sources	 and	 used	 as	 supplied,	 unless	
otherwise	stated.	Solvent	mixtures	are	given	in	(v|v).	The	water	used	for	reactions,	was	purified	on	a	
Millipore	RiOsTM	device.	The	aqueous	phase	was	concentrated	under	reduced	pressure	and	Purification	
of	 compounds	 was	 carried	 out	 by	 automated	 RP	 flash	 chromatography	 with	 preloading	 to	 a	 C18	
Samplet®	 cartridge	 (Biotage)	 before	 purification	 on	 a	 C18	 RP	 column	 (Biotage)	 or	 by	 flash	
chromatography	 using	 silica	 gel	 from	 Merck	 (Silica	 gel	 60,	 0.040–0.063	 mm).	 For	 thin	 layer	







coupling	 constant	 (J,	 Hz)	 and	 integration.	 Chemical	 shifts	 (δ)	 are	 reported	 in	 ppm	 relative	 to	 the	
residual	solvent	peak	 (CDCl3	 :	δH	7.26	and	δC	77.16;	methanol-d4	 :	δH	3.31	and	δC	49.00, deuterium	








(1.5	 equiv)	 and	 potassium	 phosphate	 (5.0	 equiv)	 were	 added.	 The	 solution	 was	 degassed	 by	
vacuum/argon	cycles	 (10	 times)	before	addition	of	PdCl2(PPh3)2	 (10	mol%)	and	 further	degassed	 (5	
times).	 The	 resulting	 mixture	 was	 stirred	 at	 95	 °C	 under	 argon	 atmosphere	 for	 16-20	 hours.	 The	
reaction	mixture	was	filtered	through	Celite	and	diluted	with	water	(approx.	30	mL)	before	washing	

























































According	 to	 procedure	 A,	 3-bromobenzoic	 acid	 (1.24	 mmol,	 250	 mg,	 1.0	 equiv),	 3-






126.9,	 125.7,	 125.3,	 125.1,	 63.4.	HRMS	 (ESI):	 Calcd.	 for	C14H11O3	 [M-H]-	227.0714;	 found	227.0716.	
UHPLC:	purity	=	95.1	%	
 2'-methoxybiphenyl-3-carboxylic	acid,	6a:		

























According	 to	 general	 procedure	 B,	 3-bromobenzoic	 acid	 (0.75	 mmol,	 150	 mg,	 1.0	 equiv),	 4-












































According	 to	 procedure	 A,	 3-bromobenzoic	 acid	 (1.24	 mmol,	 250	 mg,	 1.0	 equiv),	 3-


















































According	 to	 general	 procedure	 A,	 4-bromoaniline	 (1.45	 mmol,	 250	 mg,	 1.0	 equiv),	 3-(4,4,5,5-


















3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)	 benzoic	 acid	 (1.69	 mmol,	 418	 mg,	 1.5	 equiv),	
potassium	phosphate	(5.62	mmol,	1.19	g,	5.0	equiv),	PdCl2(PPh3)2	(0.11	mmol,	79	mg,	10	mol%),	after	
purification	by	flash	chromatography	on	silica	gel	using	a	mixture	of	an	acidic	stock	solution	(acetic	
acid/H2O/MeOH/ethyl	 acetate,	 3:2:3:3)	 and	 ethyl	 acetate	 (1:9),	 then	 acidic	 stock	 solution/ethyl	








3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)	 benzoic	 acid	 (1.69	 mmol,	 418	 mg,	 1.5	 equiv),	
potassium	phosphate	(5.62	mmol,	1.19	g,	5.0	equiv),	PdCl2(PPh3)2	(0.11	mmol,	79	mg,	10	mol%),	after	
purification	by	flash	chromatography	on	silica	gel	using	a	mixture	of	an	acidic	stock	solution	(acetic	








3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)	 benzoic	 acid	 (1.87	 mmol,	 465	 mg,	 1.5	 equiv),	
potassium	phosphate	(1.33	mmol,	1.33	g,	5.0	equiv),	PdCl2(PPh3)2	(0.12	mmol,	88	mg,	10	mol%),	after	
purification	by	flash	chromatography	on	silica	gel	using	a	mixture	of	an	acidic	stock	solution	(acetic	























and	 the	 mixture	 was	 stirred	 at	 room	 temperature.	 The	 reaction	 was	 monitored	 by	 TLC	 until	





s).	 13C	 NMR	 (101	 MHz,	 methanol-d4):	 δ	 146.5,	 132.6,	 123.8,	 113.5,	 39.0.	 HRMS	 (ESI):	 Calcd.	 for	
C7H7O2NBrS	[M+H]+	247.9386;	found	247.9389.	
Synthesis	 of	 4'-(methylsulfonamido)biphenyl-3-carboxylic	 acid,	 17:	 The	 compound	 was	 prepared	
according	to	general	procedure	B.	N-(4-bromobenzyl)methanesulfonamide,	(0.72	mmol,	180	mg,	1.5	





















Synthesis	 of	 4'-(phenylsulfonamido)biphenyl-3-carboxylic	 acid,	 18:	 The	 compound	 was	 prepared	
according	to	general	procedure	B.	N-(4-bromophenyl)benzenesulfonamide	(0.48	mmol,	150	mg,	1.0	
equiv),	 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic	 acid	 (0.72	mmol,	 180	mg,	 1.5	 equiv),	



















130.6,	 126.6,	 123.0,	 46.6,	 41.3.	 HRMS	 (ESI):	 Calcd.	 for	 C8H10O2NBrNaS	 [M+Na]+	 285.9508;	 found	
285.9503.	




















Synthesis	 of	 4'-(methylsulfonamidomethyl)biphenyl-3-carboxylic	 acid,	 19b.	 The	 compound	 was	
prepared	according	to	general	procedure	B.	N-(4-bromobenzyl)methanesulfonamide	(0.57	mmol,	150	
mg,	1.0	equiv),	3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic	acid	(0.85	mmol,	211	mg,	1.5	
equiv),	 Na2CO3	 (2.84	 mmol,	 301	mg,	 5.0	 equiv)	 and	 PdCl2(dppf)	 (0.06	 mmol,	 42	 mg,	 10	 mol%)	 in	
anhydrous	THF	(8	mL)	was	stirred	at	84	°C	for	20	h.	Additional	purification	was	carried	out	by	flash	











mg,	 2.0	 equiv)	 was	 added	 and	 the	 mixture	 was	 stirred	 at	 room	 temperature.	 The	 reaction	 was	



















































filtered	and	 the	 solvent	 removed	under	 reduced	pressure.	 The	 title	 compound	 (373	mg,	93%)	was	
obtained	as	a	yellowish	solid	and	used	without	 further	purification	 for	 the	next	step.	 1H	NMR	(400	





























stirred	 at	 85	 °C	 for	 19	 h.	 After	 RP	 chromatography,	 the	 compound	 was	 further	 purified	 by	 flash	
chromatography	on	silica	gel	using	a	mixture	of	an	acidic	stock	solution	(acetic	acid/H2O/MeOH/ethyl	
acetate,	3:2:3:3)	and	ethyl	acetate	 (1:25)	as	eluent.	To	the	resulting	solid	heptane	 (10	mL	x	3)	was	














Synthesis	 of	 4'-(2-acetamidoethyl)biphenyl-3-carboxylic	 acid,	 23b.	 The	 compound	 was	 prepared	
according	to	general	procedure	B.	N-(3'-bromobiphenyl-3-yl)methylacetamide	 (0.62	mmol,	150	mg,	
1.0	 equiv),	 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic	 acid	 (0.93	 mmol,	 231	 mg,	 1.5	




acetate	 (1:9)	 as	 eluent.	 To	 the	 resulting	 solid	heptane	 (10	mL	 x	3)	was	 added	and	 removed	under	


















134.4,	 131.1,	 130.6,	 128.7,	 67.5,	 20.8.	 HRMS	 (ESI):	 Calcd.	 for	 C9H10O4B	 [M-H]-	 193.0678;	 found	
193.0680.	
Synthesis	 of	 3'-acetoxymethyl-biphenyl-3-carboxylic	 acid	 24:	 According	 general	 procedure	 B,	 3-










































Synthesis	 of	 5-(4-bromophenyl)-1H-tetrazole:	 Dibutyltin	 oxide	 (0.33	mmol,	 82	mg,	 0.2	 equiv),	 and	
trimethylsilyl	azide	(3.33	mmol,	383	mg,	2	equiv)	were	added	to	a	solution	of	4-bromobenzonitrile	(300	
mg,	1.67	mmol,	1	equiv)	in	anhydrous	1,4-dioxane	(2	mL/mmol).	The	reaction	mixture	was	subjected	

















tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic	 acid	 (1.81	 mmol,	 448	 mg,	 1.5	 equiv),	 potassium	
























138.0,	 129.4,	 128.7,	 128.6,	 127.8,	 127.4,	 110.3.	 HRMS	 (ESI):	 Calcd.	 for	 C12H9N2O2	 [M-H]-	213.0670;	
found	213.0669.	UHPLC:	purity	=	96.3	%	
 3-(Pyrimidin-5-yl)benzoic	acid,	30:		
According	 to	 general	 procedure	 A,	 5-bromopyrimidine	 (1.57	mmol,	 250	mg,	 1.0	 equiv),	 3-(4,4,5,5-








According	 to	 general	 procedure	 A,	 5-bromo-4-methylpyrimidin-2-amine	 (0.80	 mmol,	 150	 mg,	 1.0	
equiv),	3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)	benzoic	acid	(1.20	mmol,	298	mg,	1.5	equiv),	
potassium	phosphate	(4.01	mmol,	851	mg,	5.0	equiv)	and	PdCl2(PPh3)2	(0.08	mmol,	56	mg,	10	mol%)	























132.4,	 130.6,	 129.2,	 128.7,	 126.8,	 120.6.	 HRMS	 (ESI):	 Calcd.	 for	 C10H6O2NS	 [M-H]-	204.0125;	 found	
204.0120.	UHPLC:	purity	=	96.0	%	
 3-(1H-Indol-5-yl)benzoic	acid,	34:		
According	 to	 general	 procedure	 A,	 5-bromo-1H-indole	 (1.28	 mmol,	 250	 mg,	 1	 equiv),	 3-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic	 acid	 (1.91	 mmol,	 475	 mg,	 1.5	 equiv),	 potassium	








According	 to	 general	 procedure	 A,	 3-bromobenzoic	 acid	 (1.24	 mmol,	 250	 mg,	 1.0	 equiv),	 2-































1 RuPhos-Pd G3 (10) K3PO4 60 / 24 dioxane/water (1:1) 8 : 10 : 10 nd 
2 RuPhos-Pd G3 (5) K3PO4 60 / 24 toluene/water (1:1) 10 : 6 : 0.3 nd 
3 XantPhos-Pd G3 (5) K3PO4 40 / 48 dioxane/water (1:1) 10 : 1 : 0 nd 
4 XantPhos-Pd G3 (5) K3PO4 40 / 24 toluene/water (1:1) 10 : 1 : 3 70 
5 Pd(dppf)Cl2 (5) K3PO4 60 / 24 dioxane/water (1:1) 10 : 1 : 3 80 
6 XPhos-Pd G2 (1) K3PO4 60 / 24 dioxane/water (1:1) 10 : 7 : 1 nd 
7 SPhos-Pd G3 (5) K3PO4 60 / 24 dioxane/water (1:1) 10 : 2 : 0 40 
8 Pd2(dba)3•CHCl3/SPhos 1:1 (10) K3PO4 60 / 24 dioxane/water (1:1) 10 : 1 : 0.4 55 
9 Pd2(dba)3•CHCl3/SPhos 1:1 (10) K3PO4 80 / 24 dioxane/water (1:1) 10 : 1 : 0.3 55 
8 Pd2(dba)3•CHCl3/SPhos 1:1 (10) K3PO4 40 / 24 tert-BuOH 10 : 4 : 4 nd 
9 Pd2(dba)3•CHCl3/SPhos 1:1 (10) K3PO4 40 / 20 toluene/water (1:1) 10 : 1 : 3 65 
10 Pd2(dba)3•CHCl3/SPhos 1:1 (10) K3PO4 60 / 10 dioxane:water (1:1) 5 : 4 : 10 nd 
11 Pd2(dba)3•CHCl3/SPhos 1:1 (10) K3PO4 60 / 48 dioxane:water (1:1) 10 : 4 : 1 nd 
12 Pd2(dba)3•CHCl3/SPhos 1:2 (5) K3PO4 60 / 24 dioxane/water (1:1) 10 : 0.7 : 0 40 
1.4 Synthesis	of	symmetrical	3,5-disubstituted	benzoic	acid	derivatives	
 3,5-Di(3-acetamidophenyl)benzoic	acid	36:		
3-Bromo-5-iodobenzoic	 acid	 (0.30	mmol,	 100	mg,	 1.0	 equiv),	 3-acetamidophenylboronic	 acid	 (0.45	
mmol,	816	mg,	1.5	equiv),	potassium	phosphate	(1.5	mmol,	324	mg,	5.0	equiv)	were	dissolved	in	a	
mixture	of	water/dioxane	 (1:1).	 The	 solution	was	degassed	by	 vacuum/Ar	 cycles	 (10	 times)	before	














































30	mL)	 before	washing	with	 chloroform	 (3	 x	 30	mL).	 The	 aqueous	 phase	was	 concentrated	 under	
reduced	pressure	and	applied	to	a	C18	precolumn	before	purification	by	C18	RP	flash	chromatography	
with	a	gradient	of	acetonitrile	in	water	(10–100	%	over	12	minutes).	The	fractions	were	analysed	by	







































2 NMR spectra of compounds 3–40: 
2.1 2'-methylbiphenyl-3-carboxylic acid, 3a:  
2.1.1 1H NMR of 3a 
 
 
2.1.2 13C NMR of 3a 
 
 22 
2.2 3'-methylbiphenyl-3-carboxylic acid, 3b:  
2.2.1 1H NMR of 3b 
 




2.3 2'-hydroxybiphenyl-3-carboxylic acid 4a:  
2.3.1 1H NMR of 4a 
 
 




2.4 3'-hydroxybiphenyl-3-carboxylic acid, 4b:  
2.4.1 1H NMR of 4b 
 
2.4.2 13C NMR of 4b 
 
 25 
2.5 4'-hydroxybiphenyl-3-carboxylic acid, 4c:  
2.5.1 1H NMR of 4c 
 




2.6 3'-(hydroxymethyl)biphenyl-3-carboxylic acid 5:  
2.6.1 1H NMR of 5 
 





2.7 2'-methoxybiphenyl-3-carboxylic acid, 6a:  
2.7.1 1H NMR of 6a 
 
2.7.2 13C NMR of 6a 
 
 28 
2.8 3'-methoxybiphenyl-3-carboxylic acid, 6b:  
2.8.1 1H NMR of 6b 
 
2.8.2 13C NMR of 6b: 
 
 29 
2.9 4'-methoxybiphenyl-3-carboxylic acid 6c:  
2.9.1 1H NMR of 6c 
 





2.10 4'-methylthiobiphenyl]-3-carboxylic acid, 7:  
2.10.1 1H NMR of 7 
 




2.11 2'-fluorobiphenyl-3-carboxylic acid, 8a:  
2.11.1 1H NMR of 8a 
 
2.11.2 13C NMR of 8a 
 
 32 
2.12 3'-fluorobiphenyl-3-carboxylic acid 8b:  
2.12.1 1H NMR of 8b 
 
 
2.12.2 13C NMR of 8b 
 
 33 
2.13 4'-fluorobiphenyl-3-carboxylic acid, 8c:  
2.13.1 1H NMR of 8c 
 
2.13.2 13C NMR of 8c 
 
 34 
2.14 2'-(methoxycarbonyl)biphenyl-3-carboxylic acid, 9a:  
2.14.1 1H NMR of 9a 
 




2.15 3'-(methoxycarbonyl)biphenyl-3-carboxylic acid, 9b:  
2.15.1 1H NMR of 9b 
 
 
2.15.2 13C NMR of 9b 
 
 36 
2.16 4'-acetylbiphenyl-3-carboxylic acid 10:  
2.16.1 1H NMR of 10 
 
2.16.2 13C NMR of 10 
 
 37 
2.17 3'-carbamoylbiphenyl-3-carboxylic acid, 11a:  
2.17.1 1H NMR of 11a 
 
2.17.2 13C NMR of 11a 
 
 38 
2.18 4'-carbamoylbiphenyl-3-carboxylic acid, 11b:  
2.18.1 1H NMR of 11b 
 
 





2.19 3'-(methylsulfonyl)biphenyl-3-carboxylic acid, 12a:  
2.19.1 1H NMR of 12a 
 
 





2.20 4'-(methylsulfonyl)biphenyl-3-carboxylic acid, 12b:  
2.20.1 1H NMR of 12b 
 




2.21 4'-aminobiphenyl-3-carboxylic acid, 13:  
2.21.1 1H NMR of 13 
 





2.22 4'-dimethylaminobiphenyl-3-carboxylic acid,  14:  
2.22.1 1H NMR of 14 
 





2.23 3'-aminomethylbiphenyl-3-carboxylic acid, 15a:  
2.23.1 1H NMR of 15a 
 






2.24 4'-(aminomethyl)biphenyl-3-carboxylic acid, 15b: 
2.24.1 1HNMR of 15b  
 
2.24.2 13CNMR of 15b 
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2.25 3'-(2-aminoethyl)biphenyl-3-carboxylic acid, 16a: 
2.25.1 1H NMR of 16a 
 
2.25.2 13C NMR of 16a 
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2.26 4'-(2-aminoethyl)biphenyl-3-carboxylic acid, 16b: 
2.26.1 1H NMR of 16b 
 




2.27 4'-(methylsulfonamido)biphenyl-3-carboxylic acid, 17:  
2.27.1 1H NMR of 17 
 
2.27.2 13C NMR of 17 
 
 48 
2.28 4'-(phenylsulfonamido)biphenyl-3-carboxylic acid, 18: 
2.28.1 1H NMR of 18 
 
2.28.2 13C NMR of 18 
 
 49 
2.29 3'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, 19a:  
2.29.1 1H NMR of 19a 
 





2.30 4'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, 19b:  
2.30.1 1H NMR of 19b 
 
2.30.2 13C NMR of 19b 
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2.31 3'-(2-methylsulfonamidoethyl)biphenyl-3-carboxylic acid, 20:  
2.31.1 1H NMR of 20 
 




2.32 3'-acetamidobiphenyl-3-carboxylic acid, 21a:  
2.32.1 1H NMR of 21a 
 




2.33 4'acetamidobiphenyl-3-carboxylic acid, 21b:  
2.33.1 1H NMR of 21b 
 
 




2.34 3'-(acetamidomethyl)biphenyl]-3-carboxylic acid, 22: 
2.34.1 1H NMR of 22 
 




2.35 3'-(2-acetamidoethyl)biphenyl]-3-carboxylic acid, 23a: 
2.35.1 1H NMR of 23a 
 




2.36 4'-(2-acetamidoethyl)biphenyl]-3-carboxylic acid, 23b: 
2.36.1 1H NMR of 23b 
 




2.37 3'-acetoxymethylbiphenyl-3-carboxylic acid, 24:  
2.37.1 1H NMR of 24 
 






2.38 4'-(1H-imidazol-1-yl)biphenyl-3-carboxylic acid, 25:  
2.38.1 1H NMR of 25 
 




2.39 3'-(1H-tetrazol-5-yl)biphenyl-3-carboxylic acid, 26a:  
2.39.1 1H NMR of 26a 
 
2.39.2 13C NMR of 26a 
 
 60 
2.40 4'-(1H-tetrazol-5-yl)biphenyl-3-carboxylic acid, 26b:  
2.40.1 1H NMR of 26b 
 




2.41 3-(naphthalen-2-yl)benzoic acid, 27:  
2.41.1 1H NMR of 27 
 




2.42 3-(quinolin-7-yl)benzoic acid, 28:  
2.42.1 1H NMR of 28 
 
2.42.2 13C NMR of 28 
 
 63 
2.43 3-(6-aminopyridin-3-yl)benzoic acid, 29:  
2.43.1 1H NMR of 29 
 




2.44 3-(pyrimidin-5-yl)benzoic acid, 30:  
2.44.1 1H NMR of 30 
 
2.44.2 13C NMR of 30 
 
 65 
2.45 3-(2-aminopyrimidin-4-yl)benzoic acid, 31:  
2.45.1 1H NMR of 31 
 





2.46  3-(1-methyl-1H-pyrrol-2-yl)benzoic acid, 32:  
2.46.1 1H NMR of 32 
 




2.47 3-(thiazol-5-yl)benzoic acid, 33:  
2.47.1 1H NMR of 33 
 
2.47.2 13C NMR of 33 
 
 68 
2.48 3-(1H-indol-5-yl)benzoic acid, 34:  
2.48.1 1H NMR of 34 
 
 




2.49 3-(pyridin-2-yl)benzoic acid, 35:  
 
2.49.1 1H NMR of 35 
 
2.49.2 13C NMR of 35 
 
 70 
2.50 symmetrical 3,5-disubstituted benzoic acid derivatives 
2.51 3,5-Di(3-acetamidophenyl)benzoic acid 36: 
2.51.1 1H NMR of 36 
 
2.51.2 13C NMR of 36 
 
 71 
2.52 3,5-di(4-acetamidophenyl)benzoic acid 37: 
 
2.52.1 1H NMR of 37 
 




2.53 3,5-diquinolin-6-ylbenzoic acid 38: 
2.53.1 1H NMR of 38 
 




2.54 unsymmetrical 3,5-disubstituted benzoic acid derivatives 
2.55 3-(3'-Acetamidophenyl)-5-pyridin-4-ylbenzoic acid 39: 
2.55.1 1H NMR of 39 
 
2.55.2 13C NMR of 39 
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2.56 3-Bromo-5-(quinolin-6-yl) benzoic acid int-40: 
2.56.1 1H NMR of int-40 
 
2.56.2 13C NMR of int-40 
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2.57 3-(3'-Acetamidophenyl)-5-quinolin-6-ylbenzoic acid 40:  
2.57.1 1H NMR of 40 
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Carbonylative Suzuki–Miyaura couplings of
sterically hindered aryl halides: synthesis of
2-aroylbenzoate derivatives†
Aya Ismael, a Troels Skrydstrup b and Annette Bayer *a
We have developed a carbonylative approach to the synthesis of diversely substituted 2-aroylbenzoate
esters featuring a new protocol for the carbonylative coupling of aryl bromides with boronic acids and a
new strategy to favour carbonylative over non-carbonylative reactions. Two different synthetic pathways
– (i) the alkoxycarbonylation of 2-bromo benzophenones and (ii) the carbonylative Suzuki–Miyaura coup-
ling of 2-bromobenzoate esters – were evaluated. The latter approach provided a broader substrate toler-
ance, and thus was the preferred pathway. We observed that 2-substituted aryl bromides were challenging
substrates for carbonylative chemistry favouring the non-carbonylative pathway. However, we found that
carbonylative Suzuki–Miyaura couplings can be improved by slow addition of the boronic acid, suppres-
sing the unwanted direct Suzuki coupling and, thus increasing the yield of the carbonylative reaction.
Introduction
Through our program on fragment-based design of metallo-
β-lactamase inhibitors, we became interested in the develop-
ment of efficient strategies for the synthesis of functionalized
2-aroylbenzoic acids 1 (Scheme 1).1 Among other, 2-aroylben-
zoic acids have gained keen interest as synthetic intermediates
for accessing bioactive compounds,2–7 as subunits of natural
products and pharmaceuticals e.g. (−)-balanol8 and pitfenone,
and as fragment-sized inhibitors of the human aldo-keto
reductase AKR1C3 9 and the hepatitis C virus NS3 protease.10
Most commonly, 2-aroylbenzoic acids are prepared from
phthalic anhydride by treatment with organometallic
reagents2,7,11 or by a Friedel–Crafts acylation3,5,12 with aro-
matic nucleophiles. However, these methods are incompatible
with many functional groups, requiring excess Lewis acid and
harsh reaction conditions, and often provide poor regio-
selective control. On the other hand, the biaryl ketone sub-
scaffold of 2-aroylbenzoic acids has been synthesized by tran-
sition metal-catalyzed carbonylative cross-couplings of organo-
metallic reagents and aryl electrophiles,13–15 or the non-decar-
bonylative coupling of acyl electrophiles, e.g. carboxylic
acids,16–18 esters19–21 or amides.19,22 Despite the advances in
the synthesis of biaryl ketones, only few methods have been
demonstrated to be applicable for the formation of 2-aroyl
benzoic acid derivatives. Such methods comprise of the
Pd-catalyzed ortho-C–H activation of benzoic acids followed by
decarboxylative coupling with α-oxocarboxylic acids,23 Pd-cata-
lyzed ortho-C–H activation of aryl amides followed by coupling
with aryl aldehydes,24 and the Pd-catalyzed coupling of 2-iodo-
benzoates with aldehydes.25 However, the available protocols
have limited regiocontrol and/or substrate scope especially
with regard to electron-deficient aryl groups.
In this study, we investigated two alternative routes towards
2-aroylbenzoate esters 2 featuring carbonylative couplings
using safe and easy to handle ex situ generated CO as a key
step (Scheme 1). In the first approach (route A), we examined
the Pd-catalyzed alkoxycarbonylation of 2-bromo functiona-
lized biaryl ketones, which in turn could be prepared by carbo-
nylative Suzuki–Miyaura couplings of 2-bromoiodobenzene. In
the second approach (route B), we investigated the carbonyla-
tive Suzuki–Miyaura coupling of 2-bromo substituted benzoate
esters. A new protocol for the carbonylative coupling of aryl bro-
mides and simple boronic acids preventing the use of iodide
salts as additives or high-pressure CO gas was developed.
Moreover, we demonstrate that slow addition of the nucleophilic
coupling reagent is an uninvestigated strategy to enhance for-
mation of the carbonylative product over the non-carbonylative
side-product. The latter discovery was essential for sterically-
demanding ortho-substituted aryl bromides in order to provide
useful yields of the carbonylative coupling products.
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d0ob00044b
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Results and discussion
Carbonylative Suzuki–Miyaura of 2-bromoiodobenzene (step A1)
Initially, we focused on the Pd-catalyzed carbonylative Suzuki–
Miyaura coupling of 2-bromoiodobenzene 3 with aryl boronic
acids 4 in order to prepare substituted 2-bromobenzophenone
derivatives 5 as starting materials for further alkoxycarbonyla-
tion reactions (Scheme 2). A range of catalysts derived from a
variety of Pd sources including Pd(OAc)2,26 Pd(dba)2,27 Pd
(PPh3)2Cl2,28 PdCl2, PEPPSI-IPr29 were evaluated for the carbo-
nylative coupling of the aryl iodide in presence of a bromide
using 2-bromoiodobenzene 3 and 4-methoxyphenyl boronic
acid 4a (Table ESI-1†). The yields varied from 10% to 65% of
the furnished benzophenone (Table ESI-1,† entries 1–5), and
competitive formation of the direct coupling product (biphe-
nyl) was a major limitation. The most promising catalytic
system identified from the screening used PdCl2 as catalyst
precursor, K2CO3 as base, and anisole as solvent (Table ESI-1,†
entry 5).
In addition, several methods for the ex situ generation of
carbon monoxide from formic acid,30 oxalyl chloride,31
COgen,32 and electrochemical reduction of CO2 to CO33 were
screened to prevent the risk of handling toxic carbon monox-
ide from a cylinder (Table ESI-2†). The most promising and
convenient CO source turned out to be 9-methylfluorene-9-car-
bonyl chloride (COgen) (Table ESI-2,† entry 3). Oxalyl chloride
as CO source provided comparable results if the CO gas was
generated outside the reaction chamber making the handling
more inconvenient (Table ESI-2,† entry 5), while both formic
acid and electrochemical reduction of CO2 resulted in substan-
tially reduced yields (Table ESI-2,† entries 1 and 7).
The catalytic system employing PdCl2 as precatalyst was
further optimized with regard to different reaction times,
temperatures, and slow addition of the boronic acid. Yields up
to 65% of the carbonylated product were obtained with PdCl2
(3 mol%) at 80 °C for 20 h (Table ESI-1,† entry 5). Reduction of
the catalyst loading to 1 mol% led to a slight decrease in yield
to 60% (Table ESI-1,† entry 6) and 1 mol% of precatalyst was
used in the following reactions. A lower reaction temperature
led to incomplete conversion and lower yields (Table ESI-1,†
entries 7 and 8). Addition of KI to favour carbonylative over
direct coupling28 did not improve the yield (Table ESI-1,†
entry 11). However, when the aryl boronic acid was added
slowly over 2 h, direct coupling was suppressed and the yield
Scheme 1 Routes towards 2-aroylbenzoic acid derivatives explored in this work.
Scheme 2 Carbonylative Suzuki–Miyaura coupling of 2-bromoiodo-
benzene with boronic acids. Reaction conditions: Chamber A: 3
(0.18 mmol), PdCl2 (1 mol%) and K2CO3 (0.55 mmol) in anisole (3 ml).
Chamber B: COgen (0.45 mmol), Pd(dba)2 (5 mol%) and TTBP·HBF4
(5 mol%) in anisole (3 ml). DIPEA (3 equiv.) was added to chamber B to
start CO formation, before 4 (1.2 equiv.) in anisole (3 ml) was added
slowly to chamber A (general procedure A, ESI†).a Yield obtained when 4
(1.2 equiv.) was added to chamber A before CO release (general pro-
cedure B, ESI†).
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improved up to 80% (Table ESI-1,† entry 13). Similarly, the
yield of the carbonylated product was improved from 30% to
60% by slow addition of the aryl boronic acid for reactions
with PEPPSI-IPr as the precatalyst (Table ESI-1,† entries 4
and 15).
Then, we explored the scope of the Pd-catalyzed reaction
using PdCl2 with respect to different aryl and heteroaromatic
boronic acids 4 (Scheme 2). In all cases, slow addition of the
aryl boronic acid increased the yield by 20–35 percentage
points. Both electron-rich and electron-deficient aryl boronic
acids (4a–c, e, f, j, l, m) gave moderate to high yields (60–80%)
of the products. However, some electron-deficient boronic
acids 4g, i and k provided lower yields in the range of 30–40%.
ortho-Substituents on the boronic acid (4c, h and m) and some
electron-rich heterocycles (4e and f ) were well tolerated to the
reaction conditions. However, hydroxy and N-acyl substituted
aryl boronic acids and 2-furanyl boronic acid only provided
products from the direct coupling instead of carbonylative
coupling.
Hydroxy- or alkoxycarbonylation of 2-bromo-substituted biaryl
ketones (step A2)
With a set of 2-bromobenzophenone derivatives 5a–m in hand,
we investigated the Pd-catalyzed hydroxy- and alkoxycarbonyla-
tion to transform the aryl bromide into the carboxylic acid or
ester, respectively.34 Previous reports on Pd-catalyzed
hydroxycarbonylation30,34–36 or alkoxycarbonylation26,34,37,38
have had little focus on ortho-substituted aryl bromides.
Unfortunately, all attempts to transform 2-bromo-4′-methoxy-
benzophenone 5a directly to 2-(4-methoxybenzoyl)benzoic acid
via a hydroxycarboxylation using MePh2SiCO2H35 were unsuc-
cessful (Table ESI-3†).
Next, we turned our attention to the alkoxycarbonylation of
2-bromobenzophenones 5 (Scheme 3).37 Using 5a as the test
substrate, a range of precatalysts and ligands (Pd(OAc)2, PdCl2
or Pd(dba)2 with Xantphos, dippf or PPh3, Pd(PPh3)2Cl2/
IMes,39 dppf(PdCl2), PEPPSI-IPr or PEPPSIIMes), nucleophiles
(MeOH, iPrOH, n-BuOH, t-BuONa, EtONa), bases and solvents
were screened (Table ESI-4†). Only few systems were able to
provide the corresponding alkyl 2-(4-methoxybenzoyl)benzoate
2. Comparison of the catalyst performance for 2-bromo-substi-
tuted 5a and the corresponding 4-bromo-substituted analog
showed that the yields were highly influenced by the substi-
tution pattern. For example, for catalyst systems based on dppf
(PdCl2) or Pd(OAc)2/Xantphos, the yields dropped from >95%
for the 4-bromo-substituted analog to an 11% yield for
2-bromo-substituted 5a under otherwise identical conditions
(Table ESI-5†). The best results for the latter were obtained
with PdCl2 and Xantphos as catalytic system, n-butanol as the
nucleophile, K2CO3 as the base and anisole as solvent furnish-
ing the ester 2a in acceptable yield (65%) (Table ESI-4,† entry
12). We applied these conditions to our library of 2-bromoben-
zophenone derivatives 5a–m (Scheme 2). While the substrates
5a, b, k and m gave alkoxycarbonylation products 2a–d in
acceptable yields (65%, 60%, 63% and 55%, respectively), com-
pounds 5c–h and 5l gave low yields to no product. Over all, we
conclude that while the carbonylative Suzuki–Miyaura coup-
ling was tolerant to a variety of aryl boronic acids, the alkoxy-
carbonylation of 2-bromo-biaryl ketones displayed a high
dependence on the substrate structure rendering the approach
unsuitable for the synthesis of a larger library of compounds.
Carbonylative Suzuki–Miyaura coupling with
2-bromobenzoates (route B1)
Due to the limited substrate scope of the alkoxycarbonylation
of 2-bromobenzophenone derivatives, we decided to study the
carbonylative Suzuki–Miyaura coupling of methyl 2-bromo-
benzoates 6 (Table 1). Few examples of carbonylative couplings
with aryl bromides28,40–43 have been reported and those rely on
the use of iodide salts as additives (3 equiv.),28 high pressure
of CO gas (5 bar)41–43 or the use of less accessible boronate
esters40 like DABO boronates44 or aryl trihydroxyborates45
instead of boronic acids. Only two examples of successful
Scheme 3 Palladium-catalyzed alkoxycarbonylation of 2-bromo biaryl
ketones. Reaction conditions: Chamber A: 5 (1.0 equiv., 0.18 mmol),
PdCl2 (2 mol%), Xantphos (3 mol%) K2CO3 (3 equiv., 0.55 mmol) in
anisole : n-BuOH (2 : 1, 3 ml). Chamber B: COgen (107 mg, 2.5 equiv.,
0.45 mmol), Pd(dba)2 (12 mg, 5 mol%) and TTBP·HBF4 (6.3 mg, 5 mol%)
in anisole (3 ml). DIPEA (240 mg, 3 equiv.) was added to chamber B to
start CO release.
Table 1 Boronate derivatives in carbonylative Suzuki–Miyaura
couplings





PEPPSI-IPr/slow addition of 4a 80%
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couplings with ortho-substituted substrates were reported.41
While carbonylative couplings of sterically hindered, electron-
rich aryl iodides have been achieved with PEPPSI-IPr as the
precatalyst,29 electron-poor aryl bromides like 6 have been
shown to be challenging substrates favouring non-carbonyla-
tive direct couplings providing biaryl derivatives.28,41 In this
perspective, general methods for carbonylative Suzuki–Miyaura
couplings of aryl bromides with boronic acids are still needed.
With methyl 2-bromobenzoate 6a as the test substrate, the
protocol reported by Skrydstrup and Molander40 using
Pd(acac)2/CataCXium A·HI (5/10 mol%) afforded acceptable
yields of 2aa with 65–67% when the DABO boronate44 7a or
aryl trihydroxyborate45 8 were used as the nucleophilic coup-
ling reagent (Table 1). However, the yield decreased to 30%
with the boronic acid 4a. Attempts to increase the yield by slow
addition of the DABO boronate 6 or the trihydroxyborate 7
were not successful due to low solubility of these boronic acid
derivatives in the reaction medium (toluene/water). The use of
other solvent systems dramatically reduced the yields
(Table ESI-6,† entries 4–8).
Therefore, we proceeded to identify reaction conditions for
the coupling of 2-bromobenzoate 6a with aryl boronic acids 4a
using COgen as the carbon monoxide source. A range of
experimental conditions including different palladium sources
and ligands (Pd(acac)2 or Pd(OAc)2/CataCXium A or A·HI,40
Pd(OAc)2 or PdCl2/Xantphos, Xantphos-G2, PEPPSI-IPr, [Pd
(IPr)(allyl)Cl], Pd(PPh3)2Cl2 28,43 and Ni(COD)/dcype) and sol-
vents were screened (Table ESI-6,† entries 9–20). In most of the
systems, the undesired non-carbonylative coupling was the
dominant reaction pathway (Table ESI-6,† entries 9–15). Only
the Pd(IPr)-based catalytic systems were able to accomplish the
carbonylative Suzuki–Miyaura coupling (Table ESI-6,† entries
16–19). The best system using PEPPSI-IPr (3 mol%) as catalyst
precursor, Cs2CO3 as base in chlorobenzene or anisole as
solvent provided the product 2aa in 63% yield (Table 1 and
Table ESI-6,† entry 16). The yield could be further increased to
80% by slow addition of the boronic acid (Table 1 and
Table ESI-6,† entry 17).
A range of aryl boronic acids 4 were tested to examine the
scope of the reaction as depicted in Scheme 4. Most of the
electron rich boronic acids (4a, c and d) provided good yields
(2aa: 80%; 2ac: 75%; 2ad: 76%), while electron-deficient
boronic acids (4g, i, j, k and l) generally led to lower yields
(2ag: 47%; 2ai: 32%; 2aj: 40%; 2ak: 37%; 2al: 58%). Yields
obtained with slow addition of the aryl boronic acid were con-
sistently higher (2aa: 80%; 2ac: 75%; 2ai: 32%; 2aj: 40%; 2al:
Scheme 4 Suzuki–Miyaura coupling of methyl 2-bromobenzoate 6a
with boronic acids 4. Reaction conditions: Chamber A: 6a (1.0 equiv.,
0.47 mmol), PEPPSI-IPr (3 mol%) and Cs2CO3 (3 equiv., 1.4 mmol) in
anisole (3 ml). Chamber B: COgen (282 mg, 2.5 equiv., 1.2 mmol), Pd
(dba)2 (30 mg, 5 mol%) and TTBP·HBF4 (10 mg, 5 mol%) in anisole (3 ml).
DIPEA (450 mg, 3 equiv.) was added to chamber B, before 4 (1.5 equiv.)
was added slowly to chamber A (general procedure C, ESI†).a Yield
obtained when 4 (1.5 equiv.) was added to chamber A before CO release
(general procedure D, ESI†). b Yield obtained by reaction with DABO bor-
onate 7 (1.5 equiv.) using Pd(acac)2/2 CataCXium A·HI (5 mol%) as cata-
lyst (general procedure E, ESI†).
Scheme 5 Substrate scope of carbonylative Suzuki–Miyaura coupling
of methyl 2-bromobenzoate derivatives 6 with boronic acids 4. Reaction
conditions: Chamber A: 6 (1.0 equiv., 0.47 mmol), PEPPSI-IPr (3 mol%)
and Cs2CO3 (3 equiv., 1.4 mmol) in anisole (3 ml). Chamber B: COgen
(282 mg, 2.5 equiv., 1.2 mmol), Pd(dba)2 (30 mg, 5 mol%) and TTBP·HBF4
(10 mg, 5 mol%) in anisole (3 ml). DIPEA (450 mg, 3 equiv.) was added to
chamber B, before 4 (1.5 equiv.) was added slowly to chamber A
(general procedure C, ESI†).
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58%; 2am: 65%), when compared with yields obtained by
instantaneous addition (2aa: 63%; 2ac: 26%; 2ai: 16%; 2aj:
24%; 2al: 43%; 2am: 42%). Slow addition of the boronic acid
under reaction conditions seems to favour the CO insertion
step by slowing down the faster transmetallation28,41 due to
limited access to the organometallic nucleophile.
Aryl boronic acids containing acidic protons and the hetero-
aromatic boronic acid 4n only underwent direct coupling
instead of carbonylative coupling using PEPPSI-IPr. Couplings
with heteroaromatic organometallic reagents could be achieved
using the corresponding DABO boronates providing 2an and
2ao with Pd(acac)2/CataCXium A·HI as the catalytic system.
We further investigated the scope of the reaction with
regard to a range of substituted methyl 2-bromobenzoates 6b–i
(Scheme 5). Aryl bromide 6 with both electron-withdrawing
6b–e and donating substituents 6f–i gave acceptable yields
(50–72%). Surprisingly, also the coupling of ortho di-
substituted 6g provided good yields (2ga: 68%). The lowest
yield (2bh: 40%) was obtained for the coupling of the electron-
deficient 6b with the electron-deficient boronic acid 4p.
Conclusions
In summary, two routes for accessing 2-aroylbenzoate esters
have been evaluated. In the first strategy, the key step was the
alkoxycarbonylation of 2-bromo-diarylketones, which unfortu-
nately appeared sensitive to the substitution pattern of the aryl
bromide. The second strategy employed a carbonylative
Suzuki–Miyaura coupling of 2-bromobenzoate esters, which
was more robust with regard to the structure of aryl bromide
and the aryl boronic acid. The latter approach was exploited to
prepare a range of diversely substituted 2-aroylbenzoate esters.
Moreover, we found that slow addition of the boronic acid
is a strategy to favour carbonylative over non-carbonylative pro-
cesses in Suzuki–Miyaura couplings – a finding that should be
of general value.
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1 Experimental procedures 
1.1 General  
Unless otherwise noted, purchased chemicals were used as received without further purification. Solvents 
were dried according to standard procedures on molecular sieves 4A.1 MePh2SiCO2H (silaCOgen) was 
prepared as reported previously.2 DABO boronates 7a and sodium trihydroxy(4-methoxyphenyl)borate 
8a were prepared according to the previously reported protocol.3 Flash chromatography was carried out 
on silica gel 60 (230−400 mesh). NMR spectra were obtained on a 400 MHz NMR spectrometer. The 
chemical shifts are reported in ppm relative to the solvent residual peak. Data are represented as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dt = double triplet, m = 
multiplet), coupling constant (J, Hz) and integration. Chemical shifts (δ) are reported in ppm relative to 
the residual solvent peak (CDCl3: δH 7.26 and δC 77.16; Methanol-d4: δH 3.31 and δC 49.00; deuterium 
oxide: δH 4.79; DMSO-d6 δH 2.51 and δC 39.52). Positive ion electrospray ionization mass spectrometry 
was conducted on a Thermo Electron LTQ Orbitrap XL spectrometer. The reactions were performed in 
the previously reported two-chamber system2 under an argon atmosphere, and a glovebox was employed 
for weighing out the reagents. 
 
1.2 General procedures 
General procedure A: Carbonylative Suzuki Miyaura coupling of 2-bromoiodobenzene 3 with slow 
addition.  
Chamber A: 2-Bromoiodobenzene 3 (50 mg, 1.0 equiv, 0.18 mmol), PdCl2 (0.3 mg, 1 mol%), K2CO3 
(70 mg, 3 equiv, 0.55 mmol) were dissolved in anisole (1 ml). Chamber B: COgen (107 mg, 2.5 equiv, 
0.45 mmol), Pd(dba)2 (12 mg, 5 mol%), tri-tert-butylphosphonium tetrafluoroborate (TTBP•HBF4) (6.3 
mg, 5 mol%) and DIPEA (240 mg, 3 equiv) were dissolved in anisole (3 ml). Chamber B was stirred and 
heated to 80 °C to release CO until gas evolution stops. After release of the CO, both chambers were 
stirred and heated to 80 °C and a solution of aryl boronic acid 4 (1.2 equiv) in anisole (2 ml) was added 
slowly (1-2 h) to the reaction mixture in chamber A. The two-chamber system was then placed in an oil 
bath and stirred at 80 °C for 20 hours. The reaction mixture was filtered through celite and concentrated 
on a rotavapor. The crude was purified by column chromatography with pentane: EtOAc (8:2) as eluent. 
 
General procedure B: Carbonylative Suzuki Miuara coupling of 2-bromoiodobenzene 3 with 
instantaneous addition.  
Chamber A: 2-Bromoiodobenzene 3 (50 mg, 1.0 equiv, 0.18 mmol), PdCl2 (0.3 mg, 1 mol%), K2CO3 
(70 mg, 3 equiv, 0.55 mmol) and aryl boronic acid 4 (1.2 equiv) were dissolved in anisole (3 ml). 
Chamber B: COgen (107 mg, 2.5 equiv, 0.45 mmol), Pd(dba)2 (12 mg, 5 mol%), TTBP•HBF4 (6.3 mg, 
5 mol%) were added together and dissolved in anisole (3 ml) before DIPEA (240 mg, 3 equiv) was added. 
Both chambers were stirred and heated at 80°C under tightly closed system for 20 hours. The reaction 
mixture was filtered through celite and concentrated on a rotavapor. The crude was purified by column 
chromatography with pentane: EtOAc (8:2) as eluent. 
 
General procedure C: Carbonylative Suzuki-Miyaura coupling of methyl 2-bromobenzoate 6 with 
slow addition.  
Chamber A: Methyl 2-bromobenzoate 6 (100 mg, 1.0 equiv, 0.47 mmol), PEPPSI-IPr (9.4 mg, 3 mol%), 
Cs2CO3 (450 mg, 3 equiv, 1.4 mmol) were dissolved in anisole (1 ml). Chamber B: COgen (282 mg, 2.5 
equiv, 1.2 mmol), Pd(dba)2 (30 mg, 5 mol%), TTBP•HBF4 (10 mg, 5 mol%) and DIPEA (240 mg, 3 
equiv) were dissolved in anisole (3 ml). The reaction mixture in Chamber B was stirred and heated to 80 
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°C to release CO until gas evolution stops. After release of the CO, both chambers were stirred and heated 
to 110 °C and a solution of aryl boronic acid 4 (1.5 equiv) in anisole (2 ml) was added slowly (1-2 h) to 
the reaction mixture in chamber A. The two-chamber system was then placed in an oil bath and stirred 
at 110 °C for 20 hours. The reaction mixture was filtered through celite and concentrated on a rotavapor. 
The crude was purified by column chromatography with pentane: EtOAc (7:3) as eluent.  
 
General procedure D: Carbonylative Suzuki-Miyaura coupling of methyl 2-bromobenzoate 6.  
Chamber A: Methyl 2-bromobenzoate 6 (1.0 equiv, 0.47 mmol), aryl boronic acid 4 (1.5 equiv), PEPPSI-
IPr (3 mol%), Cs2CO3 (3 equiv, 1.4 mmol) were dissolved in anisole (3 ml). Chamber B: COgen (282 
mg, 2.5 equiv, 1.2 mmol), Pd(dba)2 (30 mg, 5 mol%), TTBP•HBF4 (10 mg, 5 mol%) were dissolved in 
anisole (3 ml) before DIPEA (450 mg, 3 equiv) was added. The two-chamber system was then placed in 
an oil bath and stirred at 110 °C for 20 hours. The reaction mixture was filtered through celite and 
concentrated on a rotavapor. The crude was purified by column chromatography with pentane:EtOAc 
(7:3) as eluent. 
 
General procedure E: Carbonylative Suzuki Miuara coupling of methyl 2-bromobenzoate with 
DABO boronates or sodium borate salt.  
Chamber A: Methyl 2-bromobenzoate 6 (50 mg, 1.0 equiv, 0.23 mmol), Pd(acac)2 (3.5 mg, 5 mol%), 
CataCXium A•HI (11 mg, 10 mol%), and the DABO boronate 7 or sodium borate salt 8 (1.5 equiv) were 
dissolved in toluene: H2O (1:1; 3 ml). Chamber B: COgen (140 mg, 2.5 equiv, 0.58 mmol), Pd(dba)2 (26 
mg, 5 mol%), TTBP•HBF4 (13 mg, 5 mol%) were dissolved in anisole (3 ml) before DIPEA (241 mg, 3 
equiv) was added. The two-chamber system was then placed in an oil bath and stirred at 110 °C for 20 
hours. The reaction mixture was filtered through celite and concentrated on a rotavapor. The crude was 
purified by column chromatography with pentane:EtOAc (7:3) as eluent. 
 
General procedure F: Alkoxy carbonylation of 2-bromobenzophenone derivatives 5 with n-BuOH.  
Chamber A: 2-bromobenzophenone 5 (1 equiv), PdCl2 (2 mol%), Xantphos (4 mol%), K2CO3 (3 equiv) 
were dissolved in anisole: n-BuOH (1:1; 3 ml). Chamber B: COgen (2.5 equiv), Pd(dba)2 (5 mol%), 
TTBP•HBF4 (5 mg, 5 mol%) were dissolved in anisole (3 ml) before DIPEA (3 equiv) was added. The 
two-chamber system was then placed in an oil bath and stirred under heating for 20 hours. The reaction 
mixture was filtered through celite and concentrated on a rotavapor. The crude was purified by column 
chromatography with pentane: EtOAc (7:3). 
 
1.3 Preparation and characterization of 2-bromobenzophenone derivatives 5. 
2-Bromophenyl 4-methoxyphenyl methanone (5a). 2-Bromoiodobenzene 3 (50 mg) was reacted with 4-
methoxyphenyl boronic acid 4a (35 mg, 0.21 mmol, 1.2 equiv). Reactions were performed both by the 
general procedure A or B to provide 5a (procedure A: 41 mg, 80%; procedure B: 31 mg, 60%) as a 
colourless solid. Mp 91-93 °C. NMR: δH (400 MHz; CDCl3) 7.79 (2H, d, J 8.8), 7.64 (1H, d, J 7.9), 7.40 
(1H, d, J 7.9), 7.33 (2H, t, J 7.5), 6.94 (2H, d, J 8.8), 3.88 (3H, s). δC (101 MHz, CDCl3) 194.9, 164.6, 
141.6, 133.5, 133.1, 131.3, 129.6, 129.2, 127.6, 119.9, 114.4, 56.0. HRMS (ESI): Calcd. for 
C14H11O279BrNa [M+H]+ 312.9840; found 312.9827. The spectroscopic data is corresponding to the 
previously reported in literature.4 
2-Bromophenyl 3-methoxyphenyl methanone (5b). 2-Bromoiodobenzene 3 (50 mg) was reacted with 3-
methoxyphenyl boronic acid 4b (35 mg, 0.21 mmol, 1.2 equiv). Reactions were performed both by the 
general procedure A or B to provide 5b (procedure A: 35 mg, 65%; procedure B: 18 mg, 35%) as a white 
solid. Mp 85-87 °C. NMR: δH (400 MHz, CDCl3) 7.56 (1H, d, J 7.7), 7.36 (1H, s), 7.32 (1H, d, J 7.7), 
7.26 (3H, t, J 7.6), 7.21-7.15 (1H, m), 7.08-7.05 (1H, m), 3.77 (3H, s). δC (101 MHz, CDCl3) 195.8, 
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160.0, 140.8, 137.6, 133.3, 131.3, 129.7, 129.0, 127.3, 123.6, 120.6, 119.6, 113.8, 55.6. HRMS (ESI): 
Calcd. for C14H11O279BrNa [M+H]+ 312.9840; found 312.9827. The spectroscopic data is corresponding 
to the previously reported in literature.5 
2-Bromophenyl 2-methoxyphenyl methanone (5c). 2-Bromoiodobenzene 3 (50 mg) was reacted with (2-
methoxyphenyl) boronic acid (35 mg, 0.21 mmol, 1.2 equiv) according to the general procedure A to 
provide 5c (31 mg, 60%) as a white solid. Mp 66.3-68 °C. NMR: δH (400 MHz, CDCl3) 7.56-7.52 (1H, 
m), 7.48-7.44 (1H, m), 7.39 (1H, t, J 7.6), 7.27-7.23 (2H, m), 7.19-7.12 (1H, m), 6.91 (1H, t, J 7.6), 6.82-
6.80 (1H, m), 3.53 (s, 3H). δC (101 MHz, CDCl3) 195.3, 159.5, 142.8, 134.5, 133.1, 131.9, 131.0, 129.4, 
127.3, 127.1, 120.8, 119.6, 112.1, 55.9. HRMS (ESI): Calcd. for C14H11O279BrNa [M+H]+ 312.9840; 
found 312.9827. The spectroscopic data is corresponding to the previously reported in literature.5 
2-Bromophenyl 4-(methylthio)phenyl methanone (5d). 2-Bromoiodobenzene 3 (50 mg) was reacted with 
(4-(methylthio) phenyl) boronic acid (45 mg, 0.27mmol, 1.5 equiv) according to the general procedure 
A to provide 5d (30 mg, 55%) as a white solid. NMR: δH (400 MHz, CDCl3) 7.70 (2H, d, J 8.4), 7.63 
(1H, d, J 7.6), 7.40 (1H, d, J 7.6), 7.37-7.27 (2H, m), 7.27-7.20 (2H, m), 2.51 (3H, s). δC (101 MHz, 
CDCl3) 195.0, 147.3, 140.9, 140.5, 133.3, 132.5, 131.2, 130.7, 129.0, 128.2, 127.4, 125.0, 119.6, 14.8. 
HRMS (ESI): Calcd. for C14H1181BrOS [M+H]+ 308.9727; found 308.9756 
tert-Butyl 2-(2-bromobenzoyl)-1H-pyrrole-1-carboxylate (5e). 2-Bromoiodobenzene 3 (50 mg) was 
reacted with (1-(tert-butoxycarbonyl)-1H-pyrrol-2-yl)boronic acid 4e (45 mg, 0.21 mmol, 1.2 equiv) 
according to the general procedure A to provide 5e (43 mg, 70%) as a yellow oil. NMR: δH (400 MHz, 
CDCl3) 7.63 (1H, d, J 7.7), 7.48-7.46 (2H, m), 7.38 (2H, t, J 7.5), 7.33 (2H, t, J 7.5),  6.53-6.52 (1H, m), 
6.18 (1H, t, J 3.3), 1.56 (9H, s). δC (101 MHz, CDCl3) 184.6, 149.2, 140.9, 134.0, 133.7, 132.1, 130.6, 
129.6, 127.5, 125.3, 121.0, 110.9, 85.6, 77.8, 77.7, 77.5, 77.2, 28.0. HRMS (ESI): Calcd. for C16H16 
81BrNNaO3 [M+H]+ 374.0278; found 374.0177. 
tert-Butyl 2-(2-bromobenzoyl)-1H-indole-1-carboxylate (5f). 2-Bromoiodobenzene 3 (50 mg) was 
reacted with (1-(tert-butoxycarbonyl)-1H-indol-2-yl)boronic acid 4f (55 mg, 0.21 mmol, 1.5 equiv) 
according to the general procedure A to provide 5f (53 mg, 76%) as a yellow oil. NMR: δH (400 MHz, 
CDCl3) 8.14 (1H, d, J 9.2), 7.69-7.67 (1H, m), 7.58-7.56 (2H, m), 7.49-7.45 (1H, m), 7.44-7.36 (2H, m), 
7.28 – 7.24 (1H, m), 6.84 (1H, s), 1.58 (9H, s). δC NMR (101 MHz, CDCl3) 186.0, 149.5, 139.7, 139.2, 
137.8, 134.0, 132.4, 131.0, 127.9, 127.4, 127.3, 123.5, 122.9, 121.1, 118.7, 115.0, 84.9, 27.9. HRMS 
(ESI): Calcd. for C20H1879BrNNaO3 [M+H]+ 422.0368; found 422.0353. 
Methyl 3-(2-bromobenzoyl)benzoate (5g). 2-Bromoiodobenzene 3 (50 mg) was reacted with 3-
(methoxycarbonyl)phenyl boronic acid 4g (38 mg, 0.21 mmol, 1.2 equiv) according to the general 
procedure A to provide 5g (22 mg, 40 %) as a colorless oil. NMR: δH (400 MHz, CDCl3) 8.43 (1H, s), 
8.27 (1H, d, J 7.8), 8.01 (1H, d, J 7.8), 7.67 (1H, d, J 7.8), 7.57(1H, t, J 7.8), 7.47-7.43 (1H, m), 7.41 – 
7.36 (2H, m), 3.93 (3H, s). δC (101 MHz, CDCl3) 195.2, 166.3, 140.2, 136.7, 134.5, 134.3, 133.5, 131.7, 
131.3, 131.0, 129.3, 129.1, 127.6, 119.7, 52.7. HRMS (ESI): Calcd. for C15H11O379BrNa [M+H]+; 
340.9789 found 340.9757. 
Methyl 2-(2-bromobenzoyl)benzoate (5h). 2-Bromoiodobenzene 3 (50 mg) was reacted with 2-
(methoxycarbonyl) phenyl boronic acid 4h (35 mg, 0.21 mmol, 1.2 equiv) according to the general 
procedure A to provide 5h (33 mg, 58%) as a viscous colourless oil. NMR: δH (400 MHz, CDCl3) 7.88-
7.86 (1H, m), 7.70-7.68 (1H, m), 7.60-7.57 (2H, m), 7.50-7.48 (1H, m), 7.39-7.36 (1H, m), 7.33-7.31 
(2H, m), 3.69 (3H, s). δC (101 MHz, CDCl3) 195.49, 167.58, 140.09, 138.43, 134.68, 132.64, 131.78, 
131.27, 131.15, 129.94, 129.57, 127.16, 121.55, 77.48, 77.16, 76.84, 52.72. HRMS (ESI): Calcd. for 
C15H11O381BrNa [M+H]+; 342.9769 found 342.9757. The spectroscopic data is corresponding to the 
previously reported in literature.6 
4-(2-Bromobenzoyl)benzonitrile (5i). 2-Bromoiodobenzene 3 (50 mg) was reacted with (4-cyanophenyl) 
boronic acid 4i (31 mg, 0.21 mmol, 1.2 equiv). Reactions were performed both by the general procedure 
A or B to provide 5i (procedure A: 15 mg, 30%; procedure B: 0 mg, 0%) as a white solid. Mp 113-115 
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°C. NMR: δH (400 MHz, CDCl3) 7.90 (2H, d, J 8.2), 7.77 (2H, d, J 8.2), 7.67 (1H, d, J 7.8), 87.49 – 7.39 
(1H, m), 7.38-7.36 (1H, m). δC (101 MHz, CDCl3) 194.6, 139.6, 139.4, 133.6, 132.6, 132.1, 130.5, 129.4, 
127.7, 119.7, 118.0, 116.9. HRMS (ESI): Calcd. for C14H8 79BrNNaO [M+H]+ 307.9687; found 
307.9672. The spectroscopic data is corresponding to the previously reported in literature.7 
3-(2-Bromobenzoyl)benzonitrile (5j). 2-Bromoiodobenzene 3 (50 mg) was reacted with (3-cyanophenyl) 
boronic acid 4j (31 mg, 0.21 mmol, 1.2 equiv). Reactions were performed following the general 
procedure A or B to provide 5j (procedure A: 33 mg, 65%; procedure B: 15 mg, 30%) as a colorless oil. 
NMR: δH (400 MHz, CDCl3) 8.06 (1H, d, J 8.2), 8.03 (1H, s), 7.87 (1H, d, J 7.7), 7.68 (1H, d, J 7.7), 
7.62 (1H, t, J 7.8), 7.49-7.40 (2H, m), 7.37-7.35 (1H, m). δC (101 MHz, CDCl3) 194.0, 139.4, 137.2, 
136.6, 133.9, 133.8, 133.6, 132.1, 129.9, 129.3, 127.8, 119.6, 117.9, 113.4. HRMS (ESI): Calcd. for 
C14H8 81BrNNaO [M+H]+ 309.9666; found 309.9653. 
2-Bromophenyl 4-fluorophenyl methanone (5k). 2-Bromoiodobenzene 3 (50 mg) was reacted with (4-
fluorophenyl) boronic acid 4k (30 mg, 0.13mmol, 1.2 equiv), according to the general procedure A to 
provide 5k (15 mg, 30%) as a white solid. Mp 51-53 °C. NMR: δH (400 MHz, CDCl3) 7.84 (2H, m), 
7.65 (1H, d, J 7.8), 7.45-7.41 (1H, m), 7.40-7.30 (2H, m), 7.14 (2H, t, J 8.5). δC (101 MHz, CDCl3) 
194.5, 166.3 (d, J 256.5), 140.6, 133.4, 133.0 (d, J 10.1), 132.7 (d, J 2.9), 131.4, 129.0, 127.5, 119.6, 
116.0 (d, J 22.2). HRMS (ESI): Calcd. for C13H879 BrFNaO [M+H]+ 300.9640; found 300.9630. The 
spectroscopic data is corresponding to the previously reported in literature.8 
2-Bromophenyl 3-fluorophenyl methanone (5l). 2-Bromoiodobenzene 3 (50 mg) was reacted with 3-
fluorophenyl boronic acid 4l (30 mg, 0.13 mmol, 1.2 equiv), according to the general procedure A to 
provide 5l (37 mg, 76%) as a white solid. NMR: δH (400 MHz, CDCl3) 7.66 (1H, d, J 7.8), 7.54 (2H, t, 
J  9.7), 7.47-7.42 (2H, m), 7.40-7.34 (2H, m), 7.33-7.28 (1H, m). δC (101 MHz, CDCl3) 194.7, 162.9 (d, 
J 249.5), 140.2, 138.4 (d, J 6.1), 133.5, 131.6, 130.5 (d, J 8.1), 129.1, 127.5, 126.3 (d, J 3.0), 120.9 (d, J 
22.2), 119.6, 116.7 (d, J 22.2). HRMS (ESI): Calcd. for C13H8 79BrFNaO [M+H]+ 300.9640; found 
300.9630. 
2-Bromophenyl 2-fluorophenyl methanone (5m). 2-Bromoiodobenzene 3 (50 mg) was reacted with 2-
fluorophenyl boronic acid 4m (30 mg, 0.13 mmol, 1.2 equiv) according to the general procedure A to 
provide 5m (39 mg, 80%) as a white solid. NMR: δH (400 MHz, CDCl3) 7.61 (1H, t, J 7.5), 7.47 (1H, 
d, J 7.8), 7.44-7.38 (1H, m), 7.26-7.25 (2H, m), 7.23-7.17 (1H, m), 7.10 (1H, t, J 7.6), 6.97-6.92 (1H, 
m). δC (101 MHz, CDCl3) 192.90, 161.8 (d, J 259.6), 141.7, 135.23 (d, J 8.1), 133.5, 131.8, 129.4, 127.5, 
125.9 (d, J 10.1), 124.5 (d, J 3.0), 119.5, 116.8 (d, J 22.2). HRMS (ESI): Calcd. for C13H8 81BrFNaO 
[M+H]+ 302.9620; found 302.9608. 
  
1.4 Preparation and characterization of 2-benzoylbenzoate esters 2 from 2-
bromobenzophenones 5 by alkoxycarbonylation. 
Butyl 2-(4-methoxybenzoyl)benzoate (2a). (2-Bromophenyl)(4-methoxyphenyl)methanone 5a (40 mg, 
0.14 mmol) was transformed to 2a (28 mg, 65%) according to the general procedure F. NMR: δH (400 
MHz, CDCl3) 8.05 (1H, d, J 8.8), 7.73 (2H, d, J 8.9), 7.63-7.59 (1H, m), 7.56-7.52 (1H, m), 7.36 (1H, d, 
J 8.8), 6.90 (2H, d, J 8.9), 4.05 (2H, t, J 6.6), 3.85 (3H, s), 1.46-1.39 (2H, m), 1.27-1.18 (3H, m), 0.82 
(3H, t, J 7.4). δC (101 MHz, CDCl3) 195.82, 166.24, 163.69, 142.06, 132.32, 131.92, 130.41, 130.32, 
129.41, 129.38, 127.67, 113.83, 77.48, 77.16, 76.84, 65.53, 55.62, 30.40, 19.21, 13.78. HRMS (ESI): 
Calcd. for C19H20NaO4 [M+H]+ 335.1259; found 335.1260. 
Butyl 2-(3-methoxybenzoyl)benzoate (2b). (2-Bromophenyl)(3-methoxyphenyl)methanone 5b (30 mg, 
0.1 mmol) was transformed to 2b (19 mg, 60%) according to the general procedure F. NMR: δH (400 
MHz, CDCl3) 8.06 (1H, d, J 7.6), 7.63 (1H, t, J 7.5), 7.56 (1H, t, J 7.5), 7.44-7.43 (1H, m), 7.39-7.37 
(1H, m), 7.30 (1H, t, J 7.9), 7.21-7.18 (1H, m), 7.11-7.09 (1H, m), 4.05 (2H, t, J 6.6), 3.84 (3H, s), 1.48 
– 1.41 (2H, m), 1.28-1.15 (2H, m), 0.83 (3H, t, J 7.4). δC (101 MHz, CDCl3) 196.9, 166.1, 159.9, 141.8, 
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138.6, 132.4, 130.3, 129.7, 129.6, 129.6, 127.8, 122.9, 120.0, 113.1, 77.5, 77.2, 76.8, 65.6, 55.6, 30.4, 
19.2, 13.8. HRMS (ESI): Calcd. for C19H20NaO4 [M+H]+ 335.1259; found 335.1260. 
Butyl 2-(4-fluorobenzoyl)benzoate (2c). (2-Bromophenyl)(4-fluorophenyl)methanone 5k (15mg, 0.054 
mmol),  was transformed to 2c (10 mg, 63%) according to the general procedure F. δH (400 MHz, CDCl3) 
8.07 (1H, d, J 8.6), 7.81-7.77 (2H, m), 7.66-7.62 (1H, m), 7.59-7.55 (1H, m), 7.37 (1H, d, J 8.6), 7.10 
(2H, t, J 8.6), 4.06 (2H, t, J 6.6), 1.49-1.41 (2H, m), 1.27-1.21 (3H, m), 0.84 (3H, t, J 7.4). δC (101 MHz, 
CDCl3) 195.6, 166.0, 165.9 (d, J 255.5), 141.6, 133.8, 132.5, 132.2, 132.2 (d, J 10.1), 132.1, 130.4, 129.8, 
129.4, 127.6, 115.9, 115.7, 77.5, 77.2, 76.8, 65.6, 30.4, 19.2, 13.9, 13.8. HRMS (ESI): Calcd. for 
C18H17FNaO3 [M+H]+ 323.1059; found 323.1059. 
Butyl 2-(2-fluorobenzoyl)benzoate (2d). (2-Bromophenyl)(4-methoxyphenyl)methanone 5m (40 mg, 
0.47 mmol) was transformed to 2d (22 mg, 50%) according to the general procedure F. NMR: δH (400 
MHz, CDCl3) 8.53 (1H, d, J 7.6), 8.38-8.33 (1H, m), 8.12-8.10 (1H, m), 8.07-8.05 (1H, m), 7.89-7.87 
(2H, m), 7.77-7.75 (1H, m), 7.69-7.61 (1H, m), 7.60-7.55 (1H, m), 4.62 (2H, t, J 6.6), 2.03-1.99 (2H, m), 
1.84-1.71 (3H, m), 1.36 (3H, t, J 7.4). δC (101 MHz, CDCl3) 193.7, 166.3, 163.2, 161.9 (d, J 258.6), 
160.7, 143.5, 134.99, 135.0 (d, J 9.1), 134.6, 132.3, 131.5, 130.1, 129.7, 127.0, 125.9, 124.3 (d, J 4.0), 
124.3, 117.0, 116.9 (d, J 23.2), 116.8, 65.6, 30.5, 19.2, 13.8. HRMS (ESI): Calcd. for C18H17FNaO3 
[M+H]+ 323.1059; found 323.1059. 
 
1.5 Preparation and characterization of 2-benzoylbenzoate esters 2 from 2-bromobenzoates 6 
by Suzuki-Miyaura couplings. 
Methyl 2-(4-methoxybenzoyl)benzoate (2aa). Methyl 2-bromobenzoate 6a (100 mg for procedure C and 
D; 50 mg for procedure E) was reacted with 4-methoxyphenyl boronic acid 4a (105 mg, 1.5 equiv, 0.66 
mmol), DABO boronate 2-(4-methoxyphenyl)-1,3,6,2-dioxazaboroane 7a (82 mg, 1.5 equiv, 0.37 mmol) 
or sodium trihydroxy(4-methoxyphenyl)borate 8a (72 mg, 1.5 equiv, 0.37 mmol). Reactions were 
performed following general procedure C, D or E to provide 2aa as a colorless oil. Procedure C with 4a: 
100 mg, 80%; procedure D with 4a: 80 mg, 63%; procedure E with 7a: 45 mg, 67%; procedure E with 
8a: 44 mg, 65%. NMR: δH (400 MHz, CDCl3) 8.02 (1H, d, J 7.6), 7.71 (2H, d, J 8.8), 7.61 (1H, t, J 7.5), 
7.53 (1H, t, J 7.5), 7.37 (1H, d, J 7.6), 6.89 (2H, d, J 8.8), 3.83 (3H, s), 3.63 (3H, s). δC (101 MHz, 
CDCl3) 195.9, 166.5, 163.6, 142.1, 132.4, 132.3, 131.7, 130.3, 130.2, 129.4, 129.2, 127.8, 113.8, 55.6, 
52.3. HRMS (ESI): Calcd. for C16H14 NaO4 [M+H]+ 293.0790; found 293.0784. The spectroscopic data 
is corresponding to the previously reported in literature.6 
Methyl 2-(3-methoxybenzoyl) benzoate (2ab). Methyl 2-bromobenzoate 6a (100 mg) was reacted with 3-
methoxyphenyl boronic acid 4b (105 mg, 1.5 equiv, 0.66 mmol) according to the general procedure C to 
provide 2ab (65 mg, 52%) as a colorless oil. NMR: δH (400 MHz, CDCl3) 7.90 (1H, d, J 8.7), 7.61-7.46 
(1H, m), 7.46-7.33 (1H, m), 7.28 (2H, s), 7.21-7.08 (1H, m), 7.05 (1H, d, J 7.7), 6.96 (1H, dd, J 8.7, 3.2), 
3.70 (3H, s), 3.50 (3H, s). δC (101 MHz, CDCl3) 196.9, 166.5, 159.9, 141.8, 138.6, 132.5, 132.0, 131.2, 
130.1, 130.0, 129.7, 129.6, 129.3, 129,0, 127.8, 122.5, 119.8, 113.0, 55.5, 55.3, 52.7, 52.3. HRMS (ESI): 
Calcd. for C16H14 NaO4 [M+H]+ 293.0790; found 293.0784. 
Methyl 2-(2-methoxybenzoyl)benzoate (2ac). Methyl 2-bromobenzoate 6a (100 mg) was reacted with 2-
methoxyphenyl boronic acid 4c (105 mg, 1.5 equiv, 0.66 mmol) according to the general procedure C to 
provide 2ac (93 mg, 74%) as a white solid, Mp 100-103 °C. NMR: δH (400 MHz, CDCl3) 7.87 (1H, d, 
J 8.7), 7.74-7.67 (1H, m), 7.53 (1H, t, J 7.5), 7.50-7.42 (2H, m), 7.36 (1H, d, J 8.7), 6.99 (1H, t, J 7.9), 
6.90 (1H, d, J 8.3), 3.59 (3H, s), 3.57 (3H, s). δC (101 MHz, CDCl3) 195.7, 167.3, 159.0, 143.8, 134.2, 
131.7, 131.6, 129.5, 129.3, 127.5, 127.0, 120.5, 112.2, 77.4, 55.7, 52.1. HRMS (ESI): Calcd. for C16H14 
NaO4 [M+H]+ 293.0790; found 293.0784. 
Methyl 2-(4-(methylthio)benzoyl) benzoate (2ad). Methyl 2-bromobenzoate 6a (100 mg) was reacted 
with 4-(methylthio) phenyl boronic acid (110 mg, 1.5 equiv, 0.65 mmol) according to the general 
procedure C to provide (101 mg, 76%) as a white solid, Mp 84-87 °C. 1H NMR (400 MHz, CDCl3) δ 
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8.02 (1H, d, J 8.6), 7.64 (2H, d, J 8.5), 7.61-7.59 (1H, m), 7.53-7.51 (1H, m), 7.36 (2H, d, J 8.6), 7.21(2H, 
d, J 8.5), 3.62 (3H, s), 2.47 (3H, s). δC NMR (101 MHz, CDCl3) 196.1, 166.4, 146.1, 141.8, 133.5, 132.4, 
130.1, 129.7, 129.5, 129.1, 127.7, 124.9, 52.3, 14.7. HRMS (ESI): Calcd. for C16H14 NaO3S [M+H]+ 
309.0561; found 309.0559. 
Methyl 2-(3-(methoxycarbonyl)benzoyl)benzoate (2ag). Methyl 2-bromobenzoate 6a (100 mg) was 
reacted with 3-(methoxycarbonyl)phenyl boronic acid 4g (125 mg, 1.5 equiv, 0.70 mmol) according to 
the general procedure C to provide 2ag (65 mg, 47%) as a colorless oil. NMR: δH (400 MHz, CDCl3) 
8.37 (1H, s), 8.23-8.21 (1H, m), 8.07 (1H, d, J 8.6), 7.96-7.95 (1H, m), 7.70-7.63 (1H, m), 7.63-7.56 (1H, 
m), 7.53 (1H, t, J 7.8), 7.40 (1H, d, J 8.6), 3.90 (3H, s), 3.64 (3H, s). δC (101 MHz, CDCl3) 196.4, 166.4, 
141.4, 137.7, 134.0, 133.4, 132.8, 130.8, 130.5, 130.4, 130.0, 129.2, 128.9, 127.8, 52.5, 52.4. HRMS 
(ESI): Calcd. for C17H14 NaO5 [M+H]+ 321.0739; found 321.0730 
Dimethyl 2,2'-carbonyldibenzoate (2ah). Methyl 2-bromobenzoate 6a (100 mg) was reacted with 2-
(methoxycarbonyl)phenyl boronic acid 4h (125 mg, 1.5 equiv, 0.70 mmol). Reactions were performed 
both by the general procedure C and D to provide 2ah as a white solid, Mp 205-207 °C. Procedure C: 
103 mg, 75%; procedure D: 36 mg, 26%. NMR: δH (400 MHz, CDCl3) 7.78 (2H, d, J 8.6), 7.58-7.56 
(2H, m), 7.53-7.48 (2H, m), 7.40 (2H, d, J 8.6), 3.73 (6H, s). δC (101 MHz, CDCl3) 195.7, 168.3, 138.5, 
132.0, 131.4, 131.2, 129.7, 129.4, 128.9, 77.4, 52.6. HRMS (ESI): Calcd. for C17H14 NaO5 [M+H]+ 
321.0739; found 321.0730. 
Methyl 2-(4-cyanobenzoyl) benzoate (2ai). Methyl 2-bromobenzoate 6a (100 mg) was reacted with 4-
cyanophenyl boronic acid 4i (102 mg, 1.5 equiv, 0.7 mmol). Reactions were performed following general 
procedure C or D to provide 2ai as a colourless oil. Procedure C: 40 mg, 32%; procedure D: 20 mg, 16%. 
NMR: δH (400 MHz, CDCl3) 8.08 (1H, d, J 8.6), 7.83 (2H, d, J 8.6), 7.73 (2H, d, J 8.6), 7.69-7.67 (1H, 
m), 7.64 – 7.60 (1H, m), 7.40 (1H, d, J 8.6), 3.67 (3H, s). δC (101 MHz, CDCl3) 195.4, 165.8, 140.6, 
140.2, 132.7, 132.2, 130.1, 130.0, 129.2, 128.8, 127.4, 117.8, 116.0, 52.3. HRMS (ESI): Calcd. for 
C16H11NNaO3 [M+H]+ 288.0637; found  288.0630. 
Methyl 2-(3-cyanobenzoyl) benzoate (2aj). Methyl 2-bromobenzoate 6a (100 mg) was reacted with (3-
cyanophenyl) boronic acid 4j (102 mg, 1.5 equiv, 0.7 mmol). Reactions were performed following 
general procedure C or D to provide 2aj as a colourless oil. Procedure C: 48 mg, 40%; procedure D: 32 
mg, 26%. NMR: δH (400 MHz, CDCl3) 8.10 (1H, d, J 8.6), 8.03-7.01 (1H, m), 7.96 (1H, s), 7.83-7.81 
(1H, m), 7.70 (1H, t, J 7.5), 7.66 – 7.59 (1H, m), 7.58-7.56 (1H, m), 7.38 (1H, d, J 8.6), 3.70 (3H, s). δC 
NMR (101 MHz, CDCl3) 195.5, 166.4, 141.1, 138.6, 136.3, 133.4, 133.3, 133.2, 130.9, 130.6, 130.1, 
129.3, 127.9, 118.4, 113.5, 52.9. Calcd. for C16H11NNaO3 [M+H]+ 288.0637; found 288.0630. 
Methyl 2-(4-fluorobenzoyl) benzoate (2ak). Methyl 2-bromobenzoate 6a (100 mg for procedure C; 50 
mg for procedure E) was reacted with 4-fluorophenyl boronic acid 4k (100 mg, 1.5 equiv, 0.7 mmol) or 
2-(4-fluorophenyl)-1,3,6,2-dioxazaborocane 7k (73 mg, 1.5 equiv, 0.35 mmol) according to the general 
procedure C or E to provide 2ak as a colourless oil. Procedure C: 45 mg, 37%; procedure E: 15 mg, 25%. 
NMR: δH (400 MHz, CDCl3) 8.05 (1H, d, J 8.7), 7.79-7.75 (2H, m), 7.66-7.62 (1H, m), 7.59-7.55 (1H, 
m), 7.38 (1H, d, J 8.7), 7.12-7.07 (2H, m), 3.65 (3H, s). δC (101 MHz, CDCl3) 195.5, 166.4, 165.8 (d, J 
256.5), 164.4, 141.5, 133.8 (d, J 3.0), 132.5, 132.0 (d, J 9.1), 130.3, 129.8, 129.2, 127.6, 115.8 (d, J 20.2), 
52.3. HRMS (ESI): Calcd. for C15H11 FNaO3 [M+H]+ 281.0590; found 281.0584. The spectroscopic data 
is corresponding to the previously reported in literature.6 
Methyl 2-(3-fluorobenzoyl) benzoate (2al). Methyl 2-bromobenzoate 6a (100 mg) was reacted with (3-
fluorophenyl) boronic acid 4l (100 mg, 1.5 equiv, 0.7 mmol). Reactions were performed following 
general procedure C or D to provide 2al as a colorless oil. Procedure C: 70 mg, 58%; procedure D: 51 
mg, 43%. NMR: δH (400 MHz, CDCl3) 8.06 (1H, d, J 8.7), 7.67-7.63 (1H, m), 7.60-7.56 (1H, m), 7.50-
7.44 (2H, m), 7.41-7.35 (2H, m), 7.29-7.21 (1H, m), 3.66 (3H, s). δC (101 MHz, CDCl3) 196.2, 166.6, 
163.2 (d, J 249.5), 141.8, 139.7 (d, J 7.1), 133.0, 130.7, 130.6, 130.3, 129.5, 128.1, 125.5 (d, J 3.0), 120.6 
(d, J 21.6), 116.1 (d, J 23.2), 52.7. HRMS (ESI): Calcd. for C15H11 FNaO3 [M+H]+ 281.0590; found 
281.0584. 
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Methyl 2-(2-fluorobenzoyl) benzoate (2am). Methyl 2-bromobenzoate 6a (100 mg for procedure C and 
D; 50 mg for procedure E) was reacted with 2-fluorophenyl boronic acid 4m (100 mg, 1.5 equiv, 0.7 
mmol) or 2-(2-fluorophenyl)-1,3,6,2-dioxazaborocane 7m (73 mg, 1.5 equiv, 0.35 mmol). Reactions 
were performed following general procedure C, D or E to provide 2am as a white solid, Mp 56-59 °C. 
Procedure C: 78 mg, 65%; procedure D: 50 mg, 42%; procedure E: 21 mg, 35%. NMR: δH (400 MHz, 
CDCl3) 8.02 (1H, d, J 8.8), 7.85-7.81 (1H, m), 7.67-7.63 (1H, m), 7.61-7.52 (2H, m), 7.44-7.42 (1H, m), 
7.31-7.24 (1H, m), 7.12-7.07 (1H, m), 3.72 (3H, s). δC (101 MHz, CDCl3) 193.8, 166.8, 161.7 (d, J 
258.6),134.8 (d, J 9.1), 132.5, 131.3, 130.00 (d, J 19.2), 128.9, 127.2, 125.9 (d, J 10.0), 124.3 (d, J 4.0), 
116.87 (d, J 22.2), 52.4. HRMS (ESI): Calcd. for C15H11 FNaO3 [M+H]+ 281.0590; found 281.0584. 
Methyl 2-(thiophene-2-carbonyl) benzoate (2an). Methyl 2-bromobenzoate 6a (50 mg), was reacted with 
2-(thiophen-2-yl)-1,3,6,2-dioxazaborocane 7n (69 mg, 1.5 equiv, 0.35 mmol) according to the general 
procedure E to provide 2an (29 mg, 50%) as a colourless oil. NMR: δH (400 MHz, CDCl3) 8.02 (1H, d, 
J 7.6), 7.65-7.61 (2H, m), 7.58-7.54 (2H, m), 7.45 (1H, d, J 7.6), 7.35-7.33 (1H, m), 3.67 (3H, s). δC 
(101 MHz, CDCl3) 190.7, 166.7, 142.8, 142.2, 133.9, 132.4, 130.3, 129.9, 129.3, 127.8, 127.4, 126.8, 
52.4. The spectroscopic data is corresponding to the previously reported in literature.9 
Methyl 2-(benzo[b]thiophene-2-carbonyl) benzoate (2ao).	Methyl 2-bromobenzoate 6a (50 mg), was 
reacted with 2-(benzo[b]thiophen-2-yl)-1,3,6,2-dioxazaborocane 7o (86 mg, 1.5 equiv, 0.35 mmol) 
according to the general procedure E to provide 2ao (55 mg, 75%) as a yellow solid. Mp 78-80 °C. NMR: 
δH (400 MHz, CDCl3) 7.89 (1H, d, J 7.5), 7.68 (1H, d, J 8.0), 7.57 (1H, d, J 8.0), 7.48-7.45 (2H, m), 
7.42 – 7.39 (1H, m), 7.33(1H, d, J 7.5), 7.25-7.22 (1H, m), 7.17-7.14 (1H, m), 3.48 (3H, s). δC (101 
MHz, CDCl3) 190.7, 166.3, 144.1, 142.8, 140.8, 138.9, 132.4, 131.6, 130.3, 130.1, 129.2, 127.7, 127.5, 
126.1, 125.0, 123.0, 52.4. HRMS (ESI): Calcd. for C17H12 NaO3 S [M+H]+ 319.0405; found 319.0407.	
Methyl 5-fluoro-2-(4-methoxybenzoyl)benzoate (2ba). Methyl 2-bromo-5-fluorobenzoate 6b (50 mg, 
0.21 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (48 mg, 1.5 equiv, 0.32 mmol) 
according to the general procedure E to provide 2ba (44 mg, 72%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 7.72-7.68 (3H, m), 7.44-7.37 (1H, m), 7.33-7.28 (1H, m), 6.92-6.90 (2H, m), 3.85 (3H, s), 
3.64 (3H, s). δC (101 MHz, CDCl3) 194.8, 165.5 (d, J 3.0), 163.8, 162.8 (d, J 251.5), 138.1 (d, J 3.0), 
131.7, 130.2, 130.0 (d, J 8.1), 119.4 (d, J 22.2), 117.2 (d, J 23.2), 113.9, 77.4, 55.6, 52.6. HRMS (ESI): 
Calcd. for C16H13FNaO4 [M+H]+ 311.0696; found 311.0695. 
Methyl 4-fluoro-2-(4-methoxybenzoyl)benzoate (2ca). Methyl 2-bromo-4-fluorobenzoate 6c (57 mg, 
0.24 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (48 mg, 1.5 equiv, 0.32 mmol) 
according to the general procedure E to provide 2ca (35 mg, 50%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 8.08 (1H, dd, J 8.7, 5.4), 7.72 (2H, d, J 9.0), 7.24-7.19 (1H, m), 7.07 (1H, dd, J 8.3, 2.6), 
6.92 (2H, d, J 9.0), 3.86 (3H, s), 3.64 (3H, s). δC (101 MHz, CDCl3) 194.2, 165.5, 164.9 (d, J 257.5), 
163.9, 145.1 (d, J 7.1), 133.1 (d, J 10.1), 131.8, 129.7, 125.2 (d, J 3.0), 116.5 (d, J 21.2), 115.2 (d, J 
24.2), 114.0, 55.7, 52.4. HRMS (ESI): Calcd. for C16H13FNaO4 [M+H]+ 311.0696; found 311.0695. 
Methyl 5-chloro-2-(4-methoxybenzoyl)benzoate (2da). Methyl 2-bromo-5-chlorobenzoate 6d (50 mg, 
0.20 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (45 mg, 1.5 equiv, 0.30 mmol) 
according to the general procedure E to provide 2da (30 mg, 50%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 8.01 (1H, d, J 2.1), 7.71 (2H, d, J 9.0), 7.59 (1H, dd, J 8.1, 2.1), 7.33 (1H, d, J 8.1), 6.91 
(2H, d, J 9.0), 3.86 (3H, s), 3.65 (3H, s). δC (101 MHz, CDCl3) 194.8, 165.5, 163.9, 140.4, 135.7, 132.4, 
131.8, 131.0, 130.3, 130.1, 129.3, 114.0, 55.6, 52.7. HRMS (ESI): Calcd. for C16H13ClNaO4 [M+H]+ 
327.0400; found 327.0401. 
Methyl 4-chloro-2-(4-methoxybenzoyl)benzoate (2ea). Methyl 2-bromo-4-chlorobenzoate 6e (50 mg, 
0.20 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (46 mg, 1.5 equiv, 0.30 mmol) 
according to the general procedure E to provide 2ea (40 mg, 65%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 7.99 (1H, d, J 8.4), 7.72 (2H, d, J 9.0), 7.51 (1H, dd, J 8.4, 2.0), 7.36 (2H, d, J 2.0), 6.92 
(2H, d, J 9.0), 3.86 (3H, s), 3.65 (3H, s). δC (101 MHz, CDCl3) 194.2, 165.7, 163.9, 143.8, 139.1, 131.8, 
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131.8, 129.8, 129.6, 127.9, 127.4, 114.0, 55.7, 52.5. HRMS (ESI): Calcd. for C16H13ClNaO4 [M+H]+ 
327.0400; found 327.0402. 
Methyl 2-(4-methoxybenzoyl)-5-methylbenzoate (2fa). Methyl 2-bromo-5-methylbenzoate 6f (57 mg, 
0.19 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (49 mg, 1.5 equiv, 0.32 mmol) 
according to the general procedure E to provide 2fa (50 mg, 71%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 7.82 (1H, s), 7.72 (2H, d, J 9.0), 7.41 (1H, d, J 8.4), 7.28 (1H, d, J 7.7), 6.89 (2H, d, J 9.0), 
3.84 (3H, s), 3.60 (3H, s), 2.45 (3H, s). δC (101 MHz, CDCl3) 196.0, 166.9, 163.5, 139.8, 139.2, 132.9, 
131.7, 130.6, 129.4, 128.0, 113.8, 77.4, 55.6, 52.2, 21.3. HRMS (ESI): Calcd. for C17H16NaO4 [M+H]+ 
307.0900; found 307.0947. 
Methyl 2-(4-methoxybenzoyl)-3-methylbenzoate (2ga). Methyl 2-bromo-3-methylbenzoate 6g (59 mg, 
0.26 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (49 mg, 1.5 equiv, 0.32 mmol) 
according to the general procedure E to provide 2ga (50 mg, 68%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 7.92 (1H, d, J 8.5), 7.73-7.71 (2H, m), 7.45-7.40 (2H, m), 6.90 (2H, d, J 9.1), 3.84 (3H, 
s), 3.67 (3H, s), 2.17 (3H, s). δC (101 MHz, CDCl3) 197.0, 166.4, 163.7, 141.9, 135.6, 135.0, 131.1, 
130.7, 128.6, 128.3, 127.9, 114.0, 77.4, 19.3. HRMS (ESI): Calcd. for C17H16NaO4 [M+H]+ 307.0946; 
found 307.0945. 
Methyl 4-methoxy-2-(4-methoxybenzoyl) benzoate (2ha). Methyl 2-bromo-4-methoxybenzoate 6h (50 
mg, 0.20 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (46 mg, 1.5 equiv, 0.30 mmol) 
according to the general procedure E to provide 2ha (47 mg, 77%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 8.01 (1H, d, J 8.8), 7.73 (2H, d, J 9.0), 7.00 (1H, dd, J 8.8, 2.6), 6.89 (2H, d, J 9.0), 6.83 
(1H, d, J 2.6), 3.85 (3H, s), 3.84 (3H, s), 3.61 (3H, s). δC (101 MHz, CDCl3) 195.6, 166.0, 163.6, 162.9, 
144.6, 132.4, 131.7, 130.2, 120.9, 114.8, 113.9, 112.7, 77.4, 55.8, 55.6, 52.0. HRMS (ESI): Calcd. for 
C17H16NaO5 [M+H]+ 323.0895; found 323.0894. 
Methyl 2-(4-methoxybenzoyl)-5-methylbenzoate (2ia). Methyl 2-bromo-4,5-dimethoxybenzoate 6i (50 
mg, 0.18 mmol), was reacted with (4-methoxyphenyl) boronic acid 4a (40 mg, 1.5 equiv, 0.26 mmol) 
according to the general procedure E to provide 2ia (44 mg, 73%) as a white solid, Mp 151-153 °C. 
NMR: δH (400 MHz, CDCl3) 7.70 (2H, d, J 9.0), 7.50 (1H, s), 6.89 (2H, d, J 9.0), 6.84 (1H, s), 3.97 (3H, 
s), 3.90 (3H, s), 3.84 (3H, s), 3.55 (3H, s). δC (101 MHz, CDCl3) 195.6, 166.2, 163.5, 152.3, 149.3, 136.0, 
131.5, 130.7, 121.5, 113.8, 112.2, 110.3, 56.3, 55.6, 52.1. HRMS (ESI): Calcd. for C18H18NaO6 [M+H]+ 
353.1001; found 353.1001. The spectroscopic data is corresponding to the previously reported in 
literature.10 
Methyl 5-fluoro-2-(2-methoxybenzoyl)benzoate (2bc). Methyl 2-bromo-5-fluorobenzoate 6b (50 mg, 
0.24 mmol), was reacted with (2-methoxyphenyl) boronic acid 4c (49 mg, 1.5 equiv, 0.32 mmol) 
according to the general procedure E to provide 2bc (40 mg, 66%) as a colourless oil. NMR: δH (400 
MHz, CDCl3) 7.72 (1H, dd, J 7.7, 1.8), 7.54 (1H, dd, J 8.9, 2.6), 7.51-7.44 (1H, m), 7.42-7.38 (1H, m), 
7.25-7.20 (1H, m), 7.02 (1H, t, J 7.5), 6.92 (1H, d, J 8.4), 3.61 (3H, s), 3.60 (3H, s). δC (101 MHz, 
CDCl3) 194.6, 166.5, 166.4 (d, J 2.0), 162.9 (d, J 252.5), 158.9, 139.7 (d, J 4.0), 134.4, 132.3 (d, J 7.1), 
131.5, 130.2 (d, J 8.1), 127.0, 120.7, 118.6 (d, J 22.2), 116.4 (d, J 24.2) , 112.2, 55.7, 52.5. HRMS (ESI): 
Calcd. for C16H13 FNaO4 [M+H]+ 311.0696; found 311.0693. 
Methyl 5-fluoro-2-(2-(methoxycarbonyl)benzoyl)benzoate (2bh). Methyl 2-bromo-5-fluorobenzoate 6b 
(50 mg, 0.24 mmol), was reacted with 2-(methoxycarbonyl)phenylboronic acid 4h (58 mg, 1.5 equiv, 
0.32 mmol) according to the general procedure E to provide 2bh (30 mg, 40%) as a colorless oil. NMR: 
δH (400 MHz, CDCl3) 7.85 (1H, d, J 8.8), 7.61-7.53 (2H, m), 7.44 (1H, dd, J 5.9, 2.6), 7.42-7.41 (1H, 
m), 7.40 (1H, s), 3.78 (3H, s), 3.74 (3H, s). δC (101 MHz, CDCl3) 194.5, 167.9, 167.5 (d, J 2.0), 164.1 
(d, J 255.5) , 138.9, 135.2 (d, J 8.1), 134.3 (d, J 4.0), 132.6 (d, J 9.1), 131.5, 131.4 (d, J 27.3), 129.5 (d, 
J 37.4), 117.9, 117.8 (d, J 22.2), 116.7 (d, J 24.2), 77.4, 53.0, 52.7. HRMS (ESI): Calcd. for C17H13 
FNaO5 [M+H]+ 339.0645; found 339.0640. 
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Methyl 2-(2-naphthoyl)-4-methoxybenzoate (2hp). Methyl 2-bromo-4-methoxybenzoate 6h (50 mg, 0.20 
mmol), was reacted with 2-napthylboronic acid 4p (52 mg, 1.5 equiv, 0.30 mmol) according to the 
general procedure E to provide 2hp (57 mg, 61%) as a colourless oil. NMR: δH (400 MHz, CDCl3) 8.09-
8.07 (2H, m), 8.02 (1H, dd, J 8.6, 1.7), 7.93-7.88 (1H, m), 7.86-7.83 (2H, m), 7.60-7.56 (1H, m), 7.53-
7.48 (1H, m),7.08 (1H, dd, J 8.8, 2.6), 6.93 (1H, d, J 2.6), 3.89 (3H, s), 3.57 (3H, s). δC (101 MHz, 
CDCl3) 197.0, 166.0, 163.0, 144.4, 135.8, 134.7, 132.6, 132.5, 131.6, 129.8, 128.7, 127.9, 126.8, 124.4, 
121.1, 115.1, 112.9, 77.4, 55.8, 52.1. HRMS (ESI): Calcd. for C19H14NaO4 [M+H]+ 329.0790; found 
329.0790. 
2 Additional experimental information 
2.1 Two-chamber set-up: 
The reactions were performed in the previously reported two-chamber system (Fig 1) under an argon 
atmosphere.  
 
Fig 1. The two-chamber system used in the reactions, and the CO generator (COgen) 
 
2.2 Screening of catalysts and conditions for the Suzuki- Miyaura coupling of 2-
bromoiodobenzene 3 with 4-methoxyphenyl boronic acid 4a. 
  
Procedure:  
Chamber A: 2-Bromoiodobenzene 3 (50 mg, 1.0 equiv, 0.18 mmol), aryl boronic acid 4a (1.2 equiv), 
catalyst and base were dissolved in a solvent (3 ml). 
Chamber B: COgen (107 mg, 2.5 equiv, 0.45 mmol), Pd(dba)2 (12 mg, 5 mol%), tri-tert-
butylphosphonium tetrafluoroborate (TTBP•HBF4) (6.3 mg, 5 mol%) were dissolved in anisole (3 ml). 
DIPEA (240 mg, 3 equiv) was added to chamber B to release CO. The mixture was stirred at 80 °C in a 
tightly closed system for 20 hours. The reaction mixture was filtered through celite and concentrated on 
a rotavapor. The crude was purified by column chromatography with pentane: EtOAc (8:2) as eluent. 
The ratio (5a: A) has been evaluated based on the crude 13C NMR spectra. The experimental data and 
the NMR spectra of the byproduct A is shown later. 
Characterization of 2-bromo-4'-methoxy-1,1'-biphenyl A (from direct coupling). 
The title compound was isolated as a side product from reactions towards 5a. NMR: 
δH (400 MHz, CDCl3) 7.66 (1H, d, J 7.8), 7.40-7.31 (4H, m), 7.22-7.13 (1H, m), 6.97 
COware























Chamber B: COgen (2.5 equiv)
O
Br
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 11   – 
(2H, d, J 8.7), 3.87 (3H, s). δC (101 MHz, CDCl3) 159.2, 142.3, 133.7, 133.2, 131.5, 130.7, 128.5, 127.9, 
127.5, 123.0, 114.3, 113.5, 77.5, 77.2, 76.8, 55.5, 55.4.	
Table ESI-1. Carbonylative Suzuki-Miyaura coupling of 2-bromoiodobenzene 3 with 4-methoxyphenyl boronic 
acid 4a. 











1 Pd(PPh3)2Cl2 (3) K2CO3 20 80 Anisole normal 0.7 : 1 50 
2 Pd(OAc)2 (2) K2CO3 20 80 Anisole normal 0.1 : 1 10 
3 Pd(dba)2 (3) K2CO3 20 80 Anisole normal 0.5 : 1 35 
4 PEPPSI-IPr (3) Cs2CO3 20 80 Chlorobenzene normal 0.7 : 1 30 
5 PdCl2 (3) K2CO3 20 80 Anisole normal 0.7 : 1 65 
6 PdCl2 (1) K2CO3 20 80 Anisole normal 0.7 : 1 60 
7 PdCl2 (1) K2CO3 20 50 Anisole normal 0.2 : 1 30 
8 PdCl2 (1) K2CO3 20 60 Anisole normal 0.3 : 1 35 
9 PdCl2 (1) K2CO3 40 80 Anisole normal 1 : 1 65 
10 PdCl2b (1) K2CO3b 20 80 Anisole normal 1 : 0.9 55 
11 PdCl2 (1) K2CO3/KI 20 80 Anisole normal 0.6 : 1 55 
12 PdCl2 (1) Cs2CO3 20 80 Anisole normal 1 : 1 60 
13 PdCl2 (1) K2CO3 20 80 Anisole slowa 1 : 0.1 80 
14 PdCl2 (1) K2CO3 20 100 Anisole slowa 1 : 0.1 80 
15 PEPPSI- IPr (3) Cs2CO3 20 80 Chlorobenzene slowa 1 : 1 60 
16 PEPPSI- IPr (3) Cs2CO3 20 120 Chlorobenzene slowa 1 : 1 65 
 
a Instead of dissolving 4a in chamber A before CO release, a solution of aryl boronic acid 4a (1.2 equiv) in anisole (2 ml) was added slowly 
(1-2 h) to the reaction mixture in chamber A after CO release. See General procedure A. b PdCl2 and K2CO3 were used as a premix with 
ratio 1:300. c The ratio (5a : A) is approximately determined using 13C NMR of the crude product mixture. 
 
2.3 Screening of precursors for ex-situ generation of CO. 
Procedures:  
Chamber A: 2-Bromoiodobenzene 3 (50 mg, 1.0 equiv, 0.18 mmol), PdCl2 (0.3 mg, 1 mol%), K2CO3 (70 
mg, 3 equiv, 0.55 mmol) were dissolved in a solvent (3 ml). In case of normal addition, the aryl boronic 
acid 4a (1.2 equiv) was added to the mixture before CO generation was started. In case of slow addition, 
the aryl boronic acid 4a (1.2 equiv) was dissolved in anisole (2 ml) and added after CO generation over 
a period of 1-2 hours.  
Chamber B for entry 1 and 2: Fe-tetraphenylporphyrin (6 mg), TBABF4 (1.1g), DMF (30 ml), and 
tetrafluoroethylene (2 ml) were introduced to chamber B. Electrodes were mounted and the COware was 
sealed tightly with the screw caps fitted with teflon-coated silicon seals.  
The reaction mixture in chamber A was bubbled through with CO2 for 10-15 min until saturation. The 
ElectroWare4 was set up using galvanostatic configuration. The electrodes were connected and the 
electrolysis began, while both reaction chambers were stirring. Chamber B kept stirring at room 
temperature, while the other chamber A was placed in a preheated hotplate at 80 °C for 18 h. The reaction 
mixture was filtered through celite and concentrated on a rotavapor. The crude was purified by column 
chromatography with pentane: EtOAc (8:2) as eluent.11 
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Chamber B for entry 3 and 4: COgen (107 mg, 2.5 equiv, 0.45 mmol), Pd(dba)2 (12 mg, 5 mol%), tri-
tert-butylphosphonium tetrafluoroborate (TTBP•HBF4) (6.3 mg, 5 mol%) and DIPEA (240 mg, 3 equiv) 
were dissolved in anisole (3 ml).  
The mixture was stirred at 80 °C in a tightly closed system for 20 hours. The reaction mixture was filtered 
through celite and concentrated on a rotavapor. The crude was purified by column chromatography with 
pentane: EtOAc (8:2) as eluent.  
For entry 5 and 6: To a two necked round bottomed flask degassed and charged with aqueous solution 
of NaOH (2 M, 20 ml), a balloon was fitted via 5 ml syringe cylinder at one neck. The syringe cylinder 
was filled with CaCl2 as a drying agent, that was kept in place by cotton wool pads at both sides. Through 
the other neck oxalyl chloride was added slowly with a syringe to the basic solution. The evolved gas 
was collected in the balloon. The CO balloon was transferred to the reaction mixture vial (chamber A). 
The mixture was stirred at 80 °C in a tightly closed system for 20 hours. The reaction mixture was filtered 
through celite and concentrated on a rotavapor. The crude was purified by column chromatography with 
pentane: EtOAc (8:2) as eluent.12 
Chamber B for entry 7 and 8: Sulfuric acid (1.5 mmol) was introduced before the two-chamber system 
was tightened and heated at 80 °C. Then formic acid was added slowly to chamber B. The reaction 
mixture was allowed to stir at 80 °C for 18h.13 
Table ESI-2. Screening of CO precursors. 
 
no CO source Addition of boronic acid Isolated yield (%) 
1 CO2 reduction Normal 29 
2 CO2 reduction Slow addition 30 
3 COgen Normal 60 
4 COgen Slow addition 80 
5 Oxalyl chloride+ NaOH (aq) Normal (ballon) 60 
6 Oxalyl chloride + NaOH (aq) Slow addition (ballon) 60 
7 Formic acid+ H2SO4 (1.2 mmol) Normal (ballon) 10 
8 Formic acid+ H2SO4 (1.2 mmol) In situ 0 
 




In a dry and clean 8 ml vial equipped with a stirring bar, the aryl halide (1 equiv.), MePh2SiCOOH (64 
mg, 1.5 equiv), base (2-3 equiv.), palladium precursor and ligand were dissolved in 3 ml dioxane. The 
vial was tightly sealed with a screw cap. The reaction was allowed to stir for overnight at 40 °C. The 



























ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 13   – 
The aqueous phase was washed with DCM several times. The combined aqueous phase was acidified to 
pH 2-3 using HCl (4M) and then washed with DCM for several times. The combined organic phase was 
then dried over MgSO4, filtered by suction and concentrated in vacuo to leave the product as colorless 
solid. 
Table ESI-3. Screening of catalyst and conditions for hydroxycarbonylation of 3 or 5a. 












4 3 Pd(dba)2 (5) - TMSOLi MePh2SiCO2H dioxane 2.5 110 - 
6 3 Pd(dba)2 (5) Xantphos (5) TMSOK MePh2SiCO2H toluene 1.5 60 traces 
7 3 Pd(dba)2 (5) Xantphos (5) TMSOK MePh2SiCO2H dioxane 1.5 60 60 
8 5a Pd(dba)2  (5) Xantphos (5) TMSOLi MePh2SiCO2H dioxane 1.5 80 - 
9 5a Pd(dba)2 (5) Xantphos (5) TMSOLi MePh2SiCO2H dioxane 1.5 115 - 
10 5a Pd(dba)2 (5) PPh3 (10) TMSOLi MePh2SiCO2H dioxane 2.5 110 - 
 
The following control experiments were performed to establish that the procedure gives the wanted 













































chamber B: COgen (2.5 equiv)
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Chamber A: 2-Bromophenyl-4-methoxyphenylmethanone 5a (1.0 equiv, 0.47 mmol), Pd precursor and 
base (3 equiv) were dissolved in solvent (2 ml). The nucleophile (2 equiv) was added to the reaction 
mixture. 
Chamber B: COgen (2.5 equiv), Pd(dba)2 (5 mol%), TTBP•HBF4 (5 mol%) were dissolved in anisole (3 
ml) before DIPEA (3 equiv) was added. The mixture was stirred with heating in a tightly closed system 
for 20-24 hours.  
The reaction mixture in chamber A was filtered through celite and concentrated on a rotavapor. The crude 
was purified by column chromatography with pentane : EtOAc (7:3) as eluent. 
Table ESI-4. Screening for conditions for alkoxycarbonylation on the 2-bromobenzophenone. 
Entry Pd source (mol%) Ligand (mol%) Nucl. Base Solvent T (ºC) Isol. yield (%) 
1 dppf(PdCl2) (10)  H2O TEA H2O: THF (1:4) 120 -* 
2 dppf(PdCl2) (10) Dppf (20) iPrOH TEA DMF 80 11 
3 dppf(PdCl2) (10) Dppf (20) nBuOH TEA DMF 80 -* 
4 Pd(OAc)2  (2) Xantphos (4) iPrOH TEA TEA 80 15 
5 Pd(OAc)2 (2) Xantphos (4) nBuOH TEA TEA 80 11 
6 Pd(OAc)2 (2) Xantphos (4) MeOH TEA Dioxane 110 5 
7 dppf(PdCl2) (10) Dppf (20) MeOH TEA DMF 80 -* 
8 Pd(dba)2 (5) Dippf (5) EtONa - THF 80 -* 
9 PEPPSI-IPr (3)  nBuOH Cs2CO3 Chlorobenzene 80 -* 
10 PEPPSI (5) IMes (10) nBuOH Cs2CO3 Chlorobenzene 110 -* 
11 Pd(PPh3)2Cl2 (5) IMes (10) nBuOH Cs2CO3 Heptane 120 -* 
12 PdCl2 (2) Xantphos (2) nBuOH K2CO3 Anisole 110 65 
 
* Only starting material or the corresponding biphenyl were detected.  





Substrate Pd source 
(mol%) 
Ligand 





Pd(OAc)2 (2) Xantphos (4) nBuOH TEA TEA 99 
2 dppfPdCl2 (10) Dppf (20) iPrOH TEA DMF 97  
3 
 
Pd(OAc)2 (2) Xantphos (4) nBuOH TEA TEA 11 
4 dppfPdCl2 (10) Dppf (20) iPrOH TEA DMF 11 
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2.6 Screening for catalysts and conditions for the carbonylative Suzuki-Miyaura coupling of 
methyl 2-bromobenzoate 6a 
Table ESI-6. Optimization of reaction conditions for the palladium catalyzed carbonylative Suzuki-Miyaura 





















8 - Toluene: H2O 
(10:1) 






7a - Toluene: H2O 
(10:1) 














































7a - Dioxane: H2O 
(10:1) 
95 normal - -*,a 
9b PdCl2 (1)  4a K2CO3 Anisole 110 normal - -*,b 






110 normal - -*,b 
11b Pd(PPh)3Cl2  (10) 4a K2CO3  Anisole 110 normal 0.2 : 1 20b 
12b Pd(OAc)2 (5) Xantphos (5) 4a Cs2CO3 Toluene 80 normal 0.3 : 1 20b 
13c Xantphos G2 (5) 4a K2CO3 Anisole 100 slow - tracesc 
14b Pd(OAc)2 (5) 
CataCXium A 
(10) 
4a K2CO3 Dioxane 100 normal - tracesb 
15b PdCl2 (2) Xantphos (4) 4a K2CO3 Toluene 100 normal - -*,b 
16b PEPPSI-IPr (3) 4a Cs2CO3 Chlorobenzene 80 normal 1 : 0.5 60b 







boronic acid derivative 
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18c PEPPSI-IPr (3) 4a Cs2CO3 Anisole 110 slow 1 : 0.15 80c 
19b PEPPSI-Allyl (3) 4a Cs2CO3 Anisole 110 normal 1: 0.6 50b 
20b Ni(COD)2 dcype 4a Cs2CO3 Toluene 110 normal - -*,b 
a Following general procedure E. b Following general procedure D. c Following general procedure C. d The ratio (2aa : B) was determined 
using 13C NMR of the crudes. *Only starting material or the corresponding biphenyl B were detected.  
Characterization of methyl 4'-methoxy-[1,1'-biphenyl]-2-carboxylate B. 
The title compound was isolated as a side product from reactions towards 2aa. NMR: δH 
(400 MHz, CDCl3) 7.70 (1H, d, J 8.2), 7.41 (1H, t, J 8.3), 7.29 (2H, d, J 7.3), 7.16 (2H, 
d, J 8.8), 6.85 (2H, d, J 8.8), 3.75 (3H, s), 3.58 (3H, s). δC (101 MHz, CDCl3) 169.5, 
159.1, 142.1, 133.7, 131.3, 131.0, 130.8, 129.8, 129.6, 126.9, 113.7, 77.5, 77.2, 76.8, 
55.4, 52.1. 
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4 Spectra 
4.1 Spectra for diaryl ketones 5 
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2-bromo-4'-methoxy-1,1'-biphenyl A (from direct coupling) 
 
 
abai-85-1_180618144811 #1-4 RT: 0.00-0.09 AV: 4 NL: 2.58E7
T: FTMS + p ESI Full ms [200.00-400.00]
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ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 

































































































abai-85-1_180618144811 #1-4 RT: 0.00-0.09 AV: 4 NL: 2.58E7
T: FTMS + p ESI Full ms [200.00-400.00]






































C 14 H 12 O 2 Br = 291.0015
-0.8187 mmu
319.1316 393.2960
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2-Bromophenyl 4-(methylthio)phenyl methanone 5d 
 
abai-85-2_180618145336 #1-5 RT: 0.00-0.11 AV: 5 NL: 2.85E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 14 H 11 O 2 Br Na = 312.9835
-0.7361 mmu
291.0008
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abai-86-5_180618152120 #1-5 RT: 0.01-0.12 AV: 5 NL: 2.15E7
T: FTMS + p ESI Full ms [200.00-400.00]








































C 12 H 12 O Na S = 227.0501
-0.7818 mmu
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abai-91-2f2_180618163441 #1-5 RT: 0.02-0.13 AV: 5 NL: 1.88E7
T: FTMS + p ESI Full ms [200.00-500.00]
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Methyl 3-(2-bromobenzoyl)benzoate 5g 
 
abai-90-1_180618162022 #4 RT: 0.09 AV: 1 NL: 6.40E7
T: FTMS + p ESI Full ms [200.00-500.00]
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abai-89-1_180618154346 #1-5 RT: 0.02-0.13 AV: 5 NL: 1.39E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 15 H 11 O 3 Br Na = 340.9784
-0.8759 mmu
318.9957




C 14 H 12 O 2 81Br = 292.9995
-0.9798 mmu 369.1083
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ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 




abai-90-3p_180618164331 #3 RT: 0.07 AV: 1 NL: 3.32E7
T: FTMS + p ESI Full ms [200.00-500.00]


































C 15 H 11 O 3 81Br Na = 342.9763
-0.6234 mmu
286.9696
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abai-87-5_180618154346 #1-5 RT: 0.02-0.13 AV: 5 NL: 1.76E6
T: FTMS + p ESI Full ms [200.00-400.00]
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2-Bromophenyl 4-fluorophenyl methanone 5k 
 
abai-87-2p_180618154346 #1-5 RT: 0.00-0.11 AV: 5 NL: 7.44E6
T: FTMS + p ESI Full ms [200.00-400.00]



















































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
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2-bromophenyl 3-fluorophenyl methanone 5l 
 
abai-86-4-f1_180618150932 #1-4 RT: 0.02-0.10 AV: 4 NL: 1.09E7
T: FTMS + p ESI Full ms [200.00-400.00]


































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 













































































































































abai-86-4-f1_180618150932 #1-4 RT: 0.02-0.10 AV: 4 NL: 1.09E7
T: FTMS + p ESI Full ms [200.00-400.00]
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abai-86-3_180618173109 #1 RT: 0.01 AV: 1 NL: 3.90E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 13 H 8 O 81Br F Na = 302.9614
-0.6759 mmu
393.2962
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4.2 Spectra for butyl 2-benzoylbenzoate esters 2 
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Butyl 2-(3-methoxybenzoyl)benzoate 2b 
 
abai-112-6f3_190627172410 #1-4 RT: 0.01-0.10 AV: 4 NL: 5.01E7
T: FTMS + p ESI Full ms [150.00-500.00]



























































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 













































































































































abai-112-5f2_190627172410 #1-5 RT: 0.00-0.11 AV: 5 NL: 4.27E7
T: FTMS + p ESI Full ms [150.00-500.00]





































C 19 H 20 O 4 Na = 335.1254
0.6076 mmu
239.0705
C 15 H 11 O 3 = 239.0703
0.2749 mmu 488.1844
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 42   – 



















































































































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 43   – 
 
Butyl 2-(2-fluorobenzoyl)benzoate 2d 
 
abai-112-1f1_190627172410 #1-5 RT: 0.01-0.12 AV: 5 NL: 6.71E7
T: FTMS + p ESI Full ms [150.00-500.00]




































































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 







































































































































abai-112-2f1_190627172410 #1-5 RT: 0.01-0.12 AV: 5 NL: 3.06E7
T: FTMS + p ESI Full ms [150.00-500.00]













































C 22 H 26 O 4 Na = 377.1723
-0.1471 mmu
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 45   – 
4.3 Spectra for methyl 2-benzoylbenzoate esters 2 





































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 46   – 
 
 
methyl 4'-methoxy-[1,1'-biphenyl]-2-carboxylate B (from direct coupling). 
 
ABAI-111-1DF2_180618105745 #1-5 RT: 0.01-0.12 AV: 5 NL: 7.98E7
T: FTMS + p ESI Full ms [200.00-500.00]


































C 16 H 14 O 4 Na = 293.0784
-0.0800 mmu
239.0699










































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
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ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 


















































































































ABAI-111-17-F2 #1-4 RT: 0.02-0.11 AV: 4 NL: 6.66E7
T: FTMS + p ESI Full ms [200.00-500.00]






































C 15 H 11 O 3 = 239.0703
-0.3340 mmu
487.1361
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
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ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 50   – 
 
Methyl 2-(4-(methylthio)benzoyl) benzoate 2ad 
 
ABAI-111-3-F2_180618115027 #1-4 RT: 0.02-0.11 AV: 4 NL: 1.52E7
T: FTMS + p ESI Full ms [200.00-400.00]





































C 16 H 14 O 4 Na = 293.0784
-0.1051 mmu
271.0965


























































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 

































































































ABAI-111-14F2 #4 RT: 0.11 AV: 1 NL: 6.49E7
T: FTMS + p ESI Full ms [200.00-500.00]









































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 52   – 




ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 53   – 
 
Dimethyl 2,2'-carbonyldibenzoate 2ah 
 
ABAI-111-9_180618122059 #1-5 RT: 0.01-0.13 AV: 5 NL: 3.89E7
T: FTMS + p ESI Full ms [200.00-400.00]





































C 17 H 14 O 5 Na = 321.0733
0.2318 mmu
299.0918























































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
















































































ABAI-111-7D-F2_180618115027 #1-4 RT: 0.02-0.11 AV: 4 NL: 5.04E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 17 H 14 O 5 Na = 321.0733
-0.3282 mmu
267.0647




C 17 H 15 O 5 = 299.0914
-0.3217 mmu
378.1330248.1428
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 55   – 













































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 56   – 
 
Methyl 2-(3-cyanobenzoyl) benzoate 2aj 
 
ABAI-111-5DF2_180618113446 #1-4 RT: 0.01-0.09 AV: 4 NL: 6.45E6
T: FTMS + p ESI Full ms [200.00-400.00]















































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 





















































































































ABAI-111-4D-F2_180618113446 #1-4 RT: 0.02-0.10 AV: 4 NL: 2.03E7
T: FTMS + p ESI Full ms [200.00-400.00]







































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
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ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 59   – 
 
Methyl 2-(3-fluorobenzoyl) benzoate 2al 
 
ABAI-111-6D-F2_180618113446 #1-4 RT: 0.02-0.11 AV: 4 NL: 2.04E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 15 H 11 O 3 F Na = 281.0584
0.1099 mmu
259.0765




































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 









































































































































ABAI-111-3D_180618113446 #1-5 RT: 0.01-0.13 AV: 5 NL: 2.68E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 15 H 11 O 3 F Na = 281.0584
-0.0710 mmu
259.0764
C 15 H 12 O 3 F = 259.0765
-0.1025 mmu
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 61   – 





























































































































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 62   – 
 
Methyl 2-(thiophene-2-carbonyl) benzoate 2an 
 
ABAI-111-2DF2 #1-4 RT: 0.01-0.10 AV: 4 NL: 3.70E7
T: FTMS + p ESI Full ms [200.00-500.00]


















































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
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ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
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ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 


































































































































abai-115-4f2_181005104518 #1-5 RT: 0.01-0.12 AV: 5 NL: 6.61E7
T: FTMS + p ESI Full ms [200.00-500.00]





































C 16 H 13 O 4 F Na = 311.0690
0.5161 mmu
441.2973
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 66   – 




































































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 67   – 
 
abai-115-8f2_181005161140 #1-5 RT: 0.01-0.12 AV: 5 NL: 5.13E7
T: FTMS + p ESI Full ms [200.00-500.00]





































C 16 H 13 O 4 F Na = 311.0690
0.5094 mmu
357.0547




C 15 H 10 O 3 F = 257.0608
0.3249 mmu 457.3414
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 68   – 


































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 69   – 
 
Methyl 4-chloro-2-(4-methoxybenzoyl)benzoate 2ea 
 
abai-115-2f3_181005104518 #1-5 RT: 0.02-0.13 AV: 5 NL: 3.24E7
T: FTMS + p ESI Full ms [200.00-500.00]



















































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 











































































































abai-115-6f2_181005161140 #1-4 RT: 0.02-0.10 AV: 4 NL: 2.18E7
T: FTMS + p ESI Full ms [200.00-500.00]





































C 16 H 13 O 4 Cl Na = 327.0395
0.7275 mmu
388.9956
C 23 H 7 O 3 Cl Na = 388.9976
-1.9948 mmu
273.0318
C 15 H 10 O 3 Cl = 273.0313
0.4677 mmu
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 71   – 














































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 72   – 
 
Methyl 2-(4-methoxybenzoyl)-3-methylbenzoate 2ga 
 
abai-115-10-f3_181005163548 #1-4 RT: 0.01-0.10 AV: 4 NL: 5.33E7
T: FTMS + p ESI Full ms [200.00-400.00]





































C 17 H 16 O 4 Na = 307.0941
0.6001 mmu
285.1130
C 17 H 17 O 4 = 285.1121
0.8250 mmu
253.0863

















































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 






























































































abai-115-7f1_181005161140 #1-5 RT: 0.01-0.12 AV: 5 NL: 6.95E7
T: FTMS + p ESI Full ms [200.00-500.00]






































C 16 H 13 O 3 = 253.0859
0.2313 mmu
349.1047
C 19 H 18 O 5 Na = 349.1046
0.0350 mmu
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 74   – 





























































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 75   – 
 
Methyl 2-(4-methoxybenzoyl)-5-methylbenzoate 2ia 
 
 
abai-115-9f2_181005163548 #1-4 RT: 0.02-0.11 AV: 4 NL: 1.01E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 17 H 16 O 5 Na = 323.0890
0.3797 mmu
301.1076
C 14 H 18 O 6 F = 301.1082
-0.5471 mmu
269.0811





































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 



































































































abai-115-5f1_181005161140 #1-5 RT: 0.02-0.13 AV: 5 NL: 1.10E7
T: FTMS + p ESI Full ms [200.00-500.00]





































C 18 H 18 O 6 Na = 353.0996
0.5167 mmu
311.0695
C 21 H 11 O 3 = 311.0703
-0.7882 mmu
277.0687
C 12 H 14 O 6 Na = 277.0683
0.4163 mmu
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 77   – 































































































































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 78   – 
 
Methyl 5-fluoro-2-(2-(methoxycarbonyl)benzoyl)benzoate 2bh 
	
abai-115-12-f2_181005163548 #1-4 RT: 0.01-0.10 AV: 4 NL: 4.68E7
T: FTMS + p ESI Full ms [200.00-400.00]





































C 16 H 13 O 4 F Na = 311.0690
0.2498 mmu
289.0875
C 16 H 14 O 4 F = 289.0871
0.3905 mmu
339.0637



















































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 






















































































































































abai-115-11_181005163548 #1-4 RT: 0.02-0.11 AV: 4 NL: 3.76E7
T: FTMS + p ESI Full ms [200.00-400.00]


































C 17 H 13 O 5 F Na = 339.0639
0.1080 mmu
285.0559
C 16 H 10 O 4 F = 285.0558
0.1801 mmu
317.0823
C 17 H 14 O 5 F = 317.0820
0.3203 mmu
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 80   – 




















































































































































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 81   – 
 
abai-115-4h_190627172410 #1-5 RT: 0.00-0.11 AV: 5 NL: 5.84E7
T: FTMS + p ESI Full ms [150.00-500.00]







































C 19 H 13 O 3 = 289.0859
0.4616 mmu
ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
 – 82   – 





























































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 






























































































































































































ESI : Carbonylative Suzuki-Miyaura couplings of sterically hindered aryl halides. 
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ABSTRACT: Solvents constitute the largest component for many chemical processes and 
substitution of non-renewable solvents is a long-standing goal for green chemistry. Here we show 
that Pd-catalyzed carbonylative couplings, such as carbonylative cross couplings, 
aminocarbonylations and alkoxycarbonylations, can be successfully realized using renewable 
solvents. The present research covers not only well-established renewable solvents, such as 2-
methyltetrahydrofuran, limonene and dimethyl carbonate, but also recently introduced biomass-
derived 1,1-diethoxyethane, isosorbide dimethyl ether, eucalyptol, rose oxide, γ-terpinene and α-
pinene. The carbonylative coupling of boronic acids and aryl bromides works well in limonene. 
Aminocarbonylation gave excellent results in dimethyl carbonate, α-pinene and limonene, while 
alkoxycarbonylation was successful in 2-methyltetrahydrofuran, α-pinene, γ-terpinene and 
dimethyl carbonate. The developed renewable methodologies can be used for the synthesis of 
commercial drug Trimetozine and an analogue of Itopride.  
KEYWORDS: renewable solvents, carbonylative C-C coupling, aminocarbonylation, 
alkoxycarbonylation, palladium catalysis, carbon monoxide.  
INTRODUCTION  
According to the development plan of the United Nations General Assembly ''Transforming Our 
World: The 2030 Agenda for Sustainable Development'' initiated in 2015, considerable efforts are 
needed over the coming decade to build a better and more sustainable future.1 The realization of 
most of the aspects of ''The 2030 Agenda for Sustainable Development'' can be directly conditioned 
by sustainable innovations in chemical research.  
Today, most of the industrial processes and particularly the pharmaceutical industry are largely 
based on the application of non-renewable solvents, which usually constitute over 80% of 
 4 
materials needed for the production of the final ingredientes.2 As a result, yearly manufacture of 
non-renewable and hazardous common organic solvents exceeds 20 million metric tons.2d A recent 
survey on the solvents used in the pharmaceutical industry for the period 1997 - 2012 revealed that 
the top 10 most frequently used solvents are dichloromethane, hexane, diisopropyl ether, 1,2-
dimethoxyethane, 1,4-dioxane, 1,2-dichloroethane, diethyl ether, chloroform, diglyme and 
chlorobenzene.3 This unsustainable practice can be addressed by the development and 
popularization of renewable and safe solvent candidates.  
Liquids or low melting chemicals available from the valorization of biomass4,5 as well as 
chemicals derived from the reduction of CO26,7 have enormous potential to replace the common 
non-renewable solvents utilized in organic synthesis.3 The most frequently used solvents available 
from biomass are polar protic ethanol, glycerol and its derivatives, and choline chloride-based deep 
eutectic solvents, polar aprotic 2-methyltetrahydrofuran (2MeTHF), cyrene and γ-valerolactone 
(GVL), as well as nonpolar limonene and p-cymene (Fig. 1).4,5 Among CO2-derived chemicals 
carbonates and ethers like dimethoxymethane (methylal) have attracted attention as solvents (Fig. 
1).6,7 Recently, we have shown that biomass-derived solvents such as nonpolar ethers (1,1-
diethoxyethane (acetal), dimethyl isosorbide, eucalyptol, rose oxide) and terpenes (γ-terpinene and 








Figure 1. Overview of present work and renewable solvents used in the work (pictures taken by 
AG).  
A complete life cycle assessment (LCA) of the latter solvents is not available, but most of them 
are significantly less toxic compared to common organic solvents.8 Low toxicity is particularly 
inherent to naturally occurring dimethyl isosorbide, GVL and eucalyptol, ethanol-derived 
diethoxyethane (acetal), as well as CO2-derived diethyl carbonate (DEC), dimethyl carbonate 
(DMC) and methylal. Among others, these solvents are used in large quantities in the 
pharmaceutical and food industries as additives, antiseptic and flavoring agents.9 There is no need 
to continue increasing the consumption of non-renewable solvents for processes where renewable 










Nu = Ar, NR2, OR.
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Renewable solvents have proven to be suitable for a variety of transformations including 
classical condensation reactions and transition-metal (TM)-catalyzed cross-couplings.4-6 However, 
the use of renewable solvents as reaction media for carbonylative couplings with CO remain 
largely unexplored.10,11 The fact that the Pd-catalyzed carbonylations have found numerous 
applications in modern drug discovery and isotopic labeling of pharmaceuticals10d,e,g makes the 
development of renewable methodologies for carbonylations a task of great significance. This 
work describe the use of newly introduced biomass-derived solvents (acetal, dimethyl isosorbide, 
γ-terpinene, α-pinene, eucalyptol, and rose oxide, Fig. 1), and previously studied renewable 
solvents (2MeTHF, GVL, limonene, p-cymene, DMC, DEC, ethylene carbonate (EC), propylene 
carbonate (PC), methylal and diethoxymethane (ethylal) Fig. 1) for Pd-catalyzed carbonylations. 
RESULTS AND DISCUSSION  
A range of renewable solvents were studied for carbonylative couplings of aryl bromides with 
arylboronic acids,12 amines (aminocarbonylation)13 and alcohols (alkoxycarbonylation) (Fig. 1).14 
We decided to focus on Pd-based catalytic systems that have proven to be versatile catalysts for 
carbonylative couplings.11k,12-14 For safety reasons the reactions were conducted in two chamber 
reactors (COware) developed in the group of Skrydstrup, using stoichiometric quantities of CO 
generated ex situ from COgen (9-methyl-9H-fluorene-9-carbonyl chloride).10e The solvent´s 
polarity was approximated as nonpolar and polar based on their dielectric constant; a solvent was 
classified as polar if the dielectric constant was over 5 (Fig. 1, Table S1). 
Carbonylative C-C couplings of aryl bromides and arylboronic acids 
As a starting point, we analyzed the carbonylative coupling of 3-bromoanisole with m-
tolylboronic acid (Chart 1). We focused on the catalytic system based on Pd(acac)2 as catalyst 
precursor, and di(1-adamantyl)-n-butylphosphine hydroiodide (cataCXium AHI) as ligand, 
 7 
originally developed in the group of Skrydstrup.12g The original protocol relied on cyclic 
diethanolamine esters of boronic acids (DABO boronates) or aryl trihydroxyborates as successful 
starting materials and used toluene/H2O (10:1) or toluene as solvent.12g We initiated our work by 
developing a simplified protocol where the aryl trihydroxyborates was generated in situ from 
simple boronic acids by addition of 1M aqueous NaOH, thus preventing the external, up-front 
preparation of the organoboronate (see ESI, Table S1, entry 3). 
 
Chart 1. Screening of renewable solvents for carbonylative coupling of m-tolylboronic acid and 
3-bromoanisole.  
Using the modified protocol, we investigated the efficiency of various renewable solvents in the 
Pd-catalyzed carbonylative coupling of m-tolylboronic acid and 3-bromoanisole (Chart 1, see also 
Table S1 for a correlation of solvent polarity and yields). It has to be noted that the final reaction 
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media contained approx. 15% (v/v) of water in all cases due to the addition of aqueous NaOH. Our 
studies revealed that nonpolar ethers and carbonates (rose oxide, methylal, DMC) and polar ether 
2MeTHF provide the carbonylation product in low to moderate yields (16-50%). In contrast, 
biomass-derived nonpolar hydrocarbons (limonene, p-cymene, γ-terpinene, α-pinene) gave 
consistently better yields with p-cymene and limonene being the best solvents (75% and 80% 
isolated yield, respectively); an observation that correlates well with the use of toluene or 
toluene/water as solvent in previous studies providing the corresponding product in 90% yield.12g 
Despite the fact that limonene possesses a terminal and an internal double bond, the Heck-type 
arylation of the solvent was not observed under the reaction conditions. Neither were related side 
products noted for reactions in rose oxide, γ-terpinene and α-pinene. 
We proceeded to analyze the generality of the Pd-catalyzed carbonylative couplings in limonene 
as solvent (Scheme 1). Examination of a variety of aromatic boronic acids and aryl bromides 
indicated a good substrate scope. The yields varied from 71-95% for electron-rich (3a, 3c, 3d, 3e, 
3h, 3i), electron-deficient aryl (3f, 3g) and heterocyclic boronic acids (3j, 3k). The broad 
applicability of boronic acids is particularly interesting as the use of in situ generated aryl 
trihydroxyborates extended the substrate scope beyond the limitations associated with isolation of 
unstable trihydroxyborate salts.12g Similarly, both electron-rich (3m, 75%; 3o, 79%) and electron-
deficient (3n, 83%; 3p, 83%) aryl bromides as well as heteroaryl bromides (3l, 91%) were 
successful in the carbonylative couplings. We observed a low yield only for 2-methoxycarbonyl-
phenylboronic acid (3b, 40%), which may be due to steric hindrance or side reactions such as 
hydrolysis of the ester. Overall, the observed yields were at the same level as previously reported 
protocols using toluene as solvent,12e,g indicating that limonene is a renewable alternative for 
carbonylative couplings of boronic acids and aryl bromides. 
 9 
 
Scheme 1. Scope of carbonylative coupling of boronic acids and aryl bromides using the 
sustainable solvent limonene.  
Aminocarbonylation of aryl bromides 
Next, we examined the Pd-catalyzed aminocarbonylation reaction of aryl bromides. Here, we 
focused on the catalytic system developed in the group of Buchwald using Pd(OAc)2 as Pd source, 
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene as ligand (XantPhos) and toluene as solvent.14c 
The Pd-catalyst was tested in renewable solvents on the model reaction of N-methylaniline with 
4-bromobenzonitrile (Chart 2). 
 10 
 
Chart 2. Screening of renewable solvents for aminocarbonylation with resulting isolated yields.  
Our studies demonstrated that for this aminocarbonylation exceptional results can be obtained 
in most of the renewable solvents (Chart 2). As a general trend, all reactions in nonpolar 
hydrocarbons provided excellent yield (limonene, 99%; p-cymene, 97%; γ-terpinene, 94%; α-
pinene; 97%); in good correlation with previous work being performed in toluene as solvent 
providing the product in 97% yield.14c Excellent yields were also obtained in nonpolar carbonates 
(DMC, 97%; DEC, 94%). Other solvents like polar carbonate PC and lactone GVL, and nonpolar 
and polar ethers (ethylal, acetal, rose oxide, eucalyptol, dimethyl isosorbide, 2MeTHF) were less 
efficient with yields ranging between 62-89%.  
Noteworthy, under the conditions used for aminocarbonylation we did not observe side reactions 
like hydroamination or Mizoroki-Heck coupling for solvents possessing double bonds. 
As several renewable solvents provided good yields, we screened the top three best solvents 
(DMC, α-pinene, limonene) for several aminocarbonylations (Scheme 2). These studies revealed 
that except for the products 5m and 5n, the best solvents DMC, α-pinene and limonene gave  
 11 
 
Scheme 2. Scope of aminocarbonylation of aryl bromides. a Unless otherwise mentioned, the 
reaction was performed in DMC. b XantPhos Pd G3 was used instead of Pd(OAc)2/XantPhos.  
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comparable results for several aminocarbonylations (5d, 5h, 5l). For the product 5m, α-pinene 
(39%) turned out far less effective than other solvents, while for the product 5n, DMC provided 
low yield (16%) (Scheme 2). For an extended analysis of the substrate scope, we therefore decided 
to focus on the use of DMC, as it is considerably less toxic and less expensive than the two other 
solvents.15  
Reactions with variously substituted aryl bromides illustrated that many functional groups 
(CHO, CN, CO2Me) were well tolerated. In general, aryl bromides with electron-withdrawing 
substituents provided corresponding aminocarbonylation products in good to quantitative yields 
(5b, 99%; 5c, 98%; 5d, 87%; 5h, 97%; 5i, 81%; 5k, 83%; 5m 94%), except for 5a (51% yield). 
Electron-rich aryl bromides were less effective producing the corresponding amides from low to 
acceptable yields (5e, 62%; 5f, 35%; 5g, 64%; 5n, 16%). However, the aminocarbonylation of 
electron-rich 3,4,5-trimethoxyphenyl bromide, using XantPhos Pd G3 as catalyst, provided the 
commercial drug Trimetozine (5v, 96% yield, a sedative) and an analogue of Itopride (5u, 95% 
yield, Itopride is used for treatment of gastrointestinal symptoms) in excellent yields.13h The 
reaction worked well also with fused systems like naphthalene (5l, 99%) and heterocycles (5j, 
65%) (Scheme 2). Changes in the amine structure were tolerated well and both anilines with 
electron-donating and -withdrawing substituents, and primary and secondary aliphatic amines 
were successfully coupled with 4-bromobenzonitrile and CO (Scheme 2, 5o, 87%; 5p, 90%; 5q, 
85%; 5r, 90%; 5s, 93%; 5t, 94%). Overall, the observed trends were in agreement with reports of 
aminocarbonylations performed in non-renewable solvents.13,14c The good yields and substrate 
scope indicate that renewable solvents like DMC, α-pinene and limonene can effectively replace 
1,4-dioxane, toluene and THF frequently used in Pd-catalyzed aminocarbonylation 
reactions.10b,13,14c 
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Alkoxycarbonylation of arylbromides 
Finally, we analyzed the potential adaptation of renewable solvents for Pd-catalyzed 
alkoxycarbonylation.14 For the initial studies, we examined the alkoxycarbonylation of 2-
bromonaphthalene with sodium tert-butoxide and CO using the catalytic system based on Pd(dba)2 
as catalyst precursor and 1,1′-bis(diisopropylphosphino)ferrocene (dippf) as ligand first reported 
by Skrydstrup and coworkers for alkoxycarbonylations in THF (Chart 3).14f The screening of 
renewable solvents showed that excellent results can be achieved also for the Pd-catalyzed 
alkoxycarbonylations (Chart 3).  
Not surprisingly, the polar ether 2MeTHF (91% yield) was among the best solvents, as previous 
studies were performed in THF (88% yield).14f Interestingly, excellent yields of 93% were also 
obtained in some nonpolar hydrocarbons (γ-terpinene, α-pinene), while other nonpolar 
hydrocarbons (limonene, 56%), ethers (methylal, 45%; ethylal, 64%; acetal, 55%; rose oxide, 
36%; eucalyptol, 82%), and carbonates (DEC, 45%) provided low to moderate yields. In nonpolar 
carbonate DMC, instead of tert-butoxycarbonylation, the product of methoxycarbonylation was 
isolated in 93% yield (Chart 3, Scheme 4). This was the only observation where the solvent was 
chemically transformed in the reaction. Similar transesterifications were not observed for the other 
carbonates (DEC, PC, EC). Polar solvents (dimethyl isosorbide, 30%; GVL, 64%; PC, 60%; EC, 
30% yield) were less efficient.  
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Chart 3. Screening of renewable solvents for alkoxycarbonylation with resulting isolated yields. 
a In DMC, methoxycarbonylation was observed.  
As for aminocarbonylation, we screened the top three best solvents (2MeTHF, α-pinene and γ-
terpinene) for alkoxycarbonylations of several substrates (Chart 3, Scheme 3). These studies 
revealed that the choice of solvent is dependent on the substrate. 2MeTHF was the best solvent for 
the products 7c (52%) and 7d (45%). The best yields of 7b were seen in γ-terpinene (98%), 
whereas γ-terpinene was not a good reaction media for the product 7f (44%). α-Pinene appeared 
to be the best solvent for the products 7a (93%) and 7f (51%) and in general showed good 
performance for most of the substrates. 
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Scheme 3. Scope of tert-butoxycarbonylation of aryl bromides. a Unless otherwise mentioned, the 
reaction was performed in α-pinene.  
The following investigation of the scope of tert-butoxycarbonylation in α-pinene as solvent 
showed that both electron-rich and -deficient aryl bromides can be effectively transformed into the 
corresponding products in moderate to good yields (Scheme 3). The best yields were observed for 
tert-butoxycarbonylation of electron-rich aryl bromides (7a, 93%; 7b, 91%; 7e, 80%; 7g, 85%; 
7h, 90%; 7i, 93%). It should be noted that aryl bromides possessing electron-withdrawing groups 
and electron-deficient 3-bromopyridine were less effective and gave products in moderate yields 
(7c, 45%; 7d, 25%; 7f, 51%). Similar observations were reported by Skrydstrup et al. for 
alkoxycarbonylations performed in THF.14f Overall, our studies indicate that for 
alkoxycarbonylations renewable solvent perform on the same level, and in some cases even better, 
than previously reported non-renewable solvents.10,14 Renewable solvents such as 2MeTHF, 
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DMC, α-pinene and γ-terpinene can be useful alternatives for trimethylamine, 
hexafluoroisopropanol, THF, toluene and dimethyl sulfoxide frequently used for 
alkoxycarbonylation reactions.14 
Studies on the alkoxycarbonylation in DMC. 
In general, alkoxycarbonylation reactions rely on the use of bulky alcohols, phenols or 
corresponding alkoxides.14 Alcohols possessing α-hydrogens have found limited applications due 
to the side processes associated with  b-hydride elimination.14b,d Therefore, we had a closer look 
at the methoxycarbonylations observed in DMC. The scope of the reaction was briefly studied on 
a range of substituted aryl bromides (Scheme 4). The reaction gave good yields for electron-rich 
4-bromoanisole (8b 90%) and 4-bromotoluene (8d, 80%), as well as for 2-bromonaphthalene (8a, 
93%) and 6-bromoquinoline (8e, 93%). Moderate yields were observed for electron-deficient aryl 
bromides (8c, 58%). For most of the products in Scheme 4, traces of tert-butoxycarbonylation 
were seen along with the main methoxycarbonylation product. 
 
Scheme 4. Scope of methoxycarbonylation of aryl bromides. 
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To gain a better understanding of the mechanism of the observed methoxycarbonylation, we 
performed a set of control experiments (Scheme 5). The tert-butyl ester 7a was transformed into 
corresponding methyl ester 8a in quantitative yield when treated with NaOtBu in DMC. The 
transesterification took place in presence and absence of the Pd-catalyst (Scheme 5, A, B). In 
addition, the Pd-catalyzed methoxycarbonylation of 2-bromonaphthalene with sodium methoxide 
in DMC provided the methoxycarbonylated product in 67% yield, while an equivalent experiment 
in α-pinene did not lead to methoxycarbonylation (Scheme 5, C). These findings indicate that two 
different reaction pathways may contribute to the formation of methoxycarbonylated products: (i) 
the Pd-catalyzed alkoxycarbonlyation with tert-butoxide followed by a transesterification with 
sodium methoxide generated in situ from the reaction of excess sodium tert-butoxide with DMC; 
and (ii) the Pd-catalyzed methoxycarbonylation with in-situ generated sodium methoxide.  
 
Scheme 5. Control experiments to elucidate the formation of methoxycarbonylated products.  
CONCLUSIONS  
We have shown that Pd-catalyzed carbonylative transformations can be conducted in biomass- and 
CO2-derived solvents with exceptionally high efficiency. A vast array of renewable solvents was 
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analyzed for this purpose, including both well-established (2MeTHF, GVL, limonene, p-cymene, 
DMC, DEC, PC, EC) and recently introduced solvent candidates (acetal, dimethyl isosorbide, γ-
terpinene, α-pinene, eucalyptol, rose oxide, methylal and ethylal). The work covered Pd-catalyzed 
carbonylative coupling of boronic acids and aryl bromides, aminocarbonylation and 
alkoxycarbonylation. For each of these transformations we have found several renewable solvents, 
which can successfully substitute traditional non-renewable solvents. For carbonylative coupling 
of boronic acids and aryl bromides the best results were observed in limonene and p-cymene. 
Aminocarbonylation worked well in DMC, α-pinene and limonene, whereas the best solvents for 
alkoxycarbonylation turned out to be 2MeTHF, α-pinene, γ-terpinene and DMC. Most of the 
known methodologies on alkoxycarbonylation are limited to bulky alkoxides and alcohols. We 
could show that this drawback can be overcome by the use of DMC, which lead to 
methoxycarbonylated products. Finally, yet importantly, aminocarbonylation in renewable 
solvents can be used for the production of commercial drug Trimetozine and an analogue of 
Itopride. 
EXPERIMENTAL METHODS 
General considerations.  
Solvents used in the work are purchased from Sigma Aldrich if not otherwise stated. 2MeTHF 
(anhydrous, ≥99%, inhibitor-free, 673277-1L), methylal (absolute, over molecular sieve, ≥99.0%, 
47676-250ML), ethylal (absolute, over molecular sieve, ≥99.0%, 47675-500ML-F), DMC 
(anhydrous, ≥99%, 517127-1L), DEC (anhydrous, ≥99%, 517135-1L), PC (anhydrous, 99.7%, 
310328-1L) and EC (anhydrous, 99%, 676802-1L) were bought as anhydrous solvents equipped 
with a septa. Other renewable solvents were reagent grade; they were degassed, kept over activated 
molecular sieves (4 Å) at least a week before use and stored under Ar atmosphere. The purity of 
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the solvents used in the work were as follows: acetal (99%, inhibitor-free, A902-500ML); dimethyl 
isosorbide (98%, inhibitor-free, 247898-100G); GVL (99%, V403-500G); γ-terpinene (97%, 
223190-100ML); α-pinene (98%, 147524-250ML); limonene (97%, 183164-100ML); p-cymene 
(99%, C121452-1L); eucalyptol (99%, inhibitor-free, C80601-500ML); rose oxide (97%, 
inhibitor-free, TCI, M2363-25G).  
2MeTHF, acetal, dimethyl isosorbide, eucalyptol, rose oxide, methylal and ethylal are ethers and 
may form peroxides when stored under air. However, peroxide tests (test strips for peroxide, 
MQuant®, Supelco®, VWR/Merck 1.10081.0001) of freshly bought solvents did not show any 
noticeable levels of peroxides. Acetal, methylal and ethylal can be hydrolyzed in the presence of 
strong acids when heated. Under basic conditions, which are frequently used for the reactions 
involving organometallics, acetal, methylal and ethylal are stable. GVL, DMC, DEC, PC and EC 
can be hydrolyzed in the presence of strongly basic water solutions; under anhydrous conditions, 
they are stable. γ-Terpinene, limonene and eucalyptol can be converted to p-cymene when heated 
above 220oC.4b Overall, the examined renewable solvents appeared to be stable under the 
conditions used in this work. We have not observed the formation of side-products e.g. originating 
from hydrolysis of the carbonate, ethers and esters used as solvents in this work (an exception was 
alkoxycarbonylation in DMC). It should be noted that the oxidation products of terpenes can be 
allergens.9 
The reactions were performed in the previously reported two-chamber system (COware with 
total volume 20 mL, ESI Fig. S1) under an argon atmosphere, and a glovebox was employed for 
weighing out the reagents.  
Warning! Most of the reactions were performed in specialized glassware under pressure. The 
glassware should always be examined for damages before any manipulation. All laboratory safety 
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procedures must be followed strictly and the work with pressure tubes must be conducted behind 
a shield. 
General procedure for Pd-catalyzed carbonylative coupling of boronic acids and aryl 
bromides (Scheme 1).  
Chamber A was sequentially charged with aryl bromide (50 mg, 1.0 equiv), boronic acid (1.2 
equiv), Pd(acac)2 (5 mol%), cataCXium AHI (10 mol%), 1M NaOH (500 µl) and dry solvent (3 
mL). The reaction mixtures consisted of an organic and an aqueous layer. Precipitation of 
palladium was not observed. 
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-
butylphosphonium tetrafluoroborate (TTBP•HBF4) (5 mol%), DIPEA (3 equiv) and 1,4-dioxane 
(3 mL). The two-chamber system was closed tightly with suitable caps and Chamber B was stirred 
at 80 oC until the release of CO was stopped. This was followed by stirring of both chambers at 80 
oC for 18 hours. The resulting mixture of Chamber A was filtered through celite and concentrated 
using a rotary evaporator. The crude was purified by column chromatography with heptane: EtOAc 
(9:1) eluent.  
General procedure for Pd-catalyzed aminocarbonylation (Scheme 2).  
Chamber A was sequentially charged with aryl bromide (50 mg, 1.0 equiv), corresponding 
amine (1.5 equiv), Pd(OAc)2 (2 mol%), XantPhos (2 mol%), triethylamine (3 equiv) and dry 
solvent (3 mL). At the onset of the reaction, the mixture was homogeneous, while precipitation of 
palladium species (Pd-black) was observed during the course of the reaction both in conventional 
and renewable solvents. 
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-
butylphosphonium tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 
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equiv). Addition of DIPEA initialize the release of CO. The two-chamber system was closed 
tightly with suitable caps and stirred at 80 oC for 18 hours. The resulting mixture of Chamber A 
was filtered through celite and concentrated using a rotary evaporator. The crude was purified by 
column chromatography with heptane : EtOAc (9:2) eluent.  
General procedure for Pd-catalyzed alkoxycarbonylation (Scheme 3, 4).  
Chamber A was sequentially charged with aryl bromide (50 mg, 1.0 equiv), tBuONa (1.5 
equiv), Pd(dba)2 (5 mol%), 1,1′-bis(diisopropylphosphino)ferrocene (dippf) (5 mol%) and 
corresponding dry solvent (3 mL). At the onset of the reaction, the mixture was homogeneous, 
while precipitation of palladium species was observed during the course of the reactions both in 
conventional and renewable solvents.  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-
butylphosphonium tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 
equiv). Addition of DIPEA initialize the release of CO. The two-chamber system was closed 
tightly with suitable caps and stirred at 80 oC for 18 hours. The resulting mixture of Chamber A 
was filtered through celite and concentrated using a rotary evaporator. The crude was purified by 
column chromatography with heptane : EtOAc (9:1) eluent.  
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ABBREVIATIONS 
2MeTHF = 2-methyltetrahydrofuran; acetal = 1,1-diethoxyethane; COgen = 9-methyl-9H-
fluorene-9-carbonyl chloride; COware = two chamber reactor; cataCXium AHI = di(1-adamantyl)-
n-butylphosphine hydriodide; DMC = dimethyl carbonate; DEC = diethyl carbonate; DIPEA = 
N,N-diisopropylethylamine; dippf = 1,1′-bis(diisopropylphosphino)ferrocene; EtOAc = ethyl 
acetate; EC = ethylene carbonate; GVL = γ-valerolactone; LCA = life-cycle assessment; PC = 
propylene carbonate; Pd(acac)2 = palladium(II) acetylacetonate; Pd(OAc)2 = palladium(II) acetate; 
Pd(dba)2 = bis(dibenzylideneacetone)palladium(0); TTBP•HBF4 = tri-tert-butylphosphonium 
tetrafluoroborate; XantPhos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; XantPhos Pd 
G3 = [(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2′-amino-1,1′-
biphenyl)]palladium(II) methanesulfonate.  
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1. General considerations  
All chemicals and solvents were purchased from Sigma Aldrich and VWR and were used as received without 
further purification. Solvents were dried according to standard procedures on molecular sieves 4 Å.1 Flash 
chromatography was carried out on silica gel 60 (230−400 mesh). NMR spectra were obtained on a Bruker 
Avance 400 MHz at 20oC. Data are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, 
t = triplet, q = quartet, dt = double triplet, m = multiplet), coupling constant (J, Hz) and integration. Chemical 
shifts (δ) are reported in ppm relative to the residual solvent peak (CDCl3: δH 7.26 and δC 77.16; Methanol-
d4: δH 3.31 and δC 49.00; Deuteriumoxid: δH 4.79; DMSO-d6: δH 2.51 and δC 39.52). The raw data was 
analyzed with MestReNova (Version 10.0.2-15465). Positive ion electrospray ionization mass spectrometry 
was conducted on a Thermo electron LTQ Orbitrap XL spectrometer. The data was analyzed with Thermo 
Scientific Xcalibur software. Melting points were measured using Stuart SMP50 automatic melting point 
detector. Infrared spectra were recorded on a Agilent Cary 630 FT-IR spectrometer and absoptions are 
reported in wavenumber (cm-1); s = strong, m = medium, w = weak. 
Solvents used in the work were purchased from Sigma Aldrich if not otherwise stated. 2MeTHF (anhydrous, 
≥99%, inhibitor-free, 673277-1L), methylal (absolute, over molecular sieve, ≥99.0%, 47676-250ML), ethylal 
(absolute, over molecular sieve, ≥99.0%, 47675-500ML-F), dimethylcarbonate (anhydrous, ≥99%, 517127-
1L), diethylcarbonate (anhydrous, ≥99%, 517135-1L), propylene carbonate (anhydrous, 99.7%, 310328-1L) 
and ethylene carbonate (anhydrous, 99%, 676802-1L) were bought as anhydrous solvents equipped with a 
septa. Other renewable solvents were reagent grade; they were degassed, kept over activated molecular 
sieves (4 Å) at least for a week before use and stored under Ar atmosphere. The purity of the solvents used 
in the work were as follows: diethoxyethane (99%, inhibitor-free, A902-500ML); dimethyl isosorbide (98%, 
inhibitor-free, 247898-100G); GVL (99%, V403-500G); γ-terpinene (97%, 223190-100ML); α-pinene (98%, 
147524-250ML); (R)-(+)-limonene (97%, 183164-100ML); p-cymene (99%, C121452-1L); eucalyptol (99%, 
inhibitor-free, C80601-500ML); (+)–rose oxide (97%, inhibitor-free, Chemtronica/TCI M2363-25G).  
2MeTHF, acetal, dimethyl isosorbide, eucalyptol, rose oxide, methylal and ethylal are ethers and may form 
peroxides when stored under air; however, peroxide tests (Test strips for peroxide, MQuant®, Supelco®, 
VWR/Merck 1.10081.0001) of freshly bought solvents did not show any noticeable levels of peroxides. Acetal, 
methylal and ethylal can be hydrolyzed in the presence of strong acids when heated. Under basic conditions, 
which are frequently used for the reactions involving organometallics, acetal, methylal and ethylal are stable. 
GVL, DMC, DEC, PC and EC can be hydrolyzed in the presence of strongly basic water solutions; under 
anhydrous conditions, they are stable. γ-Terpinene, limonene and eucalyptol can be converted to p-cymene 
when heated above 220oC. Overall, the examined renewable solvents appeared to be stable under the 
conditions used in this work. It should be noted that the oxidation products of terpenes can be allergens. 
The reactions were performed in the previously reported two-chamber system (COware with total volume 
of 20 mL, Fig. S1) under an argon atmosphere, and a glovebox was employed for weighing out the reagents.  
Warning! Most of the reactions were performed in specialized glassware under pressure. The glassware 
should always be examined for damages before any manipulation. All laboratory safety procedures must be 




2. The two-chamber system used in the work  
 
Fig. S1. The two-chamber system used in the work, and the CO generator (COgen). 
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4. Optimization of carbonylative Suzuki-Miyaura coupling with boronic acids 
Table S2. Catalyst screening for the carbonylative coupling of boronic acids and 3-bromoanisole.  
 




























NaOH Toluene 82 
 
The reagents were weighed in the glove box!  
Chamber A was sequentially charged with 3-methoxybromobenzene (50 mg, 1.0 equiv), corresponding 
organoboronate (1.2 equiv), Pd-catalyst (3-5 mol%), ligand (4-10 mol%), base (0-2 equiv) and corresponding 
solvent (3 mL).  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 equiv). Addition of DIPEA initialize 
the release of CO. The two-chamber system was closed tightly with suitable caps and stirred at 80oC for 18 
hours. The resulting mixture of Chamber A was filtered through celite and concentrated using a rotary 
evaporator. The crude was purified by column chromatography with heptane : EtOAc (9:2) eluent.  
5. Screening of solvents  
5.1 Screening of solvents for carbonylative coupling of boronic acids and aryl halides.  
 
The reagents were weighed in the glove box!  
Chamber A was sequentially charged with 3-methoxybromobenzene (50 mg, 1.0 equiv), m-tolylboronic acid 
(1.2 equiv), Pd(acac)2 (5 mol%), cataCXium AHI (10 mol%), 1M NaOH (500 µl) and corresponding dry solvent 
(3 mL).  














Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 equiv). Addition of DIPEA initialize 
the release of CO. The two-chamber system was closed tightly with suitable caps and stirred at 80oC for 18 
hours. The resulting mixture of Chamber A was filtered through celite and concentrated using a rotary 
evaporator. The crude was purified by column chromatography with heptane : EtOAc (9:2) eluent.  
5.2 Screening of solvents for the aminocarbonylation.  
 
Chamber A was sequentially charged with 4-bromobenzonitrile (50 mg, 1.0 equiv), N-methylaniline (1.5 
equiv), Pd(OAc)2 (2 mol%), XantPhos (2 mol%), triethylamine (3 equiv) and corresponding dry solvent (3 mL).  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 equiv). Addition of DIPEA initialize 
the release of CO. The two-chamber system was closed tightly with suitable caps and stirred at 80oC for 18 
hours. The resulting mixture of Chamber A was filtered through celite and concentrated using a rotary 
evaporator. The crude was purified by column chromatography with heptane : EtOAc (9:2) eluent.  
5.3 Screening of solvents for the alkoxycarbonylation.  
 
Chamber A was sequentially charged with 2-bromonaphthalene (50 mg, 1.0 equiv), tBuONa (1.5 equiv), 
Pd(dba)2 (5 mol%), 1,1ʹ-bis(diisopropylphosphino)ferrocene (dippf) (5 mol%) and corresponding dry solvent 
(3 mL).  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 equiv). Addition of DIPEA initialize 
the release of CO. The two-chamber system was closed tightly with suitable caps and stirred at 80oC for 18 
hours. The resulting mixture of Chamber A was filtered through celite and concentrated using a rotary 
evaporator. The crude was purified by column chromatography with heptane : EtOAc (9:1) eluent.  
6. General procedures  
The reagents were weighed in the glove box!  
6.1 General procedure A: Carbonylative coupling of boronic acids and aryl halides.  
Chamber A was sequentially charged with aryl bromide (50 mg, 1.0 equiv), boronic acid (1.2 equiv), Pd(acac)2 
(5 mol%), cataCXium AHI (10 mol%), 1M NaOH (500 µl) and dry solvent (3 mL).  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), DIPEA (3 equiv) and 1,4-dioxane (3 mL). The two-chamber system 
was closed tightly with suitable caps and Chamber B was stirred at 80oC until the release of CO was stopped. 




filtered through celite and concentrated using a rotary evaporator. The crude was purified by column 
chromatography with heptane : EtOAc (9:1) eluent.  
6.2 General procedure B: Aminocarbonylation.  
Chamber A was sequentially charged with aryl bromide (50 mg, 1.0 equiv), corresponding amine (1.5 equiv), 
Pd(OAc)2 (2 mol%), XantPhos (2 mol%), (in the case of 5u and 5v Pd(OAc)2/XantPhos system was replaced by 
XantPhos Pd G3 (2 mol%)), triethylamine (3 equiv) and corresponding dry solvent (3 mL).  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 equiv). Addition of DIPEA initialize 
the release of CO. The two-chamber system was closed tightly with suitable caps and stirred at 80oC for 18 
hours. The resulting mixture of Chamber A was filtered through celite and concentrated using a rotary 
evaporator. The crude was purified by column chromatography with heptane : EtOAc (9:2) eluent.  
6.3 General procedure C: Alkoxycarbonylation.  
Chamber A was sequentially charged with aryl bromide (50 mg, 1.0 equiv), tBuONa (1.5 equiv), Pd(dba)2 (5 
mol%), 1,1ʹ-bis(diisopropylphosphino)ferrocene (dippf) (5 mol%) and corresponding dry solvent (3 mL).  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 equiv). Addition of DIPEA initialize 
the release of CO. The two-chamber system was closed tightly with suitable caps and stirred at 80oC for 18 
hours. The resulting mixture of Chamber A was filtered through celite and concentrated using a rotary 
evaporator. The crude was purified by column chromatography with heptane : EtOAc (9:1) eluent.  
7. Control experiments on methoxycarbonylation.  
Transesterification in the absence of Pd-catalyst 
10 mL pressure vial was sequentially charged with tert-butyl 2-naphthoate (26 mg, 1.0 equiv), tBuONa (1.5 
equiv) and dry DMC (3 mL). The pressure vial was closed tightly with suitable cap and stirred at 80oC for 18 
hours. The resulting mixture was filtered through celite and concentrated using a rotary evaporator. The 
crude was purified by column chromatography with heptane : EtOAc (9:1) eluent.  
Transesterification in the presence of Pd-catalyst 
10 mL pressure vial was sequentially charged with tert-butyl 2-naphthoate (26 mg, 1.0 equiv), tBuONa (1.5 
equiv), Pd(dba)2 (5 mol%), 1,1ʹ-bis(diisopropylphosphino)ferrocene (dippf) (5 mol%) and dry DMC (3 mL). The 
pressure vial was closed tightly with suitable cap and stirred at 80oC for 18 hours. The resulting mixture was 
filtered through celite and concentrated using a rotary evaporator. The crude was purified by column 
chromatography with heptane : EtOAc (9:1) eluent.  
Pd-catalyzed methoxycarbonylation with sodium methoxide 
Chamber A was sequentially charged with 2-bromonaphthalene (50 mg, 1.0 equiv), MeONa (1.5 equiv), 
Pd(dba)2 (5 mol%), 1,1ʹ-bis(diisopropylphosphino)ferrocene (dippf) (5 mol%) and dry DMC (3 mL).  
Chamber B was sequentially charged with COgen (2 equiv), Pd(dba)2 (5 mol%), tri-tert-butylphosphonium 
tetrafluoroborate (TTBP•HBF4) (5 mol%), 1,4-dioxane (3 mL) and DIPEA (3 equiv). Addition of DIPEA initialize 
the release of CO. The two-chamber system was closed tightly with suitable caps and stirred at 80oC for 18 
hours. The resulting mixture of Chamber A was filtered through celite and concentrated using a rotary 





8. Characterisation of products  
 
Bis(3-methoxyphenyl)methanone, 3a.2 1-Bromo-3-methoxybenzene (50 mg, 
0.26 mmol) was reacted with (3-methoxyphenyl)boronic acid (48 mg, 0.32 
mmol) according to the general procedure A to provide the product (57 mg, 
89%) as red oil. 1H NMR (400 MHz, CDCl3): δ = 7.24-7.20 (m, 6H), 7.00-6.99 
(m, 2H), 3.72 (s, 6H). 13C NMR (101 MHz, CDCl3): δ = 196.6, 159.9, 139.3, 129.6, 123.2, 119.2, 114.7, 55.8. 
HRMS (ESI): Calcd. for C15H14O3Na [M+Na]+ 265.0835; found 265.0837. 
Methyl 2-(3-methoxybenzoyl)benzoate, 3b.3 1-Bromo-3-methoxybenzene (50 
mg, 0.26 mmol) was reacted with (2-(methoxycarbonyl)phenyl)boronic acid (57 
mg, 0.32 mmol) according to the general procedure A to provide the product (25 
mg, 40%) as yellow oil. 1H NMR (400 MHz, CDCl3): δ = 7.90 (d, J = 8.7 Hz, 1H), 7.61-7.46 (m, 1H), 7.46-7.33 
(m, 1H), 7.28 (s, 2H), 7.21-7.08 (m, 1H), 7.05 (d, J = 7.7 Hz, 1H), 6.96 (dd, J = 8.7, 3.2 Hz, 1H), 3.70 (s, 3H), 3.50 
(s, 3H). 13C NMR (101 MHz, CDCl3): δ = 196.9, 166.5, 159.9, 141.8, 138.6, 132.5, 131.2, 130.1, 129.7, 129.6, 
129.0, 127.8, 122.5, 119.8, 113.0, 55.5, 52.3. HRMS (ESI): Calcd. for C16H14O4Na [M+Na]+ 293.0784; found 
293.0787.  
(3-Methoxyphenyl)(m-tolyl)methanone, 3c.4 1-Bromo-3-methoxybenzene (50 
mg, 0.26 mmol) was reacted with m-tolylboronic acid (44 mg, 0.32 mmol) 
according to the general procedure A to provide the product (48 mg, 80%) as 
yellow oil. 1H NMR (400 MHz, CDCl3): δ = 7.63 (s, 1H), 7.58 (d, J = 7.3 Hz, 1H), 7.43-7.29 (m, 5H), 7.14-7.11 
(m, 1H), 3.85 (s, 3H), 2.41 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 196.8, 159.6, 139.1, 138.2, 137.7, 133.3, 
130.5, 129.2, 128.1, 127.4, 122.9, 118.8, 114.4, 55.5, 21.4. HRMS (ESI): Calcd. for C15H14O2Na [M+Na]+ 
249.0886; found 249.0886.  
(3-Methoxyphenyl)(o-tolyl)methanone, 3d.5 1-Bromo-3-methoxybenzene (50 mg, 
0.26 mmol) was reacted with o-tolylboronic acid (44 mg, 0.32 mmol) according to 
the general procedure A to provide the product (57 mg, 79%) as brown oil. 1H NMR 
(400 MHz, CDCl3): δ = 7.47-7.46 (m, 1H), 7.45-7.40 (m, 1H), 7.38-7.36 (m, 1H), 7.35-7.33 (m, 1H), 7.32-7.31 
(m, 2H), 7.30-7.28 (m, 1H), 7.18-7.15 (m, 1H), 3.88 (s, 3H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 198.5, 
159.8, 139.2, 138.7, 136.8, 131.1, 130.3, 129.5, 128.5, 125.3, 123.4, 119.9, 113.9, 55.5. HRMS (ESI): Calcd. 
for C15H14O2Na [M+Na]+ 249.0886; found 249.0886.  
(3-Methoxyphenyl)(naphthalen-2-yl)methanone, 3e.6 1-Bromo-3-
methoxybenzene (50 mg, 0.26 mmol) was reacted with naphthalen-2-ylboronic 
acid (55 mg, 0.32 mmol) according to the general procedure A to provide the 









(m, 2H), 7.61 (t, J = 7.5 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.43-7.40 (m, 3H), 7.22-7.10 (m, 1H), 3.87 (s, 3H). 13C 
NMR (101 MHz, CDCl3): δ = 196.6, 159.7, 139.3, 135.4, 134.9, 132.3, 131.9, 129.5, 129.4, 128.4, 128.4, 127.9, 
126.9, 125.9, 123.0, 118.9, 114.5, 55.6. HRMS (ESI): Calcd. for C18H14O2Na [M+Na]+ 285.0886; found 
285.0889.  
(3-Fluorophenyl)(3-methoxyphenyl)methanone, 3f.7 1-Bromo-3-
methoxybenzene (50 mg, 0.26 mmol) was reacted with (3-
fluorophenyl)boronic acid (44 mg, 0.32 mmol) according to the general 
procedure A to provide the product (59 mg, 96%) as yellow oil. 1H NMR (400 
MHz, CDCl3): δ = 7.58 (d, J = 7.7 Hz, 1H), 7.51-7.49 (m 1H), 7.48-7.43 (m, 1H), 7.41-7.37 (m, 1H), 7.35 (s, 1H), 
7.33 (s, 1H), 7.32-7.27 (m, 1H), 7.15 (dd, J = 8.1, 3.7 Hz, 1H), 3.86 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 195.2 
(d, J = 2.3Hz), 162.6 (d, J = 248.2 Hz), 159.8, 139.8 (d, J = 6.4 Hz), 138.5, 130.1 (d, J = 7.7 Hz), 129.5, 125.9 (d, 
J = 3.2 Hz), 122.9, 119.6 (d, J = 21.3 Hz), 119.3, 116.9 (d, J = 22.6 Hz), 114.4, 55.6. HRMS (ESI): Calcd. for 
C14H11O2FNa [M+Na]+ 253.0635; found 253.0637.  
3-(3-Methoxybenzoyl)benzonitrile, 3g.8 1-Bromo-3-methoxybenzene (50 mg, 
0.26 mmol) was reacted with (3-cyanophenyl)boronic acid (47 mg, 0.32 mmol) 
according to the general procedure A to provide the product (45 mg, 71%) as 
yellow oil. 1H NMR (400 MHz, CDCl3): δ = 8.06 (s, 1H), 8.02 (d, J = 7.9 Hz, 1H), 
7.85 (d, J = 7.9 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.32 (s, 1H), 7.28-7.25 (m, 1H), 7.18-
7.15 (m, 1H), 3.86 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 194.3, 159.9, 138.8, 137.7, 135.4, 133.9, 133.5, 
129.7, 129.5, 122.8, 119.7, 118.0, 114.4, 112.9, 55.6. HRMS (ESI): Calcd. for C15H12NO2 [M+H]+ 238.0863; 
found 238.0882.  
Dibenzo[b,d]furan-4-yl(3-methoxyphenyl)methanone, 3h. 1-Bromo-3-
methoxybenzene (50 mg, 0.26 mmol) was reacted with dibenzo[b,d]furan-
4-ylboronic acid (68 mg, 0.32 mmol) according to the general procedure A 
to provide the product (76 mg, 95%) as orange oil. 1H NMR (400 MHz, 
CDCl3): δ = 8.15 (d, J = 8.8 Hz, 1H), 8.00 (d, J = 8.2 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.52-
7.51 (m, 1H), 7.49-7.45 (m, 1H), 7.44-7.43 (m, 1H), 7.42-7.41 (m, 1H), 7.40-7.35 (m, 2H), 7.18-7.16 (m, 1H), 
3.86 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 193.8, 159.8, 156.5, 154.0, 139.1, 129.4, 128.7, 127.9, 125.7, 
124.2, 123.5, 123.4, 123.3, 122.5, 120.8, 119.9, 114.2, 112.3, 55.6. IR (ATR, cm–1) ν = 2959 (s), 2929 (s), 1873 
(m), 1719 (s), 1614 (w), 1462 (w), 1369 (s), 1294 (s), 1261 (s), 1171 (s), 1123 (s), 780 (s). HRMS (ESI): Calcd. 
for C20H14O3Na [M+Na]+ 325.0835; found 325.0840.  
(3-(Dimethylamino)phenyl)(3-methoxyphenyl)methanone, 3i. 1-Bromo-3-
methoxybenzene (50 mg, 0.26 mmol) was reacted with 3-








general procedure A to provide the product (56 mg, 82%) as yellow oil. 1H NMR (400 MHz, CDCl3): δ = 7.30-
7.27 (m, 3H), 7.24-7.14 (m, 1H), 7.09-7.08 (m, 1H), 7.04-6.99 (m, 1H), 6.97 (d, J = 7.6 Hz, 1H), 6.85-7.83 (m, 
1H), 3.76 (s, 3H), 2.90 (s, 6H). 13C NMR (101 MHz, CDCl3): δ = 197.6, 159.7, 150.8, 139.7, 138.7, 129.5, 129.1, 
123.3, 119.1, 119.1, 116.8, 114.8, 113.6, 55.9, 40.9. HRMS (ESI): Calcd. for C16H17O2NNa [M+Na]+ 278.1151; 
found 278.1156.  
(3-Methoxyphenyl)(thiophen-3-yl)methanone, 3j.9 1-Bromo-3-methoxybenzene 
(50 mg, 0.26 mmol) was reacted with thiophen-2-ylboronic acid (41 mg, 0.32 mmol) 
according to the general procedure A to provide the product (45 mg, 77%) as 
orange oil. 1H NMR (400 MHz, CDCl3): δ = 7.72 (d, J = 6.1 Hz, 1H), 7.67 (d, J = 4.9 Hz, 
1H), 7.47-7.41 (m, 1H), 7.40-7.38 (m, 2H), 7.17-7.15 (m, 1H), 7.14-7.12 (m, 1H), 3.87 (s, 3H).13C NMR (101 
MHz, CDCl3): δ = 188.1, 159.7, 143.7, 139.6, 135.0, 134.4, 129.5, 128.1, 121.9, 118.8, 113.9, 55.6. HRMS (ESI): 
Calcd. for C12H10O2NaS [M+Na]+ 241.0294; found 241.0295.  
Benzo[b]thiophen-3-yl(3-methoxyphenyl)methanone, 3k. 1-Bromo-3-
methoxybenzene (50 mg, 0.26 mmol) was reacted with benzo[b]thiophen-3-
ylboronic acid (57 mg, 0.32 mmol) according to the general procedure A to 
provide the product (47 mg, 80%) as orange oil. 1H NMR (400 MHz, CDCl3): δ 8.58 
(d, J = 8.2 Hz, 1H), 8.02 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.52 (t, J = 8.2 Hz, 1H), 7.47-7.43 (m, 1H), 7.40-7.42 (m, 
2H), 7.17- 7.15 (m, 1H), 7.14-7.12 (m, 1H), 3.87 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 190.6, 159.8, 140.7, 
140.1, 138.4, 137.5, 134.8, 129.5, 125.8, 125.7, 125.3, 122.4, 122.3, 118.8, 114.0, 55.6. HRMS (ESI): Calcd. 
for C16H12O2NaS [M+Na]+ 291.0450; found 291.0453.  
Quinolin-6-yl(m-tolyl)methanone, 3l. 6-Bromoquinoline (50 mg, 0.24 mmol) was 
reacted with m-tolylboronic acid (39 mg, 0.29 mmol) according to the general 
procedure A to provide the product (54 mg, 91%) as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ = 9.02 (d, J = 5.9 Hz, 1H), 8.25 (s, 1H), 8.22-8.21 (m, 1H), 8.19 (s, 1H), 8.15-8.13 (m, 1H), 7.67 (s, 1H), 
7.61 (d, J = 7.4 Hz, 1H), 7.48 (dd, J = 8.3, 4.2 Hz, 1H), 7.41 (dt, J = 14.9, 7.6 Hz, 2H), 2.43 (s, 3H). 13C NMR (101 
MHz, CDCl3): δ = 196.4, 152.6, 149.9, 138.5, 137.6, 137.5, 135.8, 133.6, 131.4, 130.6, 129.9, 129.7, 128.4, 
127.5, 127.4, 122.1, 21.5. HRMS (ESI): Calcd. for C17H13ONNa [M+Na]+ 270.0889; found 270.0893.  
(4-Methoxyphenyl)(m-tolyl)methanone, 3m.4 1-Bromo-4-methoxybenzene (50 
mg, 0.28 mmol) was reacted with m-tolylboronic acid (44 mg, 0.32 mmol) 
according to the general procedure A to provide the product (45 mg, 75%) as 
yellow oil. 1H NMR (400 MHz, CDCl3): δ = 7.83 (d, J = 8.9 Hz, 2H), 7.58 (s, 1H), 7.53 (d, J = 7.0 Hz, 1H), 7.39-
7.33 (m, 2H), 6.96 (d, J = 8.9 Hz, 2H), 3.89 (s, 3H), 2.42 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 195.9, 163.3, 
138.5, 138.2, 132.8, 132.7, 130.4, 130.3, 128.1, 127.1, 113.6, 55.6, 21.5. HRMS (ESI): Calcd. for C15H14O2Na 








4-(3-Methylbenzoyl)benzonitrile, 3n.10 4-Bromobenzonitrile (50 mg, 0.27 mmol) 
was reacted with m-tolylboronic acid (45 mg, 0.33 mmol) according to the general 
procedure A to provide the product (50 mg, 83%) as white solid. Mp 118-121 oC. 
1H NMR (400 MHz, CDCl3): δ = 7.86 (d, J = 8.5 Hz, 2H), 7.78 (d, J = 8.5 Hz, 2H), 7.60 (s, 1H), 7.54 (d, J = 7.5 Hz, 
1H), 7.45 (d, J = 7.5 Hz, 1H), 7.40-7.37 (m, 1H), 2.43 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 195.4, 141.5, 
138.7, 136.5, 134.2, 132.3, 130.3, 128.6, 127.5, 118.2, 115.7, 21.5. HRMS (ESI): Calcd. for C15H12ON [M+H]+ 
222.0913; found 222.0914.  
m-Tolyl(p-tolyl)methanone, 3o.11 1-Bromo-4-methylbenzene (50 mg, 0.29 mmol) 
was reacted with m-tolylboronic acid (48 mg, 0.35 mmol) according to the general 
procedure A to provide the product (48 mg, 79%) as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ = 7.65 (d, J = 8.0 Hz, 2H), 7.54 (s, 1H), 7.50-7.48 (m, 1H), 7.34-7.28 (m, 2H), 7.21 (d, J = 8.0 Hz, 2H), 
2.37 (s, 3H), 2.35 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 196.8, 143.2, 138.1, 138.1, 135.1, 133.0, 130.4, 130.4, 
129.0, 128.1, 127.3, 21.7, 21.5. HRMS (ESI): Calcd. for C15H14ONa [M+Na]+ 233.0937; found 233.0938.  
4-(3-Methylbenzoyl)benzaldehyde, 3p. 4-Bromobenzaldehyde (50 mg, 0.27 
mmol) was reacted with m-tolylboronic acid (44 mg, 0.32 mmol) according to the 
general procedure A to provide the product (50 mg, 83%) as white solid. Mp 79-
82 oC. 1H NMR (400 MHz, CDCl3): δ = 10.12 (s, 1H), 7.99 (d, J = 8.2 Hz, 2H), 7.90 (d, J = 8.2 Hz, 2H), 7.62 (s, 
1H), 7.56 (d, J = 7.5 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.39-7.35 (m, 1H), 2.42 (s, 3H). 13C NMR (101 MHz, CDCl3): 
δ = 196.1, 191.7, 142.8, 138.6, 136.9, 134.0, 130.4, 129.6, 128.4, 127.5, 21.5. HRMS (ESI): Calcd. for C15H13O2 
[M+H]+ 225.0910; found 225.0907.  
N-Methyl-N-phenyl-3,5-bis(trifluoromethyl)benzamide, 5a. 1-Bromo-3,5-
bis(trifluoromethyl)benzene (50 mg, 29.5 µl, 0.17 mmol) was reacted with N-
methyl aniline (28 µl, 0.26 mmol) according to the general procedure B to provide 
the product (30 mg, 51%) as white solid. Mp 85-88 oC. 1H NMR (400 MHz, CDCl3): 
δ = 7.73 (s, 3H), 7.30-7.27 (m, 2H), 7.24-7.20 (m, 1H), 7.04 (d, J = 7.4 Hz, 2H), 3.54 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ = 167.3, 143.9, 137.9, 131.3 (q, J = 33.6 Hz), 130.8, 129.9, 129.3, 127.8, 127.1, 124.3, 123.7-122.8 
(m), 121.6, 118.9, 38.6. HRMS (ESI): Calcd. for C16H11ONF6Na [M+Na]+ 370.0637; found 370.0641.  
4-Formyl-N-methyl-N-phenylbenzamide, 5b.12 4-Bromobenzaldehyde (50 mg, 0.27 
mmol) was reacted with N-methyl aniline (43 µl, 0.43 mmol) according to the general 
procedure B to provide the product (66 mg, 99%) as colourless oil. 1H NMR (400 
MHz, CDCl3): δ = 9.90 (s, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.22-7.18 (m, 2H), 7.15-7.12 (m, 
1H), 7.02-7.00 (d, J = 7.5 Hz, 2H), 3.49 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 191.6, 169.4, 144.2, 141.8, 










N-Methyl-N-phenyl-4-(trifluoromethyl)benzamide, 5c.13 4-Bromobenzotrifluoride 
(50 mg, 31.1 µl, 0.22 mmol) was reacted with N-methyl aniline (36 µl, 0.33 mmol) 
according to the general procedure B to provide the product (61 mg, 98%) as white 
solid. Mp 80-83 oC. 1H NMR (400 MHz, CDCl3): δ = 7.43-7.38 (m, 4H), 7.25-7.21 (m, 2H), 7.18-7.14 (m, 1H), 
7.02 (d, J = 7.5 Hz, 2H), 3.50 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 169.2, 144.3, 139.6, 131.4 (q, J = 32.6 Hz), 
129.5, 129.1, 127.8, 127.1, 127.0, 125.1, 124.9 (q, J = 3.8 Hz), 122.4, 119.7, 38.5. HRMS (ESI): Calcd. for 
C15H13ONF3 [M+H]+ 280.0944; found 280.0948.  
N-Methyl-N-phenyl-3-(trifluoromethyl)benzamide, 5d.14 3-Bromobenzotrifluoride 
(50 mg, 36 µl, 0.22 mmol) was reacted with N-methyl aniline (36 µl, 0.33 mmol) 
according to the general procedure B to provide the product (54 mg, 87%) as yellow 
oil. 1H NMR (400 MHz, CDCl3): δ = 7.53 (s, 1H), 7.43 (t, J = 6.6 Hz, 2H), 7.24-7.22 (m, 1H), 7.20 (d, J = 7.6 Hz, 
2H), 7.15-7.12 (m, 1H), 7.00 (d, J = 7.6 Hz, 2H), 3.48 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 169.4, 144.4, 
136.7, 132.0, 130.3 (q, J = 32.7 Hz), 129.8, 129.5, 128.4, 127.1, 127.0, 126.3 (q, J = 3.8 Hz), 125.9 (q, J = 3.8 
Hz), 125.0, 122.3, 38.5. HRMS (ESI): Calcd. for C15H13ONF3 [M+H]+ 280.0944; found 280.0948.  
3-Methoxy-N-methyl-N-phenylbenzamide, 5e.15 1-Bromo-3-methoxybenzene (50 
mg, 33.8 µ, 0.27 mmol) was reacted with N-methyl aniline (44 µl, 0.43 mmol) 
according to the general procedure B to provide the product (40 mg, 62%) as yellow 
oil. 1H NMR (400 MHz, CDCl3): δ = 7.24-7.20 (m, 2H), 7.15-7.11 (m, 1H), 7.06-7.02 (m, 3H), 6.86 (s, 1H), 6.84-
6.82 (m, 1H), 6.77-6.75 (m, 1H), 3.64 (s, 3H), 3.48 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 170.5, 159.0, 145.0, 
137.2, 129.2, 128.8, 126.9, 126.6, 121.3, 116.1, 113.8, 55.3, 38.5. HRMS (ESI): Calcd. for C15H15O2NNa [M+Na]+ 
264.0995; found 264.0997.  
4-(tert-Butyl)-N-methyl-N-phenylbenzamide, 5f.16 1-Bromo-4-(tert-butyl)benzene 
(50 mg, 40.7 µl, 0.23 mmol) was reacted with N-methyl aniline (38 µl, 0.35 mmol) 
according to the general procedure B to provide the product (22 mg, 35%) as white 
solid. Mp 100-103 oC. 1H NMR (400 MHz, CDCl3): δ = 7.25-7.22 (m, 4H), 7.18 (s, 1H), 7.17-7.12 (m, 2H), 7.05 
(d, J = 7.3 Hz, 2H), 3.49 (s, 3H), 1.22 (s, 9H). 13C NMR (101 MHz, CDCl3): δ = 170.7, 153.0, 145.3, 132.9, 129.2, 
128.8, 127.0, 126.5, 124.7, 38.7, 34.8, 31.4, 31.2. HRMS (ESI): Calcd. for C18H21ONNa [M+Na]+ 290.1515; 
found 290.1526.  
N,3-Dimethyl-N-phenylbenzamide, 5g.17 1-Bromo-3-methylbenzene (50 mg, 35.6 µl, 
0.29 mmol) was reacted with N-methyl aniline (47 µl, 0.43 mmol) according to the 
general procedure B to provide the product (42 mg, 64%) as yellow oil. 1H NMR (400 
MHz, CDCl3): δ = 7.24-7.20 (m, 3H), 7.14-7.11 (m, 1H), 7.04-7.02 (m, 3H), 7.00-6.99 (m, 2H), 3.48 (s, 3H), 2.21 
(s, 3H). 13C NMR (101 MHz, CDCl3): δ = 170.9, 145.1, 137.6, 135.9, 130.4, 129.5, 129.2, 127.5, 127.0, 126.5, 









4-Cyano-N-methyl-N-phenylbenzamide, 5h.18 4-Bromobenzonitrile (50 mg, 0.27 
mmol) was reacted with N-methyl aniline (45 µl, 0.43 mmol) according to the general 
procedure B to provide the product (63 mg, 97%) as colourless oil. 1H NMR (400 MHz, 
CDCl3): δ = 7.43 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.24-7.20 (m, 2H), 7.17-7.13 (m, 1H), 7.00-6.98 (d, 
J = 7.5 Hz, 2H), 3.47 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 168.3, 143.6, 140.0, 131.3, 129.2, 128.9, 126.9, 
126.6, 117.8, 112.8, 38.0. HRMS (ESI): Calcd. for C15H13ON2 [M+H]+ 237.1022; found 237.1033.  
4-Fluoro-N-methyl-N-phenylbenzamide, 5i.15 1-Bromo-4-fluorobenzene (50 mg, 32 µl, 
0.28 mmol) was reacted with N-methyl aniline (46.4 µl, 0.43 mmol) according to the 
general procedure B to provide the product (53 mg, 81%) as orange oil. 1H NMR (400 
MHz, CDCl3): δ = 7.32-7.30 (m, 2H), 7.28-7.22 (m, 2H), 7.18-7.15 (m, 1H), 7.03-7.02 (m, 2H), 6.84 (t, J = 8.7 
Hz, 2H), 3.49 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 169.7, 163.3 (d, J = 250.2 Hz), 145.0, 132.0, 132.0, 131.2 
(d, J = 8.6 Hz), 129.4, 127.0, 126.8, 114.9 (d, J = 21.8 Hz), 38.6. HRMS (ESI): Calcd. for C14H12ONFNa [M+Na]+ 
252.0795; found 252.0798.  
N-Methyl-N-phenylquinoline-6-carboxamide, 5j.19 6-Bromo-quinoline (50 mg, 32.5 
µl, 0.24 mmol) was reacted with N-methyl aniline (39 µl, 0.35 mmol) according to the 
general procedure B to provide the product (41mg, 65%) as colourless oil. 1H NMR 
(400 MHz, CDCl3): δ = 8.88 (d, J = 5.9 Hz, 1H), 8.03 (d, J = 9.0 Hz, 1H), 7.88 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.53 
(d, J = 8.8 Hz, 1H), 7.36 (dd, J = 8.3, 4.2 Hz, 1H), 7.22-7.18 (m, 2H), 7.13-7.12 (m, 1H), 7.08-7.06 (m, 2H), 3.56 
(s, 3H). 13C NMR (101 MHz, CDCl3): δ = 169.9, 151.6, 148.3, 144.7, 136.8, 134.3, 129.5, 129.3, 129.3, 128.9, 
127.5, 127.1, 126.9, 121.7, 38.7. HRMS (ESI): Calcd. for C17H14ON2Na [M+Na]+ 285.0998; found 285.1004.  
Methyl 3-(methyl(phenyl)carbamoyl)benzoate, 5k. Methyl 3-bromobenzoate 
(50 mg, 0.23 mmol) was reacted with N-methyl aniline (38 µl, 0.35 mmol) 
according to the general procedure B to provide the product (52 mg, 83%) as 
colourless oil. 1H NMR (400 MHz, CDCl3): δ = 8.00 (s, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.22-
7.18 (m, 2H), 7.15-7.11 (m, 2H), 7.03 (d, J = 7.4 Hz, 2H), 3.83 (s, 3H), 3.49 (s, 3H). 13C NMR (101 MHz, CDCl3): 
δ = 169.7, 166.3, 144.6, 136.4, 132.9, 130.7, 130.1, 129.9, 129.4, 128.0, 127.1, 126.9, 52.3, 38.5. HRMS (ESI): 
Calcd. for C16H15O3NNa [M+Na]+ 292.0944; found 292.0949.  
N-Methyl-N-phenyl-2-naphthamide, 5l.17 2-Bromonaphthalene (50 mg, 0.24 mmol) 
was reacted with N-methyl aniline (40 µl, 0.40 mmol) according to the general 
procedure B to provide the product (64 mg, 99%) as colourless oil. 1H NMR (400 
MHz, CDCl3): δ = 7.91 (s, 1H), 7.71 (d, J = 7.8 Hz, 2H), 7.59 (d, J = 8.6 Hz, 1H), 7.47-7.40 (m, 2H), 7.33 (d, J = 
8.5 Hz, 1H), 7.21-7.17 (m, 2H), 7.12-7.07 (m, 3H), 3.56 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 170.3, 144.7, 
133.3, 133.0, 132.1, 129.2, 129.0, 128.4, 127.3, 127.0, 126.9, 126.6, 126.2, 126.0, 125.2, 38.3. HRMS (ESI): 









3-Cyano-N-methyl-N-phenylbenzamide, 5m. 3-Bromobenzonitrile (50 mg, 0.27 
mmol) was reacted with N-methyl aniline (45 µl, 0.43 mmol) according to the 
general procedure B to provide the product (61 mg, 94%) as white solid. Mp 72-75 
oC. 1H NMR (400 MHz, CDCl3): δ = 7.54 (s, 1H), 7.48-7.45 (m, 2H), 7.24-7.20 (m, 3H), 7.17-7.15 (m, 1H), 6.99 
(d, J = 7.6 Hz, 2H), 3.46 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 168.2, 144.0, 137.3, 133.0, 132.9, 132.4, 129.6, 
128.8, 127.4, 127.0, 118.1, 112.2, 38.5. HRMS (ESI): Calcd. for C15H13ON2 [M+H]+ 237.1022; found 237.1033.  
4-Methoxy-N-methyl-N-phenylbenzamide, 5n.13 1-Bromo-4-methoxybenzene (50 
mg, 33.5 µl, 0.27 mmol) was reacted with N-methyl aniline (44 µl, 0.43 mmol) 
according to the general procedure B to provide the product (10 mg, 16%) as yellow 
oil. 1H NMR (400 MHz, CDCl3): δ = 7.27-7.23 (m, 2H), 7.21 (d, J = 7.9 Hz, 2H), 7.13 (t, J = 7.4 Hz, 1H), 7.02 (d, J 
= 8.2 Hz, 2H), 6.64 (d, J = 8.9 Hz, 2H), 3.72 (s, 3H), 3.47 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 170.4, 160.7, 
145.6, 131.0, 129.3, 128.1, 127.0, 126.4, 113.1, 55.3, 38.8. HRMS (ESI): Calcd. for C15H15O2NNa [M+Na]+ 
264.0995; found 264.0997.  
4-Cyano-N-(4-methoxyphenyl)benzamide, 5o.20 4-Bromobenzonitrile (50 mg, 
0.27 mmol) was reacted with p-anisidine (50 mg, 0.41 mmol) according to the 
general procedure B to provide the product (60 mg, 87%) as white solid. Mp 157-
160 oC. 1H NMR (400 MHz, CDCl3): δ = 7.96 (d, J = 8.4 Hz, 2H), 7.78-7.76 (m, 3H), 7.52 (d, J = 8.4 Hz, 2H), 6.92 
(d, J = 8.9 Hz, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 163.9, 157.2, 139.1, 132.7, 130.4, 127.9, 122.4, 
118.1, 114.5, 55.7. HRMS (ESI): Calcd. for C15H12O2N2Na [M+Na]+ 275.0791; found 275.0795.  
4-Cyano-N-(p-tolyl)benzamide, 5p.21 4-Bromobenzonitrile (50 mg, 0.27 mmol) was 
reacted with p-toluidine (44 mg, 0.41 mmol) according to the general procedure B 
to provide the product (60 mg, 90%) as white solid. Mp 178-180 oC. 1H NMR (400 
MHz, CDCl3): δ = 7.96 (d, J = 8.2 Hz, 2H), 7.81 (bs, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.19 (d, 
J = 8.3 Hz, 2H), 2.35 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 162.3, 139.1, 135.2, 134.8, 132.7, 129.9, 127.9, 
120.6, 118.1, 115.5, 21.1. HRMS (ESI): Calcd. for C15H12ON2 [M+Na]+ 237.1022; found 237.1024.  
4-Cyano-N-(3-(trifluoromethyl)phenyl)benzamide, 5q. 4-Bromobenzonitrile (50 
mg, 0.27 mmol) was reacted with 3-(trifluoromethyl)aniline (51.4 µl, 0.41 mmol) 
according to the general procedure B to provide the product (68 mg, 85%) as 
white solid. Mp 166-168 oC. 1H NMR (400 MHz, CDCl3): δ = 8.01 (m, 3H), 7.93 (s, 1H), 7.86 (d, J = 8.1 Hz, 1H), 
7.80 (d, J = 8.3 Hz, 2H), 7.52 (t, J = 7.9 Hz, 1H), 7.47-7.44 (m, 1H). 13C NMR (101 MHz, CDCl3): δ = 164.2, 138.4, 
137.9, 132.9, 131.8 (d, J = 32.7 Hz), 130.0, 127.9, 123.6, 121.9 (d, J = 3.7 Hz), 117.9, 117.3 (d, J = 4.0 Hz), 115.9. 










Bromobenzonitrile (50 mg, 0.27 mmol) was reacted with 2-(4-
(aminomethyl)phenoxy)-N,N-dimethylethan-1-amine (80 mg, 0.41 
mmol) according to the general procedure B to provide the product (80 mg, 90%) as white solid. Mp 109-112 
oC. 1H NMR (400 MHz, CDCl3): δ = 7.87 (d, J = 8.5 Hz, 2H), 7.72-7.25 (d, J = 8.5 Hz, 2H), 7.25 (m, 2H), 6.90 (d, J 
= 8.7 Hz, 2H), 6.45 (bs, 1H), 4.57 (d, J = 5.5 Hz, 2H), 4.08 (t, J = 5.6 Hz, 2H), 2.78 (t, J = 5.6 Hz, 2H), 2.38 (s, 6H). 
13C NMR (101 MHz, CDCl3): δ = 165.6, 158.6, 138.5, 132.6, 129.9, 129.5, 127.8, 118.1, 115.3, 115.1, 66.0, 58.2, 
45.9, 44.1. HRMS (ESI): Calcd. for C19H22O2N3 [M+H]+ 324.1707; found 324.1714.  
4-(Morpholine-4-carbonyl)benzonitrile, 5s.22 4-Bromobenzonitrile (50 mg, 0.27 mmol) 
was reacted with morpholine (36 µl, 0.41 mmol) according to the general procedure B 
to provide the product (55 mg, 93%) as white solid. Mp 143-145.6 oC. 1H NMR (400 
MHz, CDCl3): δ = 7.70 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 3.75-3.60 (m, 6H), 3.41-3.35 (m, 2H). 13C NMR 
(101 MHz, CDCl3): δ = 165.8, 138.3, 137.7, 132.5, 128.9, 127.9, 127.9, 127.8, 118.1, 115.1, 44.3. HRMS (ESI): 
Calcd. for C12H12O2N2Na [M+Na]+ 239.0791; found 239.0809.  
N-Benzyl-4-cyanobenzamide, 5t.23 4-Bromobenzonitrile (50 mg, 0.27 mmol) was 
reacted with phenylmethanamine (45 µl, 0.41 mmol) according to the general 
procedure B to provide the product (61 mg, 94%) as white solid. Mp 148-150 oC. 
1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.36-7.27 (m, 5H), 6.93 (bs, 1H), 
4.59 (d, J = 5.7 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ = 165.8, 138.3, 137.7, 132.5, 128.9, 127.9, 127.9, 127.8, 
118.1, 115.1, 44.3. HRMS (ESI): Calcd. for C15H12ON2Na [M+Na]+ 259.0842; found 259.0841.  
N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4,5-
trimethoxybenzamide, 5u. 5-Bromo-1,2,3-trimethoxybenzene 
(50 mg, 0.20 mmol) was reacted with 2-(4-
(aminomethyl)phenoxy)-N,N-dimethylethan-1-amine (78 mg, 
0.40 mmol) and XantPhos Pd G3 (38 mg, 2 mol%) according to the general procedure B to provide the product 
(75 mg, 95%) as white solid. Mp 105-108 oC. 1H NMR (400 MHz, CDCl3): δ = 7.22 (d, J = 8.6 Hz, 2H), 7.04 (s, 
2H), 6.89 (bs, 1H), 6.82 (d, J = 8.6 Hz, 2H), 4.49 (d, J = 5.7 Hz, 2H), 4.07 (t, J = 5.5 Hz, 2H), 3.82 (s, 9H), 2.82 (t, 
J = 5.5 Hz, 2H), 2.39 (s, 6H). 13C NMR (101 MHz, CDCl3): δ = 167.0, 158.0, 153.1, 140.8, 130.9, 129.9, 129.3, 
114.7, 104.6, 65.4, 60.9, 58.0, 56.6, 45.5, 43.6. HRMS (ESI): Calcd. for C21H29O5N2 [M+H]+ 389.2071; found 
389.2080.  
Morpholino(3,4,5-trimethoxyphenyl)methanone, 5v.24 5-Bromo-1,2,3-
trimethoxybenzene (50 mg, 0.20 mmol) was reacted with morpholine (36 µl, 0.40 
mmol) and XantPhos Pd G3 (38 mg, 2 mol%) according to the general procedure B to 









CDCl3): δ = 6.59 (s, 2H), 3.84-3.82 (m, 10H), 3.65 (bs, 7H). 13C NMR (101 MHz, CDCl3): δ = 170.5, 153.7, 139.7, 
131.0, 104.7, 67.3, 61.3, 56.6. HRMS (ESI): Calcd. for C14H19O5NNa [M+Na]+ 304.1155; found 304.1165.  
 
tert-Butyl 2-naphthoate, 7a.25 2-Bromonaphthalen (50 mg, 0.24 mmol) was reacted 
with tBuONa (34 mg, 0.35 mmol) according to the general procedure C to provide the 
product (51 mg, 93%) as yellow oil. 1H NMR (400 MHz, CDCl3): δ = 8.56 (s, 1H), 8.06-
8.03 (m, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.87-7.85 (m, 2H), 7.62-7.47 (m, 2H), 1.67 (s, 9H). 13C NMR (101 MHz, 
CDCl3): δ = 166.0, 135.4, 132.6, 130.8, 129.4, 128.0, 128.0, 127.8, 126.6, 125.5, 81.2, 28.4. HRMS (ESI): Calcd. 
for C15H16O2Na [M+Na]+ 251.1043; found 251.1044.  
tert-Butyl 4-methoxybenzoate, 7b.25 1-Bromo-4-methoxybenzene (50 mg, 33.5 µl, 0.27 
mmol) was reacted with tBuONa (39 mg, 0.36 mmol) according to the general 
procedure C to provide the product (54 mg ,98%) as colourless oil. 1H NMR (400 MHz, 
CDCl3): δ = 7.94 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 1.58 (s, 9H). 13C NMR (101 MHz, CDCl3): 
δ = 165.7, 163.1, 131.5, 124.6, 113.5, 80.6, 55.5, 28.4. HRMS (ESI): Calcd. for C12H16O3Na [M+Na]+ 231.0992; 
found 231.0988.  
tert-Butyl nicotinate, 7c.25 3-Bromopyridine (50mg, 30.5 µl, 0.32 mmol) was reacted with 
tBuONa (46 mg, 0.48 mmol) according to the general procedure C to provide the product (29 
mg, 52%) as yellow oil. 1H NMR (400 MHz, CDCl3): δ = 9.15 (s, 1H), 8.73-8.72 (m, 1H), 8.22 (d, 
J = 7.9 Hz, 1H), 7.45-7.30 (m, 1H), 1.59 (s, 9H). 13C NMR (101 MHz, CDCl3): δ = 164.5, 153.0, 151.0, 137.0, 
127.9, 123.3, 82.2, 28.3. HRMS (ESI): Calcd. for C10H14O2N [M+H]+ 180.1019; found 180.1014.  
tert-Butyl 4-cyanobenzoate, 7d.25 1-Bromo-4-benzonitrile (50mg, 0.27 mmol) was 
reacted with tBuONa (40 mg, 0.48 mmol) according to the general procedure C to 
provide the product (25 mg, 45%) as colourless oil. 1H NMR (400 MHz, CDCl3): δ = 8.07 
(d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.5 Hz, 2H), 1.60 (s, 9H). 13C NMR (101 MHz, CDCl3): δ = 164.4, 136.3, 132.5, 
130.4, 118.6, 116.3, 82.8, 28.5. HRMS (ESI): Calcd. for C12H13O2NNa [M+Na]+ 226.0838; found 226.0855.  
tert-Butyl 4-methylbenzoate, 7e.26 1-Bromo-4-methylbenzene (50mg, 0.27 mmol) was 
reacted with tBuONa (42 mg, 0.43 mmol) according to the general procedure C to 
provide the product (50 mg, 80%) as yellow oil. 1H NMR (101 MHz, CDCl3): δ = 7.88 (d, J 
= 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 2.39 (s, 3H), 1.59 (s, 9H). 13C NMR (101 MHz, CDCl3): δ = 166.3, 143.3, 









tert-butyl 4-(trifluoromethyl)benzoate, 7f.25 4-Bromobenzotrifluoride (50 mg, 31.1 µl, 
0.22 mmol) was reacted with tBuONa (40 mg, 0.48 mmol) according to the general 
procedure C to provide the product (28 mg, 51%) as yellow oil. 1H NMR (101 MHz, 
CDCl3): δ 8.10 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 1.61 (s, 9H). 13C NMR (101 MHz, 
CDCl3): δ 164.6, 135.4, 134.1 (d, J = 32.5 Hz), 129.9, 125.8 – 124.5 (m), 82.1, 28.3. HRMS (ESI): Calcd. for 
C12H13F3O2Na [M+Na]+ 269.0760; found 269.0756.  
tert-Butyl quinoline-6-carboxylate, 7g. 6-Bromoquinoline (50 mg, 0.24 mmol) was 
reacted with tBuONa (34 mg, 0.34 mmol) according to the general procedure C to 
provide the product (47 mg, 85%) as yellow oil. 1H NMR (400 MHz, CDCl3): δ = 8.97-8.96 
(m, 1H), 8.50 (s, 1H), 8.33-8.16 (m, 2H), 8.10 (d, J = 8.8 Hz, 1H), 7.43 (dd, J = 8.3, 4.2 Hz, 1H), 1.63 (s, 9H). 13C 
NMR (101 MHz, CDCl3): δ = 165.3, 152.3, 150.0, 137.4, 130.7, 130.1, 129.6, 129.2, 127.5, 121.8, 81.7, 28.3. 
HRMS (ESI): Calcd. for C14H15O2N [M+Na]+ 230.1176; found 230.1195.  
tert-Butyl 4-(tert-butyl)benzoate, 7h.25 1-Bromo-4-(tert-butyl)benzene (50 mg, 0.23 
mmol) was reacted with tBuONa (33 mg, 0.34 mmol) according to the general procedure 
C to provide the product (50 mg, 90%) as colourless oil. 1H NMR (400 MHz, CDCl3): δ = 
7.94 (d, J = 8.6 Hz, 2H), 7.44 (d, J = 8.6 Hz, 2H), 1.60 (s, 9H), 1.34 (s, 9H). 13C NMR (101 MHz, CDCl3): δ = 165.6, 
155.8, 129.1, 124.9, 80.4, 34.8, 31.0, 28.0. HRMS (ESI): Calcd. for C15H22O2Na [M+Na]+ 257.1512; found 
257.1537.  
tert-Butyl 3,4-dimethoxybenzoate, 7i.25 4-Bromo-1,2-dimethoxybenzene (50 mg, 0.23 
mmol) was reacted with tBuONa (33 mg, 0.34 mmol) according to the general 
procedure C to provide the product (51 mg, 93%) as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ = 7.62-7.60 (m, 1H), 7.51-750 (m, 1H), 6.85 (d, J = 8.4 Hz, 1H), 3.92 (s, 6H), 1.58 (s, 9H). 13C NMR 
(101 MHz, CDCl3): δ = 165.8, 152.7, 148.6, 124.7, 123.4, 112.0, 110.2, 80.8, 56.1, 28.4. HRMS (ESI): Calcd. for 
C13H18O4Na [M+Na]+ 261.1097; found 261.1095.  
tert-Butyl 3-methylbenzoate, 7j.27 1-Bromo-3-methylbenzene (50 mg, 35.6 µl, 0.27 
mmol) was reacted with tBuONa (42 mg, 0.43 mmol) according to the general 
procedure C to provide the product (32 mg, 52%) as orange oil. 1H NMR (400 MHz, 
CDCl3): δ = 7.80-7.78 (m, 2H), 7.34-7.28 (m, 2H), 2.39 (s, 3H), 1.60 (s, 9H). 13C NMR (101 MHz, CDCl3): δ = 
166.1, 138.0, 133.3, 132.1, 130.1, 128.2, 126.7, 28.4, 21.4. HRMS (ESI): Calcd. for C12H16O2Na [M+Na]+ 
215.1043; found 215.1037.  
Methyl 2-naphthoate, 8a. 1-Bromo-4-methoxybenzene (50 mg, 33.5 µl, 0.27 mmol) was 
reacted with tBuONa (39 mg, 0.36 mmol) in dimethyl carbonate according to the general 
procedure C to provide the product (49 mg, 93%) as yellow oil. 1H NMR (400 MHz, 










2H), 3.99 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 167.3, 135.6, 132.6, 131.2, 129.4, 128.3, 128.2, 127.9, 127.5, 
126.7, 125.3, 52.3. HRMS (ESI): Calcd. for C12H10O2Na [M+Na]+ 209.0573; found 209.0566.  
Methyl 4-methoxybenzoate, 8b.28 1-Bromo-4-methoxybenzene (50 mg, 33.5 µl, 0.27 
mmol) was reacted with tBuONa (39 mg, 0.36 mmol) in dimethyl carbonate according 
to the general procedure C to provide the product (40 mg, 90%) as yellow oil. 1H NMR 
(400 MHz, CDCl3): δ = 7.99 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H), 3.84 (s, 3H). 13C NMR (101 
MHz, CDCl3): δ = 167.0, 163.4, 131.7, 122.7, 113.7, 55.5, 52.0. HRMS (ESI): Calcd. for C9H10O3Na [M+H]+ 
167.0705; found 167.0717.  
Methyl nicotinate, 8c.29 3-Bromopyridine (50 mg, 30.5 µl, 0.32 mmol) was reacted with 
tBuONa (46 mg, 0.48 mmol) in dimethyl carbonate according to the general procedure C to 
provide the product (25 mg, 58%) as orange oil. 1H NMR (400 MHz, CDCl3): δ = 9.21 (s, 1H), 
8.76 (s, 1H), 8.28 (d, J = 7.9 Hz, 1H), 7.38 (dd, J = 7.7, 4.9 Hz, 1H), 3.94 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 
165.9, 153.5, 151.0, 137.1, 126.1, 123.4, 52.5. HRMS (ESI): Calcd. for C7H8O2N [M+H]+ 138.0550; found 
138.0545.  
Methyl 4-methylbenzoate, 8d.30 1-Bromo-4-methylbenzene (50mg, 0.27 mmol) was 
reacted with tBuONa (42 mg, 0.43 mmol) in dimethyl carbonate according to the general 
procedure C to provide (35 mg, 80%) as colourless oil. 1H NMR (400 MHz, CDCl3): δ = 7.93 
(d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 3.89 (s, 3H), 2.40 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 167.3, 
143.7, 129.7, 129.2, 127.5, 52.0, 21.8. HRMS (ESI): Calcd. for C9H10O2Na [M+H]+ 151.0754; found 151.0757.  
Methyl quinoline-6-carboxylate, 8e.31 6-Bromoquinoline (50 mg, 0.24 mmol) was 
reacted with tBuONa (34 mg, 0.34 mmol) in dimethyl carbonate according to the general 
procedure C to provide the product (42 mg, 93%) as white solid. Mp 80-82 oC. 1H NMR 
(400 MHz, CDCl3): δ = 8.95-8.94 (m, 1H), 8.51 (s, 1H), 8.25-7.23 (m, 1H), 8.18 (d, J = 7.8 Hz, 1H), 8.10-8.08 (m, 
1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 3.94 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 166.6, 152.5, 150.1, 137.3, 
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